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Chapter 1: General introduc  on
1.1. Current prenatal tes  ng in the Netherlands
In the Netherlands, prenatal screening has been off ered to pregnant women since the 
1970s. The main focus has been on screening for fetal aneuploidies, such as Down syndrome 
(trisomy 21, T21). In the past few decades, screening approaches have changed. Originally 
risk assessments were only based on alpha-fetoprotein concentra  ons in maternal serum. 
Currently, prenatal screening is performed by use of a fi rst trimester combined test (FCT), to-
gether with a 20-week anomaly scan to screen for neural tube defects and other structural ab-
normali  es. FCT is a noninvasive screening method that uses an individualized risk-calcula  on 
to es  mate the chance of carrying a fetus with a fetal trisomy (G , 2001; V -
, 2014). In the fi rst trimester, several parameters have been established for FCT calcula-
 ons, such as biomarker measurement in maternal serum (e.g. intact or total human chorionic 
gonadotropin and pregnancy-associated plasma protein A) and a nuchal translucency (NT) 
scan. During this scan, the amount of fl uid at the back of the neck of the fetus is determined. 
Increased amounts of this fl uid will result in an increased NT and this may indicate that the 
fetus has a chromosomal abnormality. Both these parameters, combined with maternal age 
are subsequently used to calculate the a posteriori risk for women of carrying a fetus with fetal 
trisomy 13, 18 or 21 (M  et al., 2004). Subsequently, women can be off ered amniocentesis 
or chorionic villi sampling (CVS) for further prenatal tes  ng. Both methods involve an invasive 
procedure to obtain fetal DNA for subsequent DNA analysis in the laboratory and have a small 
procedure-related risk of miscarriage (M  et al., 2007; T  et al., 2010;  
et al., 2014). Because of this risk, currently only women with an increased risk a  er FCT (i.e. an 
a priori risk of >1:200) or women at risk because of gene  c indica  ons (e.g. a familial mono-
genic disease or a previous child with a chromosomal anomaly) are off ered invasive prenatal 
tes  ng (www.rivm.nl). 
Figure 1: Transcervical chorionic villus sampling of fetal material from the chorion membrane of the placenta (le  ) 
and amniocentesis; sampling of amnio  c fl uid from the uterus (right). Adapted from www.hopkinsmedicine.org.
CVS is usually performed around 11-14 wks of gesta  on and can be executed both tran-
scervically or transabdominally. Ultrasound is used to guide the catheter/ forceps to obtain 
placental  ssue for DNA isola  on (Fig. 1). However, when performing gene  c tes  ng on cho-
rionic villi DNA, false posi  ve and false nega  ve results are possible due to confi ned placental 
mosaicism (CPM; Appendix 1). In case of suspected mosaicism amniocentesis is recommend-
ed to determine the type of mosaicism (i.e. CPM or true fetal mosaicism (TFM)). With am-
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niocentesis or amnio  c fl uid sampling a small amount of amnio  c fl uid is sampled from the 
amnio  c sac surrounding a developing fetus (Fig. 1). Amniocentesis can be performed as early 
as 15 weeks though it is usually performed between 16 and 22 weeks of gesta  on.
Fetal gene  c material obtained through either one of these invasive procedures is sub-
sequently used for prenatal diagnosis in the laboratory and this analysis can be performed 
with cytogene  c as well as molecular techniques. Cytogene  c techniques include G-banding 
analysis/ karyotyping or FISH (fl uorescent in situ hybridiza  on) analysis of chromosomes and 
are used to facilitate interpreta  on of possible transloca  ons and/or mosaic fi ndings (Appen-
dix 1). Both amniocytes and chorionic villi can be cultured ex vivo. For CVS analysis in general a 
combined approach of both direct prepara  on/short-term culture (STC) and long-term culture 
(LTC) is preferred. This culturing process on average takes about two weeks. Direct DNA isola-
 on or DNA isola  on from cultured cells for molecular analysis can be performed in a shorter 
 me frame. Results of subsequent molecular analysis can be obtained within a few hours. 
An example of a molecular technique for prenatal diagnosis is quan  ta  ve fl uorescent poly-
merase chain reac  on (QF-PCR). QF-PCR was introduced as a fast, precise and cost-eff ec  ve 
alterna  ve to analyze the most common autosomal and sex chromosomal aneuploidies and is 
based on mul  plex PCR amplifi ca  on of mul  ple gene  c markers on chromosome 13, 18, 21, 
X and Y, together with some addi  onal controls on diff erent autosomes. Karyotyping, which is 
s  ll considered to be the gold standard for prenatal gene  c tes  ng, should be performed ad-
di  onally to QF-PCR to confi rm results in case of an aneuploidy. Moreover, karyotyping is per-
formed in case of a parental/familial chromosomal anomaly such as transloca  ons (balanced/
unbalanced) or inversions, o  en complimented with addi  onal FISH analysis or chromosomal 
microarrays. The diagnos  c accuracy of performing prenatal diagnosis on fetal material ob-
tained in these invasive procedures is virtually 100%. However, similar to every other medical 
interven  on, the invasive procedures used for obtaining the fetal gene  c material are asso-
ciated with procedure-related risks such as miscarriage (M  et al., 2007; T  et 
al., 2010; A  et al., 2014). Therefore, researchers have been exploring other minimally 
invasive or noninvasive ways to sample fetal material, to diminish such procedure associated 
risks of miscarriage and to have prenatal diagnosis available to more women. 
In addi  on to invasive tes  ng, with the start of the TRIDENT study (TRial by Dutch labo-
ratories for Evalua  on of Noninvasive prenatal Tes  ng) in April 2014, in the Netherlands wom-
en with high risk pregnancies (i.e. a priori risk >1:200 in the FCT) are off ered an addi  onal 
op  on for fetal trisomy screening. During this na  onal implementa  on study, women with 
high risk pregnancies may opt for noninvasive prenatal tes  ng (NIPT) in which fetal trisomy 
screening is performed by use of Next Genera  on Sequencing (NGS). With the availability of 
this addi  onal screening method, the number of invasive procedures and subsequent risk of 
miscarriage can be reduced.
1.2. Noninvasive prenatal diagnosis
In the past decades, a lot of eff ort has been put into developing tests for noninvasive 
prenatal diagnosis (NIPD) that would eliminate the small but signifi cant risk (< 1%) of proce-
dure-related fetal loss and would be equally reliable as the results of prenatal tes  ng a  er 
invasive sampling (M  et al., 2007; T  et al., 2010; A  et al., 2014). Already 
at the end of the 19th century, maternal blood was considered to be a useful source of fetal 
gene  c material for noninvasive prenatal diagnosis when the fi rst observa  on of fetal cells 




Georg Schmorl is considered to be the fi rst researcher to document on feto-maternal 
cellular traffi  cking a  er iden  fying trophoblast cells in lung capillaries of woman dying of ec-
lampsia (S , 1893; L  et al., 2007). He also speculated that feto-maternal traf-
fi cking might occur in normal gesta  ons. This theory has indeed been confi rmed in the past 
century by many others scien  sts that have reported fi ndings of a variety of fetal cells present 
in maternal circula  on. 
The presence of fetal leukocytes in maternal circula  on was fi rst described by the group 
of Walknowska et al. (W  et al., 1969). They iden  fi ed metaphases of male origin 
in cultured lymphocytes isolated from blood of healthy pregnant woman, who subsequently 
gave birth to a male infant. Fetal leukocytes do not have a limited life span and are therefore 
likely to persist between pregnancies. In addi  on to the study of Walknowska et al., Bianchi 
et al. described the prolonged persistence of male progenitor cells in a woman who had her 
last son 27 years prior to blood sampling (B  et al., 1996). As fetal leukocytes may persist 
through mul  ple pregnancies for long periods of  me, they are not likely to be considered the 
best source for NIPD on fetal cells, since it is very diffi  cult to dis  nguish between cells derived 
from the current or a previous pregnancy. 
In contrast to fetal leukocytes, nucleated red blood cells (NRBCs) and their precursors 
could be a be  er source of fetal gene  c material for NIPD. They are of interest because they 
are mononuclear and present in abundance in the fetus in the fi rst trimester, while rare in ma-
ternal blood (B , 1995). In contrast to fetal leukocytes, NRBCs do have a limited life span 
with a rela  vely short half-life of about 25-35 days (P , 1967). 
Placental trophoblast cells are another poten  al source of fetal material to be sam-
pled from maternal blood. Trophoblasts are the main cellular components of the placenta and 
originate from the trophectoderm of the blastocyst early in pregnancy (S -C  
et al., 2005). One of the poten  al drawbacks to the use of throphoblasts for noninvasive fe-
tal cytogene  c diagnosis includes the previously men  oned phenomenon of CPM (Appendix 
1). As a developing organ, the placenta undergoes constant  ssue remodeling. The turnover 
 me of a villous trophoblast cell is around 3-4 wks (H  et al., 2004). Deporta  on of the 
detached end stage syncy  al cells to the maternal lung is a process that occurs in all human 
pregnancies. The number of cells increases with gesta  on and has been described to increase 
even further in pa  ents with pathologic condi  ons such as (pre-)eclampsia (T  et al., 2006; 
B  et al., 2010). 
Even though there are some cell types that can be a poten  al source of fetal gene  c 
material to be used in NIPD, the number of fetal cells that can be isolated from maternal blood 
is limited. Isola  on and enrichment of these cells remains therefore challenging because of 
their low frequency in maternal blood (O  et al., 1996). 
1.2.2. Cell-free fetal DNA
Instead of looking for intact fetal cells, in 1997 the group of Lo et al. was the fi rst to show 
the presence of fetal gene  c material in the acellular component of blood. They demonstrat-
ed the detec  on of Y chromosomal sequences in plasma and serum of woman pregnant with 
male fetuses (L  et al., 1997). However, they were actually not the fi rst scien  sts to observe el-
evated levels of gene  c material in maternal plasma. Elevated levels of nucleic acids (DNA and 
RNA) in plasma of a pregnant woman had already been observed over 60 years ago by Mandel 
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and Métais, who were the fi rst to measure nucleic acids in human plasma in 10 healthy sub-
jects and 15 subjects with various condi  ons, including 1 pregnant female at 7 months of ges-
ta  on (M  et al., 1948). In two independent measurements they found dis  nct elevated 
levels of nucleic acids in maternal plasma and already expressed their interest in a follow-up 
of this interes  ng study object. A few decades later increased quan   es of DNA were also 
found in serum of cancer pa  ents in the study of Leon et al. (L  et al., 1977). Reasoning that 
the rapidly growing fetus and placenta possessed “pseudomalignant” tumor-like quali  es, the 
group of Lo et al. was the fi rst to show that there is signifi cantly more placental DNA present 
in cell-free plasma (or serum) of pregnant women as compared to the number of intact fetal 
cells in the cellular frac  on of maternal blood during pregnancy (L  et al., 1997). Moreover, 
placental DNA fragments could also be detected in maternal urine (T  et al., 2012). These 
circula  ng placental DNA fragments in the maternal circula  on are (perhaps erroneously) re-
ferred to as cell free fetal DNA (cff DNA), since the placenta may not always fully refl ect the 
actual fetal karyotype.
Low levels of circula  ng cell free DNA (cfDNA) in plasma are a common phenomenon 
in every individual as a result of clearance of cells dying of apoptosis. However, during preg-
nancy, total levels of circula  ng cfDNA increase due to the addi  onal placental contribu  on. 
These levels of placental cff DNA have been reported to be present from as early as 4 weeks 
of gesta  on (I  et al., 2007). Nevertheless, the fetal frac  on or percentage of placental 
cff DNA in plasma is rela  vely small in the fi rst trimester. The majority of total cfDNA in mater-
nal plasma is of maternal hematopoie  c origin (L  et al., 2002). Fetal frac  on is one of most 
crucial factors infl uencing NIPD or NIPT results and has been subject of study in many publica-
 ons (C  et al., 2010; J  et al., 2012b; C  et al., 2013; H  et al., 2014). Blood 
withdrawal for noninvasive tes  ng is usually performed around 10-11 weeks of gesta  on. The 
percentage of cff DNA in the fi rst trimester is on average ~10%, but diff ers quite extensively in 
range depending on gesta  onal age and between individuals (L  et al., 1998; L  et al., 2008a; 
G  et al., 2010; S  et al., 2010; C  et al., 2011a; H  et al., 2011). Sampling later on in 
pregnancy (e.g. second or third trimester) will consequently result in a higher percentage of 
placental sequences and thus a higher fetal frac  on. However, the great advantages of NIPD 
and NIPT is that it can be applied already very early on in gesta  on. Moreover, since maternal 
blood withdrawal has no risk for the fetus, it is preferred over invasive sampling procedures. 
High maternal weight and inherent increased body-mass index (BMI) have been shown 
to nega  vely infl uence the amount of placental DNA recovered from maternal plasma and 
consequently infl uence the success rate of downstream tes  ng (P  et al., 2011; S  
et al., 2012a; A  et al., 2013; W  et al., 2013; H  et al., 2014). There is an in-
creased turnover of adipocytes in obese women. A high level of apoptosis in maternal blood 
may result in a lower fetal frac  on, since the total amount of maternal cfDNA in plasma in-
creases, at the expense of the percentage of placental DNA fragments. There has been some 
debate about whether BMI or maternal weight alone would be the best indicator for success 
rate. BMI corrects for length. However, tall women may also have a higher total blood volume 
as compared to smaller women with similar weight. This higher blood volume may also result 
in a dilu  on eff ect on the percentage of cff DNA (W  et al., 2013). For coun  ng-based tech-
nologies such as shotgun whole genome sequencing or targeted sequencing a fetal frac  on > 
4% is required for analysis (E  et al., 2011; P  et al., 2011; P  et al., 2012). 
Several studies show that the failure rate of tes  ng with insuffi  cient fetal frac  on increases 
extensively with a maternal weight of 100 kg or higher (W  et al., 2013; C  et al., 2013; 
A  et al., 2013). The ul  mate covariates for the predic  on of the success rate for NIPD or 
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NIPT have not been determined yet. Preferably, covariates such as weight, height, body type 
and BMI should be provided and documented with each request for NIPT to determine which 
of these covariates would be the best predictor of the success rate and ul  mately results in 
the best fetal frac  on determina  on in a large data set.
Total cfDNA can be isolated from maternal plasma. Plasma separa  on from blood is 
mostly performed by centrifuga  on. More recently, op  ons for microscale methods for plas-
ma isola  on have become available with microfl uidic chips. Plasma can be isolated from blood 
cells passively either through sedimenta  on of cells, microfi ltra  on of cells through pores or 
cell devia  on of cells fl owing in microchannels. Another op  on is ac  ve separa  on by use of 
an external fi eld (e.g. acous  c, electric or magne  c) (K -K  et al., 2013; K -
-K  et al., 2014). Cff DNA in plasma from pregnant women appears to be stable up to 
5 days a  er blood withdrawal (M  et al., 2011). Maternal blood cells on the other hand 
are not stable. Lysis of maternal blood cells will lead to a massive increase of the total amount 
of cfDNA, resul  ng in a dilu  on eff ect of the fetal frac  on. Several studies show that per-
forming plasma separa  on within 24 hrs a  er collec  on is essen  al to prevent maternal cell 
lysis (M  et al., 2011; B  et al., 2013). The addi  on of formaldehyde may reduce or 
prevent cell lysis and has been described to enrich for cff DNA (D  et al., 2004). However, 
confl ic  ng results have been obtained in other studies (C  et al., 2005; C  
et al., 2005). 
Enrichment of placental sequences can be achieved through an epigene  c approach 
by using methyla  on specifi c/dependent techniques (e.g. bisulfi te conversion in combina  on 
with methyla  on specifi c PCR, restric  on enzyme diges  on or MeDIP (methylated DNA immu-
noprecepita  on)) (O  et al., 2007; T  et al., 2007; P  et al., 2009). At sequence 
level, there are no diff erences between the maternal contribu  on to the fetal genome and 
the maternal genome itself. At epigene  c level however, several markers have been described 
that diff er between mother and fetus. Epigene  c modifi ca  ons are soma  c altera  ons to the 
DNA that do not alter the actual gene  c sequence but do aff ect gene expression. One of the 
most common and best-known forms of modifi ca  ons is methyla  on. Cytosine methyla  on 
at the 5-carbon posi  on is the only known stable base modifi ca  on found in the mammali-
an genome (P  et al., 2008). It typically occurs at the cytosine-phosphate-guanine (CpG) 
sites where DNA methyltransferases turn a cytosine into a 5-methylcytosine (B  et al., 
2012). CpG rich sites are mainly located in the promoter region of genes and DNA methyla  on 
results in diff eren  al expression of maternally and paternally inherited genes due to transcrip-
 onal silencing of either one of these genes (i.e. genomic imprin  ng) (B  et al., 2012). 
A diff erence in size has been observed between maternal and placental cfDNA. This 
diff erence may permit the development of size-based strategy for selec  ve enrichment of 
the fetal frac  on from maternal plasma (L  et al., 2004; J  et al., 2009; Y  et al., 2014). In 
earlier studies, a diff erence in size had already been no  ced between circula  ng DNA mole-
cules in plasma of pregnant and non-pregnant women (C  et al., 2004). Analysis of a range 
of amplicon sizes targe  ng the lep  n and SRY (sex determining region Y) genes, showed that 
the plasma of pregnant women contained a higher percentage of smaller size fragments (<201 
bp), sugges  ng that the fetal/placental contribu  on to circula  ng cfDNA molecules is causa-
 ve for this size diff erence. Post-transplanta  on chimerism studies in sex-mismatched bone 
marrow transplanta  on recipients showed that DNA in plasma and serum is predominantly of 
hematopoie  c origin (L  et al., 2002). Moreover, data from paired-end (PE) massively paral-
lel sequencing (MPS) of plasma DNA samples from sex-mismatched hematopoie  c stem cell 
transplant recipients and one liver transplant recipient indicated that non-hematopoie  cally 
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derived DNA, resembling the fetal frac  on, is shorter than hematopoie  cally derived DNA, 
which can be considered the bulk of maternal cfDNA (L  et al., 2002; Z  et al., 2012). 
Concordant to this, several studies indeed demonstrate that placental cff DNA fragments are 
shorter than maternal cfDNA (C  et al., 2004; L  et al., 2004; L  et al., 2010; F  et al., 
2010). Analysis of paired-end sequencing reads show that the en  re fetal genome is repre-
sented in maternal plasma, displaying an average fetal fragment size of ~143 bp against an 
average maternal fragment size of ~166 bp (L  et al., 2010; Z  et al., 2012). These meas-
ured sizes of fragmented DNA seem to correspond to the number of bp that is packaged in 
a single nucleosome. A nucleosome is the fundamental repea  ng subunit of chroma  n and 
consists of two of each of the histones H2A, H2B, H3 and H4 that come together to form a his-
ton octamer (A , 2008). Chromosomal DNA is  ghtly wrapped around such a histon 
octamer forming a nucleosome. This way of packaging allows the DNA to be condensed into 
a smaller volume. An octamer binds on average 1.7 turns or 146 bp of chromosomal DNA. H1 
histone with a binding capacity of minimal 20 bp stabilizes the two full turns of DNA around a 
single octamer, crea  ng a nucleosome with a total length of at least 166 bp. Each chromosome 
consists of hundreds of thousands of nucleosomes, which are joined together by H1 bound 
to linker DNA (varying in size between ~20-80 bp in length) like beads on a string (O  et 
al., 2003; L , 2003). The diff erence in average size between placental and maternal frag-
mented DNA is likely due to presence of linker fragments (L  et al., 2010; B , 2011). This 
may also indicate that placental DNA is cleaved or degraded in a diff erent non-hematological 
manner in the maternal circula  on.
The kine  cs of the cff DNA contribu  on within the maternal circula  on suggests that the 
placenta is the predominant source of this DNA. Non-reproduc  ve syncy  al cells of the troph-
oblast are cleared eff ec  vely as they enter the pulmonary circula  on (B , 1994). Ap-
propriate removal of dying cells prior to the release of its intracellular components is cri  cal 
for the preven  on of fetal rejec  on (A  et al., 2004). The clearance of these apopto  c 
cells is driven by apoptosis or programmed cell death in which macrophages play a key role 
(A  et al., 2004; S -C  et al., 2005; T  et al., 2006; B  et al., 
2010). Degenera  on of these non-reproduc  ve syncy  al cells results in the release of placen-
tal cff DNA and cff RNA into the maternal circula  on within micropar  cles that protects them 
from degrada  on by plasma nucleases (B , 2004; B  et al., 2005; T  et al., 2006; 
A  et al., 2007; F  et al., 2012; H  et al., 2013). Concentrated plasma pellets sub-
jected to electron microscopic analysis demonstrated the presence of nucleosomes among 
structures containing chroma  n that are likely to be ruptured apopto  c bodies (B  et 
al., 2005). In addi  on, the same group fl ow-sorted nucleic acid posi  ve material from the 
acellular frac  on of plasma samples taken from maternal plasma samples at 12-16 wks of 
gesta  on. Microscopic analysis revealed the presence of apopto  c bodies and nucleosomes. 
They further demonstrated that fetal Y chromosome sequences could be amplifi ed from these 
apopto  c bodies, showing that at least a part of the circula  ng cfDNA is packed in apopto  c 
bodies or micropar  cles (MPs) (B  et al., 2005; O  et al., 2008). Because MPs are 
heterogeneous in nature, further characteriza  on is required before clinical use. If fetal-spe-
cifi c MPs would express unique surface markers from their original cells (i.e. trophoblasts), 
these markers could be used for enrichment strategies. By isola  ng fetal specifi c MPs, the fetal 




Placental cff DNA is cleared rapidly from maternal plasma following delivery with a short 
circula  on half-life of ~16 min in a range between 4-30 min. Results from quan  ta  ve detec-
 on of the Y chromosomal marker SRY by PCR showed that cff DNA is virtually undetectable in 
the maternal circula  on within 2 hrs postpartum (L  et al., 1999). A more recent study by Yu 
et al. describes the use of MPS for the detec  on of fetal sequences in maternal plasma and 
urine and describes a somewhat diff erent clearance pa  ern. This study shows that clearance 
of cff DNA occurred in 2 phases; an ini  al rapid phase with a mean half-life of approximately 1 
hr and a subsequent slow phase with a mean half-life of approximately 13 hrs, with a complete 
clearance at about 1-2 days postpartum (Y  et al., 2013). This rapid clearance makes NIPD 
on cff DNA pregnancy specifi c and in addi  on, brings clear benefi ts of early tes  ng, improved 
safety and ease of access. 
1.3. The use of cff DNA in clinical prac  ce
In the years since the discovery of cff DNA in maternal plasma, remarkable develop-
ments in noninvasive prenatal diagnosis have taken place. Early eff orts focused on the detec-
 on of paternally inherited sequences absent in the maternal genome. Recent development 
in technologies have also enabled the detec  on of fetal trisomies and have allowed analysis of 
several monogenic disorders. Ever since, many of these applica  ons have made the step from 
research to clinically applicable and available technologies.
1.3.1. Rhesus D genotyping and fetal sex determina  on 
The fi rst and currently leading applica  on of NIPD in the Netherlands has been Rhesus 
D (RhD) genotyping in maternal plasma at around 27 weeks of gesta  on (www.rivm.nl). RhD 
blood group incompa  bility between mother and fetus can occasionally result in maternal 
alloimmuniza  on; an immune response to foreign an  gens of the same species. An  -D an  -
bodies can subsequently cross the placenta and a  ack fetal red cells, causing fetal anaemia 
and ul  mately fetal death. Knowledge of the fetal an  gen status of the RhD locus is benefi cial 
to facilitate pregnancy management in alloimmunized women with a heterozygote partner 
or for RhD nega  ve women carrying a RhD posi  ve foetus (M , Jr., 2008). Fetal RhD gen-
otyping is currently performed as a standard screening in the Netherlands (  H  et al., 
2014). Around 12 weeks of gesta  on, all women are screened for blood group and RhD status. 
Around 27 weeks of gesta  on addi  onal fetal RhD typing is performed on cff DNA in maternal 
blood of RhD nega  ve women (www.rivm.nl, www.sanquin.nl). Historically, fetal tes  ng could 
only be performed a  er birth using cord blood (   S  et al., 2008). Performing RhD 
genotyping on cff DNA makes it possible to restrict immunoprofylaxis (administered antenatal 
in the 30th week of gesta  on and postnatal) only to non-immunized RhD nega  ve women 
carrying a RhD posi  ve foetus (F  et al., 1998; S  et al., 2011;  H  et al., 2014).
Since half of the fetal genotype is similar to the maternal genotype, most of the earlier 
NIPD applica  ons were based on the detec  on of diff erences between mother and fetus, such 
as paternally inherited sequences. Amplifi ca  on of a fetal marker that confi rms the presence 
of cff DNA allows a nega  ve result to be interpreted as a true nega  ve result. Failure to detect 
these sequences could be due to lack of amplifi ca  on of the targeted sequence or may be 
indica  ve of low concentra  ons or even complete absence of cff DNA in maternal plasma, and 
thus may lead to a false nega  ve result. 
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The most studied fetal markers for male pregnancies are sequences of the Y chromo-
some, such as DYS14, a mul  copy marker located within the TSPY(1) (tes  s specifi c protein, 
Y-linked (1)) gene or specifi c loci on the SRY gene (A  et al., 1987; S  et al., 2010). 
Both these markers have been studied extensively in fetal sex determina  on, which is also one 
of the fi rst and well described applica  ons for the use of cff DNA in diagnos  cs in addi  on to 
fetal RhD genotyping. Fetal sex determina  on is important in case of X-linked gene  c condi-
 ons where pregnancies with male fetuses are primarily at risk. Furthermore, early determi-
na  on of fetal sex is also clinically indicated for those at risk of condi  ons associated with am-
biguous development of the external genitalia (e.g. congenital adrenal hyperplasia or CAH). 
Early maternal treatment with dexamethasone can reduce the degree of virilisa  on of female 
fetuses with CAH (F  et al., 1998; R  et al., 2002). Noninvasive determina  on of 
fetal sex can also be performed by ultrasound at as early as 11 weeks’ gesta  on, though not 
always reliably (O  et al., 2009). In contrast, Y chromosomal sequences in maternal plasma 
can be detected as early as 4 wks of gesta  on, although reliably from 7 wks onwards (I  
et al., 2007; D  et al., 2011). Both SRY and DYS14 have been used for the iden  fi ca  on 
of male cff DNA in maternal plasma (Z  et al., 2005; B  et al., 2007; L  et al., 
2008a; W  et al., 2012; K  et al., 2012). This was mostly performed by quan  ta  ve 
Real-  me PCR. Even though Y chromosomal sequences can be detected with high sensi  vity 
and specifi city early in gesta  on, a posi  ve result can only be obtained in pregnancies with a 
male fetus, and alterna  ve markers are required to confi rm the presence of female cff DNA in 
maternal plasma in an universal and sex independent fashion. 
1.3.2. Universal fetal markers
A sex independent approach to confi rm the presence of fetal DNA is to analyze panels of 
SNPs or inser  on/dele  on polymorphisms for the detec  on of paternally inherited sequences 
(A  et al., 2002; P -C  et al.; 2006; T  et al., 2011). However, this meth-
od of detec  on can be quite laborious when not all markers are informa  ve. In this case, a 
large panel of diff erent markers needs to be tested for both biological parents along with the 
plasma sample.
Markers that are diff eren  ally methylated between mother and fetus could also be 
used to confi rm the presence of fetal DNA in maternal plasma in a sex-independent approach. 
The use of genomic imprin  ng in NIPD was fi rst shown by the group of Poon et al. displaying 
methyla  on diff erences between mother and fetus in a region of the human IGF2-H19 locus 
(P  et al., 2002). Since it has been shown that cff DNA in maternal plasma originates from 
trophoblast cells of the placenta, the search for diff eren  ally methylated markers has focused 
on genes expressed in placental  ssues (B , 2004; B  et al., 2005; T  et al., 2006; 
A  et al., 2007; B  et al., 2010; F  et al., 2012; H  et al., 2013). The two main 
fetal specifi c markers that have been studied in NIPD are SERPINB5 (serpin pep  dase inhibitor, 
clade B (ovalbumin) member 5, also known as MASPIN or mammary serine protease inhibitor) 
and RASSF1A (Ras associa  on (RalGDS/AF-6) domain family member 1, isoform or transcript 
variant A ) (C  et al., 2005; C  et al., 2006; C  et al., 2007; T  et al., 2007; B  et 
al., 2010; D  et al., 2010; Z  et al., 2010; W  et al., 2012; L  et al., 2013). 
Both SERPINB5 and RASSF1A are tumor suppressor genes. SERPINB5 is located on 
chromosome 18q21.3 and is diff eren  ally expressed during human placental development 
(D  et al., 2002). In maternal blood SERPINB5 is hypermethylated, while in the placenta 
this gene is hypomethylated (C  et al., 2005). In contrast to SERPINB5, the methyla  on 
pa  ern of RASSF1A in the developing placenta shows an opposite pa  ern, with fetal RASSF1A 
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being hypermethylated, while maternal blood cells are hypomethylated (C  et al., 2006; 
C  et al., 2007; W  et al., 2012). The RASSF1 locus at 3p21.3 contains eight exons. Alter-
na  ve splicing and usage of two diff erent promoters give rise to eight diff erent transcripts; 
RASSF1A-RASSF1H (D  et al., 2007; R  et al., 2009). The RASSF1A isoform is a 
39 kDa protein and the gene is frequently inac  vated by methyla  on rather than muta  onal 
events (A  et al., 2005). Inac  va  on through promoter region hypermethyla  on 
of RASSF1A has also been reported in a large variety of tumors in both adult and childhood 
cancers, including lung, breast, kidney, neuroblastoma and gliomas (A  et al., 
2005). During fetal development, the promoter region of RASSF1A is described to be diff eren-
 ally methylated between mother and fetus, which makes it an interes  ng universal marker 
to quan  fy or confi rm the presence of cff DNA in maternal plasma (C  et al., 2006; C  et 
al., 2007; Z  et al., 2010; W  et al., 2012). Addi  onally, several studies show that the 
concentra  ons of fetal hypermethylated RASSF1A sequences not only increase according to 
advancing gesta  on, but also before the onset of clinical manifesta  on of pregnancy compli-
ca  ons secondary to placental dysfunc  on, such as preeclampsia (H  et al., 2010; 
K  et al., 2013; P  et al., 2013). 
1.3.3. Fetal aneuploidy screening
The majority of requests for prenatal diagnosis a  er invasive sampling are related to fe-
tal aneuploidy tes  ng due to aberrant results a  er FCT. Therefore, the need for novel reliable 
noninvasive sampling and/or screening methods for subsequent fetal aneuploidy detec  on 
had created a strong interest in the fi eld of NIPT. The main focus has been on the detec  on of 
fetal T21 with a prevalence of 1 in 700 live born children, although many studies also address 
T18 detec  on, T13 detec  on and/or aneuploidy of the sex chromosomes (M  et al., 
2009). Even though the percentage of placental cff DNA in maternal plasma is rela  vely small, 
the addi  on or absence of a par  cular chromosome in the fetus can be detected with high ac-
curacy using various approaches, such as a targeted or whole genome sequencing approach. 
Targeted approach
Besides the use as fetal specifi c epigene  c markers for the confi rma  on of the presence 
of cff DNA in maternal plasma, several markers located on chromosome 21 or 18 have also 
been described for use in fetal aneuploidy detec  on. These markers are located in regions 
with a diff erence in methyla  on pa  ern which are described as diff eren  ally methylated re-
gions (DMRs). SERPINB5 has been described as a diff eren  ally methylated marker for fetal 
T18 detec  on in NIPT. The group of Tong et al. showed that the aneuploidy status of the fetus 
could be determined using bisulfi te modifi ca  on followed by methyla  on specifi c PCR (MSP). 
The epigene  c allelic ra  o (EAR) of a SNP present within diff eren  ally methylated SERPINB5 
promoter sequences in maternal plasma can be calculated to determine fetal aneuploidy sta-
tus for T18 in a fetus as compared to a control group of euploid fetuses (Appendix 2) (T  
et al., 2006).
For T21 detec  on 3 epigene  c markers (i.e. HLCS, PDE9A and DSCR4) on chromosome 
21 have been described for NIPT. The puta  ve promoter of HLCS is hypermethylated in the 
placenta while hypomethylated in maternal blood cells. The group of Tong et al. fi rst devel-
oped a male specifi c test for detec  on of T21 by comparing chromosome dosage (Appendix 
2) of the number of copies from the HLCS marker to the ZFY (zinc fi nger protein, Y-linked) on 
chromosome Y to determine the presence of an addi  onal copy of chromosome 21 (T  
et al., 2010b). Addi  onally, they developed a sex independent test where they used meth-
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yla  on-sensi  ve restric  on endonuclease diges  on followed by Real-Time or digital PCR to 
analyze chromosome dosage (Appendix 2). Instead of using sequences on the Y-chromosome, 
in the subsequent study they compared the results of the diges  on-resistant HLCS gene to 
a paternally inherited SNP (T  et al., 2010a). Another marker that has been described for 
epigene  c based T21 detec  on is PDE9A, which is hypomethylated in placental  ssues and 
hypermethylated in maternal blood (C  et al., 2008; L  et al., 2011b). Here, diff erences 
in levels of maternal methylated (M-PDE9A) and fetal unmethylated (U-PDE9A) levels were 
quan  fi ed for detec  on of T21 detec  on using quan  ta  ve MSP with two diff erent primer 
sets specifi c for either M-PDE9A or U-PDE9A sequences a  er bisulfi te conversion (L  et al., 
2011b). Levels of U-PDE9A were signifi cantly elevated in women carrying T21 fetuses as com-
pared to women carrying normal fetuses. DSCR4 is also considered to be a candidate fetal 
specifi c marker for fetal T21 detec  on and the promoter region shows a similar methyla  on 
pa  ern compared to PDE9A (D  et al., 2011). Other groups have also described the search for 
more candidate DMR for noninvasive T21 detec  on (C  et al., 2008; P  et al., 
2011; L  et al., 2014).
For fetal aneuploidy detec  on using digital PCR the focus is not on detec  ng specifi c 
fetal markers, muta  ons or sequences. For this approach it is no longer required to dis  nguish 
between maternal or fetal sequences. Digital PCR is a single molecule coun  ng technique 
that allows the quan  fi ca  on of DNA by coun  ng one molecule at the  me. Single molecules 
are isolated by dilu  on and individually amplifi ed by PCR. Each PCR product is then analyz-
ed individually. This technique is very useful in quan  fying the contribu  on of an addi  onal 
chromosome, for example an addi  onal copy of chromosome 21 in case of fetal T21, when 
compared to euploid pregnancies (L  et al., 2007a; F  et al., 2007; Z  et al., 2008; 
F  et al., 2009).
For iden  fying fetal trisomies, also SNP based approaches have been described. Total 
cfDNA isolated from maternal plasma is amplifi ed in a single mul  plex PCR reac  on target-
ing 11,000 SNPs on chromosome 13, 18, 21, X and Y (Z  et al., 2012). Sta  s  cal 
methods that incorporate parental genotypes are used to determine copy number of these 
chromosomes. Even higher sensi  vity and specifi city of the detec  on of fetal aneuploidies 
could be obtained when expanding the number of polymorphic loci to 19,488 SNPs (S -
-S  et al., 2013). Ghanta et al. analyzed highly heterozygous tandem SNP sequences 
as short haplotypes by using capillary electrophoresis (G  et al., 2010). Heterozygous 
informa  ve tandem SNPs from maternal buccal swaps were subsequently measured in ma-
ternal plasma by capillary electrophoresis and were used to determine fetal aneuploidy sta-
tus through haplotype ra  o analysis (Appendix 2) (G  et al., 2010). A similar approach 
described by Sparks et al., also enriched cfDNA for chromosomes of interest (S  et al., 
2012b). They developed the digital analysis of selected regions (DANSR™) method, which was 
developed to reduce the amount of sequencing required for NIPT. This method selec  vely 
evaluates specifi c clinical relevant genomic fragments or loci for each chromosomes of inter-
est (i.e. 13, 18 and 21) to es  mate the chromosome propor  on and fetal frac  on by calculat-
ing the chromosome to reference chromosome ra  o for each of the chromosomes of interest 
(e.g. chr. 21 from sample vs reference chr. 21). The DANSR method can be combined with the 
addi  onal FORTE™ (fetal frac  on op  mized risk of trisomy evalu  on) algorithm to calculate 
the likelihood of fetal trisomy. In addi  on to the fetal frac  on, also age-related risks are taken 
into account in this algorithm to provide an individualized risk score for fetal trisomy (S  




Instead of using specifi c markers or SNPs, shotgun massively parallel whole genome 
sequencing (WGS) permits locus independent simultaneous sequencing of extreme large 
quan   es of fetal and maternal DNA molecules. In 2008, the fi rst studies that described the 
applica  on of WGS for fetal aneuploidy screening were published (F  et al., 2008; C  et al., 
2008). Since, many studies for the valida  on and implementa  on of fetal aneuploidy screen-
ing have been published (C  et al., 2011a; S  et al., 2011; E  et al., 2011; L  et 
al., 2012b; B  et al., 2012). The majority of these studies have used Illumina sequence 
analyzers, although the SOLiD (Sequencing by Oligonucleo  de Liga  on and Detec  on) plat-
form and Ion Torrent have been described as well for noninvasive aneuploidy detec  on (F  
et al., 2012; Y  et al., 2013). Both SOLiD and Illumina use fl uorescently labeled nucleo  des 
for visualiza  on. In contrast to SOLiD sequencing by liga  on, the Illumina pla  orm uses se-
quencing by synthesis technology, tracking the addi  on of fl uorescently labeled nucleo  des 
as the DNA chain is copied, in a massively parallel fashion. Also the Ion Torrent pla  orm or 
ion semiconductor sequencing pla  orm is a sequencing by synthesis method. However, this 
method is based on the detec  on of hydrogen ions that are released during dNTP incorpora-
 on. The semiconductor chip measures diff erences in pH with each incorpora  on.
A  er sequencing each fragment (i.e. read) can be assigned back to the chromosome of 
origin. If a fetal aneuploidy is present, there should be a rela  ve excess or defi cit for the chro-
mosome in ques  on. However, it is necessary to sequence many millions of fragments in WGS 
to ensure suffi  cient counts since, for instance, chromosome 21 represents only ~1.5% of the 
human genome. The count of fragments or reads mapped back to a par  cular chromosome 
can subsequently be compared with the expected counts for euploid fetuses to determine 
the presence of a fetal aneuploidy (Appendix 3). With the improvement of the techniques, 
the possibility of running mul  ple samples simultaneously (i.e. mul  plexing) is available. The 
addi  on of a sample specifi c bar-code or tag sequence to each fragment allows the iden  fi -
ca  on of the fragment to the sample of origin. Originally, the fi rst mul  plex studies described 
only duplexed samples (2-plex) since the total number of reads produced by the sequence 
analyzers was rela  vely low. Currently with improved technology, suffi  cient numbers of reads 
are produced to run 8-plexed, 12-plexed  or even 24-plexed samples for noninvasive aneu-
ploidy detec  on on the Illumina pla  orm (L  et al., 2012b; B  et al., 2014, B  et 
al., 2015). 
In the majority of these studies for NIPT, the main focus is on T21 screening. When com-
paring DNA sequencing to standard prenatal aneuploidy screening (i.e. FCT), the false posi  ve 
rates when using cfDNA from maternal plasma were signifi cantly lower than those with stand-
ard fi rst trimester screening (B  et al., 2014). Both the sensi  vity and specifi city of fetal 
T21 detec  on exceed 99% (B  et al., 2012; M  et al., 2013; G  et al., 2014). In addi  on, 
performance for fetal trisomy 18 and 13 screening has also been reported, with detec  on 
rates of 96.8% and 92.1% respec  vely (G  et al., 2014). 
Preferen  al amplifi ca  on of sequences has been observed on PCR-based MPS plat-
forms (F  et al., 2008; D  et al., 2008). Many studies reported have suggested that this 
lower performance for T18 and T13 detec  on is due to the guanine and cytosine (GC) content 
(C  et al., 2011; B  et al., 2012; L  et al., 2012b; P  et al., 2012; N  et al., 
2012; S  et al., 2012b). Together with the dynamics and development in the sequencing 
technology, bioinforma  cs so  ware and analysis tools are constantly changing and improved. 
New algorithms used for the analysis of WGS and targeted NGS data are con  nuously devel-
oped and upgraded. For example, the RAPID (Reliable Accurate Prenatal non-Invasive Diag-
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nosis) analysis method is available as RAPIDR, an open source R package for the detec  on of 
monosomy X and fetal sex in addi  on to trisomy 13, 18 and 21. This pipeline implements a 
combina  on of several published and validated NIPT analysis methods such as NCV (Normal-
ized Chromosomal Value; Appendix 3) calcula  ons and correc  on to account for GC bias (L  et 
al., 2014). With the WISECONDOR (WIthin SamplE COpy Number aberra  on DetectOR) tool, 
copy number aberra  ons can be detected and, in contrast to the RAPIDR method, analysis is 
no longer restricted to chromosome 13, 18 and 21 only (S  et al., 2014).
1.3.4. Monogenic disorders
The large majority of prenatal requests in the laboratory are related to fetal aneuploidy 
detec  on. With NIPT for common aneuploidies already available, the next step is to focus on 
NIPD for monogenic disorders. This research area represents a smaller part of the total diag-
nos  c fi eld in noninvasive prenatal gene  c tes  ng. Nevertheless, there is also a request from 
pa  ents and physicians to expand the NIPD repertoire. 
NIPD for single gene disorder has been described for a variety of monogenic disorders, 
such as achondroplasia, cys  c fi brosis and α- and β-thallassaemia (G -G  et al., 
2002; L  et al., 2007; L  et al., 2011a; Y  et al., 2011; P  et al., 2012). NIPD can be 
applied for both autosomal dominant and recessive cases, most effi  ciently when the moth-
er does not carry the mutant allele or carries a diff erent muta  on as the biological father 
(B -A  et al., 2012; D  et al., 2014). In addi  on, detec  on of de novo 
muta  ons can be performed as well. Several approaches to perform NIPD for the detec  on of 
paternally inherited muta  ons or de novo muta  ons have been described, ranging from more 
basic molecular methods such as quan  ta  ve PCR and QF-PCR to more complex methods 
such as MALDI-TOF mass spectrometry (G -G  et al., 2003a; L  et al., 2007; S -
 et al., 2012; C  et al., 2013). The detec  on of maternally inherited muta  ons 
or autosomal recessive monogenic diseases with parents sharing iden  cal muta  ons is more 
challenging in NIPD. Since maternally inherited fetal alleles are genotypically iden  cal to the 
maternal background, one cannot determine fetal status by simply detec  ng the presence of 
a maternal muta  on in maternal plasma. A rela  ve muta  on dosage (RMD) approach using 
digital PCR is an example of an approach that can be used for NIPD of monogenic diseases for 
cases where the mother also carries a muta  on (Appendix 3) (L  et al., 2008a; Z  
et al., 2008; C  et al., 2009). By measuring the rela  ve amounts of the maternal mutant and 
wild type alleles in maternal plasma, the inherited dosage of the mutant fetal allele can be 
determined.
1.4. Scope of the thesis
There is a growing need in the fi eld of prenatal diagnos  cs for alterna  ve laboratory 
tests to complement and/or replace current invasive tes  ng. With the discovery of the pres-
ence of cell-free fetal DNA (cff DNA) in maternal plasma, an alterna  ve method for obtaining 
fetal gene  c material is now available. Many studies describing applica  ons for the use of 
cff DNA show promising results for noninvasive prenatal diagnosis (NIPD) or noninvasive pre-
natal tes  ng (NIPT). The aim of this thesis is to develop and validate new applica  ons for the 
use of cff DNA that may complement or replace current diagnos  c tests. 
In order to study the use of cff DNA, it is crucial that the presence of cff DNA in maternal 
plasma can be confi rmed. Many studies have shown that confi rma  on can be accomplished 
in a sex-dependent manner through the detec  on of Y-chromosomal sequences. However, in 
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case of a female fetus, this sex-dependent method is not informa  ve. In chapter 2 we describe 
the valida  on of a novel approach for the detec  on of fetal methylated RASSF1A (mRASSF1A) 
in maternal plasma. We describe the use of bisulfi te conversion in combina  on with pyroph-
osphorolysis-ac  vated polymeriza  on (PAP) to confi rm the presence of fetal DNA in maternal 
plasma in a sex-independent manner. 
An applica  on for NIPT that previously has been described is fetal trisomy screening by 
means of shotgun massive parallel sequencing (MPS). With this technique millions of short 
sequencing reads are produced that can be mapped back to the chromosome of origin to 
determine fetal aneuploidy status through a rela  ve overrepresenta  on for chromosome 21 
in case of fetal T21. Studies have reported that high-throughput next genera  on sequencing 
(NGS) pla  orms previously tested use a PCR step during sample prepara  on, which results in 
amplifi ca  on bias in GC-rich areas of the human genome. This GC bias may result in a lower 
sensi  vity for fetal trisomy screening. In chapter 3 we describe an alterna  ve method for fetal 
trisomy 21 (T21) detec  on by means of single molecule sequencing (SMS) on the Helicos plat-
form to eliminate this bias and we compare SMS to the previously described Illumina pla  orm. 
In addi  on to this, we also describe the applica  on of single molecule sequencing for trisomy 
18 (T18) and trisomy 13 (T13) detec  on in chapter 4.
Instead of the detec  on of a rela  ve overrepresenta  on of an en  re chromosome, NIPD 
can also be used for the detec  on of paternally inherited pathogenic repeats or alleles. De-
tec  ng low levels of fetal sequences in the excess of maternal cell-free DNA is s  ll challenging. 
Whole genome shotgun NGS as currently applied for NIPT may not always be the fastest and 
available method of choice for the detec  on of merely 1 or 2 variants at a short turn-around 
 me as is required when performing prenatal diagnos  cs for monogenic disorders. Moreover, 
the detec  on of large repeat sequences with NGS is currently diffi  cult, if not impossible. In 
chapter 5 we describe the development of a sensi  ve, muta  on specifi c and fast alterna  ve 
for NGS-mediated NIPD. We report a novel PCR based applica  on of high-resolu  on mel  ng 
curve analysis in combina  on with a blocking locked nucleic acid (LNA) probe to detect pa-
ternally inherited muta  ons in both autosomal dominant and recessive disorders. In chapter 
6 we addi  onally show the applica  on of NIPD for the detec  on of paternally inherited CAG 
repeats in maternal plasma. We describe the valida  on for use of NIPD aimed at the detec  on 
of polymorphic paternally inherited CAG repeats in the Hun  ng  n (HTT) gene for fetuses at 
risk of Hun  ngon disease (HD). 
A general discussion of the data is presented in chapter 7 and a summary of the major 
fi ndings of this thesis is presented in chapter 8.
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Abstract
Objec  ves: RASSF1A has been described to be diff eren  ally methylated between fetal 
and maternal DNA and can therefore be used as a universal sex-independent marker to con-
fi rm the presence of fetal sequences in maternal plasma. However, this requires highly sen-
si  ve methods. We have previously shown that Pyrophosphorolysis-ac  vated Polymeriza  on 
(PAP) is a highly sensi  ve technique that can be used in noninvasive prenatal diagnosis. In this 
study, we have used PAP in combina  on with bisulfi te conversion to develop a new universal 
methyla  on-based assay for the detec  on of fetal methylated RASSF1A sequences in mater-
nal plasma.
Methods: Bisulfi te sequencing was performed on maternal genomic (g)DNA and fetal 
gDNA from chorionic villi to determine diff eren  ally methylated regions in the RASSF1A gene 
using bisulfi te specifi c PCR primers. Methyla  on specifi c primers for PAP were designed for 
the detec  on of fetal methylated RASSF1A sequences a  er bisulfi te conversion and validated. 
Results:  Serial dilu  ons of fetal gDNA in a background of maternal gDNA show a rela-
 ve percentage of ~3% can be detected using this assay. Furthermore, fetal methylated RASS-
F1A sequences were detected both retrospec  vely as well as prospec  vely in all maternal 
plasma samples tested (n=71). No methylated RASSF1A specifi c bands were observed in cor-
responding maternal gDNA. Specifi city was further determined by tes  ng anonymized plasma 
from non-pregnant females (n=24) and males (n=21). Also, no methylated RASSF1A sequences 
were detected here, showing this assay is very specifi c for methylated fetal DNA. Combining all 
samples and controls, we obtain an overall sensi  vity and specifi city of 100% (95% CI 98.4%-
100%).
Conclusions:  Our data demonstrate that using a combina  on of bisulfi te conversion and 
PAP fetal methylated RASSF1A sequences can be detected with extreme sensi  vity in a univer-
sal and sex-independent manner. Therefore, this assay could be of great value as an addi  on 




Over the past years, the use of cell-free fetal DNA (cff DNA) for noninvasive prenatal 
diagnosis (NIPD) has proven its clinical poten  al in a wide range of fi elds. Although the pos-
sibili  es for using cff DNA in NIPD are numerous, they do require highly sensi  ve and specifi c 
techniques to detect the low levels of fetal sequences in the pool of maternal plasma DNA 
early in gesta  on. 
For the detec  on and/or quan  fi ca  on of fetal DNA, many inves  gators have based 
their strategy on the detec  on of Y-chromosomal-specifi c sequences (SRY and DYS14), or on 
the use of paternally inherited SNPs or polymorphic loci that are either absent or diff erent in 
the mother (T  et al., 1999; A  et al., 2002; P -C  et al., 2006; H  et al., 
2010; S  et al., 2010). Even though Y-chromosomal sequences can be detected using 
several diff erent techniques with high sensi  vity and specifi city early in gesta  on, a posi  ve 
result can only be obtained in pregnancies with a male fetus. Addi  onal detec  on of paternal-
ly inherited sequences could be used to discriminate between a true nega  ve result in case of 
a female pregnancy, or a false nega  ve result in case of low levels of circula  ng cff DNA. How-
ever, these methods are quite laborious since both biological parents need to be tested along 
with the plasma sample and not all SNPs and loci tested will be informa  ve. Therefore, a large 
panel of diff erent markers need to be tested for each individual case (S  et al., 2010).
Other fetal iden  fi ers have been described which are based on epigene  c diff erences 
between fetus and mother. These diff erences are caused by so-called genomic imprin  ng and 
are characterized by diff eren  al expression of maternally and paternally inherited genes due 
to transcrip  onal silencing of either one of these genes through DNA methyla  on (B  
et al., 2012). The use of genomic imprin  ng in NIPD was fi rst shown by the group of Poon et 
al. displaying diff erences in methyla  on status between fetal and maternal sequences in a 
region of the human IGF2-H19 locus (P  et al., 2002). Since it has been shown that cff DNA 
in maternal plasma originates from trophoblast cells of the placenta, the search for diff eren-
 ally methylated pa  erns has focused on genes expressed in placental  ssues (T  et al., 
2006; A  et al., 2007; B , 2004; F  et al., 2012; C  et al., 2005; C  et al., 
2007; C  et al., 2008; T  et al., 2006; T  et al., 2007; P  et al., 2009; B -
 et al., 2010). One of such genes that have been reported to be diff eren  ally methylated 
between mother (hypomethylated) and fetus (hypermethylated) is Ras-Associa  on Domain 
Family Member 1, transcript variant A (RASSF1A) (C  et al., 2006; C  et al., 2007; L  et 
al., 2007; D  et al., 2010; B  et al., 2010; Z  et al., 2010; Tsui et al., 2007; White et 
al., 2012). Previous studies used these diff erences in methyla  on in RASSF1A to confi rm the 
presence of cff DNA in maternal plasma, independent of fetal sex and without the restric  on of 
only detec  ng paternally inherited sequences (C  et al., 2006; C  et al., 2007; L  et al., 
2007; D  et al., 2010; B  et al., 2010; Z  et al., 2010; T  et al., 2007; W  et al., 
2012). Methyla  on-sensi  ve restric  on enzyme diges  on, (Real-Time) methyla  on specifi c 
PCR (MSP), mass spectrometry and bisulfi te conversion in combina  on with direct sequenc-
ing were the main techniques used in these studies. Some of the aforemen  oned techniques 
require a rela  vely high DNA input. This may indicate that not all of these techniques are sen-
si  ve enough to detect the low levels of cff DNA in maternal plasma early in gesta  on. We have 
previously shown that Pyrophosphorolysis-ac  vated polymeriza  on (PAP) is a highly sensi  ve 
method for the detec  on of fetal sequences in a large pool of maternal plasma (B  et al., 
2007; P  et al., 2012). PAP was ini  ally developed to detect rare known muta  ons with 




(PAP) or bidirec  onal (bi-PAP) blocked oligonucleo  des on the 3’end. These blocks need to be 
removed by pyrophosphorolysis for DNA extension to occur. This is only possible when the 
oligonucleo  des completely match the template strand. This makes PAP a highly specifi c and 
sensi  ve method to use in NIPD (L  et al., 2000; B  et al., 2007; S  et al., 2007; L  et al., 
2004; P  et al., 2012).
In this study we have used this method to develop a new universal sex-independent 
methyla  on-based assay to detect fetal methylated RASSF1A (mRASSF1A) sequences in ma-
ternal plasma for NIPD.
Materials and Methods
Samples 
Wri  en informed consent was obtained and this study was approved by the Medical 
Ethics Commi  ee (CME) of the Leiden University Medical Center. Maternal peripheral blood 
samples (10-20 mL) were collected in EDTA coated tubes from pregnant women for noninva-
sive fetal sexing at the Laboratory for Diagnos  c Genome Analysis of the Leiden University 
Medical Center (LUMC), Leiden, the Netherlands. Maternal blood samples (n=71) were drawn 
at a median gesta  onal age of 10.6 weeks (range 8.0 – 18.1 wks.) and were processed within 
24 hrs. a  er collec  on as described previously (   O  et al., 2012). The retrospec  ve 
samples used were previously tested for fetal sexing (n=60) using a combina  on of Real-Time 
PCR and Pyrophosphorolysis-ac  vated polymeriza  on (Y-PAP) for the detec  on of Y-chromo-
somal sequences as previously described (B  et al., 2007). All fetal gender was confi rmed 
by karyotyping or a  er birth. In the prospec  ve samples (n=11) fetal sexing was determined 
using a combina  on of tests men  oned above, supplemented with Real-Time PCR detec  on 
of a panel of 8 high frequency paternal dele  on/inser  on polymorphisms (A  et al., 
2002). As a control, anonymized plasma control samples from males (n=21) and non-pregnant 
females (age>48, n=24) were used. 
DNA isola  on
Cell-free DNA was isolated from plasma with the EZ1 Virus Mini Kit v2.0 on the EZ1 Ad-
vanced (QIAGEN, Venlo, The Netherlands; www.qiagen.com) according to the manufacturer’s 
instruc  ons with an input volume of 800 (2*400) μL plasma and an elu  on volume of 120 
(2*60) μL.
Bisulfi te conversion
Bisulfi te conversion was performed using the EZ DNA Methyla  on-Gold™ kit (Zymo 
Research, USA) according to manufactures’ instruc  ons, with an input of 100 ng gDNA per 
reac  on (maximum DNA reac  on volume of 50 μL) and an elu  on volume of 10 μL. Bisulfi te 
conversion of plasma DNA was performed as men  oned previously, with an input of 2*50 μL 
total cell-free DNA (cfDNA) from plasma per bisulfi te reac  on. (N.B. two corresponding plas-
ma DNA samples were pooled a  er conversion and purifi ed over 1 column). Elu  on volume 
used was 10 μL.
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Bisulfi te sequencing and mRASSF1A-PAP primer design
Two sets of Bisulfi te Sequencing Primers (BSP) containing an M13 tag for Sanger se-
quencing were designed for two subsequent fragments (BisA 191 bp and BisB 297 bp, Fig. 1, 
Table 1) in the promoter region of the RASSF1A gene (NM_007182.4) outside predicted CpG 
islands or other poten  ally methylated cytosines using MethPrimer v1.1 beta (L  et al., 2002; 
C  et al., 2007; M  et al., 2007).  A  er bisulfi te conversion, we assessed methyla  on pat-
terns of these two regions by conven  onal Sanger sequencing using these 2 sets of BSP-M13 
primers and SeqScape So  ware (Applied Biosystems). Three sets of fetal gDNA derived from 
chorionic villus samples (CVS) and corresponding maternal gDNA sequences from maternal 
blood cells were compared to determine diff eren  ally methylated regions of the RASSF1A 
gene at nucleo  de level. Methyla  on specifi c PAP primers for the detec  on of mRASSF1A 
were subsequently designed and a so-called bi-PAP reac  on was performed. 
mRASSF1A-PAP
The mRASSF1A-PAP reac  on mixture contained 1x PAP-PCR buff er (250 mM Tris-HCl 
pH 7.5 (Gibco, Life Technologies Corpora  on), 80 mM (NH4)2SO4 (J.T. Baker), 17.5 mM MgCl2 
(J.T. Baker), 125 μM of each of the four dNTP’s (Thermo Scien  fi c), 450 μM Na4PPi pH 8.0 (Sig-
ma-Aldrich)), 2.5 IU Klentaq S (ScienTech Corp), 4 μM of each PAP-primer (Biolegio, Nijmegen, 
the Netherlands, Table 1) and 10 μL of bisulfi te converted cfDNA from maternal plasma. Cy-
cling condi  ons were 15 s 94°C, 40 s 60°C, 40 s 64°C, 40 s 68°C and 40 s 72°C for a total of 45 
cycles. PAP reac  on product was visualized on a 3.5% 1x TBE agarose gel. 
As an internal nega  ve control, maternal gDNA from the buff y coat (input 100 ng) was 
always converted and analyzed together with the cfDNA isolated from the corresponding ma-
ternal plasma sample. A fully methylated human cell line (CpGenome, S7821, Merck Milli-
pore) and/or a gDNA sample from CVS (both 100 ng input per reac  on) were used as posi  ve 
controls to check the bisulfi te conversion and the PAP reac  on. For the la  er, this control 
had been converted in an independent separate reac  on, aliquoted and stored at -20°C un  l 
further use. 
Serial dilu  ons (range 1000-7 pg) of fetal gDNA from CVS in H2O were performed to de-
termine the analy  cal sensi  vity of the assay. In addi  on, comparable serial dilu  ons of fetal 
gDNA in a background of 1000 pg maternal gDNA were performed. Input men  oned is the 
total amount of fetal gDNA per bisulfi te conversion reac  on.
Results
Determina  on of diff eren  ally methylated regions in RASSF1A
To determine regions in the RASSF1A gene which are diff eren  ally methylated between 
mother and fetus, bisulfi te sequencing was performed on maternal gDNA and fetal gDNA from 
CVS (n=3 sets). Two diff erent regions (BisA and BisB) were analyzed by conven  onal Sanger 
sequencing using two sets of BSP-M13 primers (Fig. 1, Table 1). Diff eren  ally methylated se-
quences were found in both regions (Fig. 2). mRASSF1A-PAP primers PAP primers were de-
signed in the region covered by the BisB BSP primers and are specifi c for fetal methylated 
sequences a  er bisulfi te conversion (Figure 3, Table 1). This region was also previously de-




most suitable for PAP primer design since it contains many methylated cytosines in the fetal 
(hypermethylated) sequences, while in the mother, these cytosines are unmethylated and will 
convert into uracil a  er bisulfi te conversion. This resulted in 5 mismatches between each PAP 
primer and maternal DNA template and will increase the specifi city of this assay (Fig. 3). To 
increase specifi city of the PAP primers even more, the length of the oligonucleo  des was at 
least 28 nt. In addi  on, this assay was designed as a bi-PAP, containing a 3’ddC block on both 
the forward as well as the reverse primer.
Figure 1: Sequences a  er Methprimer predic  on. 
Predicted sequences of the RASSF1A for Bisulfi te Specifi c Primers (BSP) design using Methprimer (L  et al., 2002). BSP 
primers are located outside diff eren  ally methylated regions. Methylated nucleo  des are indicated with +, unmethyl-
ated nucleo  des with : and other nucleo  des with |. A: The predicted sequence of the BisB forward primer (indicated  
as >>>). B: The predicted sequence of the BisB reverse primer (indicated as <<<). 
Analy  cal sensi  vity and specifi city of the mRASSF1A-PAP assay
The analy  cal sensi  vity of the mRASSF1A-PAP assay was fi rst determined by tes  ng 
serial dilu  ons of gDNA derived from CVS in water. Our results show that this assay is sensi-
 ve enough to detect fetal sequences in amounts as low as 16 pg in a 50 μL sample reac  on 
volume (data not shown). To simulate the situa  on in maternal plasma, gDNA from CVS was 
serially diluted in a background of maternal gDNA. Our data show that in a background of 
1000 pg maternal gDNA, as low as 30 pg of fetal gDNA can be detected, represen  ng a rela  ve 
percentage of around 3% (Fig. 4). These serial dilu  ons thus showed that this assay is highly 
sensi  ve.
Figure 2: Diff eren  ally methylated regions a  er bisulfi te sequencing. 
Sanger sequencing results for RASSF1A of a fully methylated control cell line (A), maternal gDNA (B) and fetal gDNA 
derived from CVS (C) a  er bisulfi te sequencing. A representa  ve part of the complete sequence is shown. All unmeth-
ylated cytosines are converted to uracil a  er bisulfi te sequencing. Diff erences between maternal and fetal (methylat-

























































































































































































































































































































































































































































































































































































































































































To demonstrate that this assay is also highly specifi c for methylated fetal DNA sequenc-
es, several controls were tested. As an internal nega  ve control, corresponding maternal 
gDNA samples were always converted and analyzed in parallel to the maternal plasma sam-
ples. No mRASSF1A specifi c bands were observed in these samples. In addi  on, anonymized 
plasma samples were tested from non-pregnant females (age >48, n=24) and males (n=21). 
Also, no mRASSF1A-specifi c products were observed here. Therefore, the assay is also very 
specifi c since no false posi  ves were present in all control samples tested (n=116), resul  ng in 
an analy  cal sensi  vity and specifi city of 100% (95% CI 97.4%-100%). 
Figure 3: Predicted and confi rmed sequences for PAP-primer design. 
Sequences of the RASSF1A gene were analyzed a  er bisulfi te sequencing of maternal gDNA and fetal gDNA derived 
from CVS. Diff eren  ally methylated regions of the BisB region predicted by MethPrimer (L  et al., 2002) could be con-
fi rmed using bisulfi te sequencing. Both forward (A, upper panel, underlined) and reverse PAP-primer (B, upper panel, 
underlined) are specifi c for fetal sequences (middle panels) a  er bisulfi te conversion and both primers have several 
mismatches to the maternal sequences (lower panels). Mismatches between fetal specifi c PAP-primers and maternal 
sequences are indicated with an * for each primer.
Tes  ng of retrospec  ve and prospec  ve clinical samples
In a retrospec  ve study, fi  y three samples previously tested for fetal gender using a 
combina  on of Real Time PCR and Y-PAP (B  et al., 2007) and indicated as undetermined 
(no Y chromosomal sequences detected), were tested for the presence of cff DNA using the 
mRASSF1A-PAP assay (Table 2). Fetal mRASSF1A sequences were detected in all maternal plas-
ma samples tested (n= 53). As a control, the presence of mRASSF1A was also confi rmed in 7 
samples already tested posi  ve for Y-chromosomal sequences. In these samples the presence 
of fetal DNA could be confi rmed both in a sex-dependent and sex-independent assay, showing 
that the results from the mRASSF1A detec  on are concordant with the detec  on of Y chromo-
somal sequences. The data also confi rmed that since this assay is sex-independent, it can be 
applied to all pregnancies. Altogether, the presence of cff DNA in maternal plasma was shown 
retrospec  vely with a sensi  vity and specifi city of 100% (95% CI 95.0%-100%). 
Moreover, in a prospec  ve study, several clinically relevant samples (n=11) were tested 
with the mRASSF1A-PAP assay in parallel to our current diagnos  c protocol for fetal sexing us-
ing the detec  on of Y-chromosomal sequences and, in case of a nega  ve (e.g. undetermined 
or no Y chromosomal sequences detected) result, addi  onal tes  ng for 8 paternal dele  on/
inser  on polymorphisms (Table 3) (A  et al., 2002; B  et al., 2007). Although a pan-
el of high frequency polymorphisms was used, informa  ve polymorphisms were either not 
present (n=4), not inherited (n=3) or results for the detec  on of these polymorphisms did not
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meet our quality criteria (e.g. at least 2/3 Ct values < 40) used for diagnos  cs (n=1) (Table 3). In 
parallel, these samples were tested using the mRASSF1A-PAP. In all 11 cases tested, the pres-
ence of fetal sequences could be confi rmed using this new assay. In combina  on with both 
Real-Time PCR and Y-PAP results fetal gender could be determined as female (Table 3) and in 
all cases, our results were concordant with fetal gender determined a  er addi  onal tes  ng 
later on in gesta  on or a  er birth (Table 3). 
Figure 4: mRASSF1A-PAP serial dilu  on range of gDNA from CVS.
Serial dilu  ons were performed with gDNA from CVS in a background of 1000 pg maternal gDNA. Input (pg) men-
 oned is the total amount of fetal gDNA. M= 50 bp marker, 1= 1000 pg, 2= 500 pg, 3= 250 pg, 4= 125 pg, 5= 60 pg, 
6= 30 pg, 7= 15 pg, 8= 7 pg, 9= posi  ve control for bisulfi te conversion, 10= NTC for bisulfi te conversion, 11= nega  ve 
control for bisulfi te conversion (non-bisulfi te converted fetal gDNA), 12= posi  ve control for mRASSF1A-PAP, 13= NTC 
for mRASSF1A-PAP. A 110 bp product (arrow) is obtained in cases where mRASSF1A sequences could be detected 
using mRASSF1A-PAP.
Discussion
We have developed a novel sex- and polymorphism independent, methyla  on-based 
diagnos  c test for the detec  on and confi rma  on of fetal DNA sequences in maternal plasma. 
In contrast to methods most widely used in noninvasive diagnos  cs (e.g. detec  on of Y chro-
mosomal sequences or paternal polymorphisms), this assay can be applied to all pregnancies. 
Our test, based on the epigene  c diff erences between maternal (hypomethylated) and fetal 
(hypermethylated) RASSF1A sequences, was found to be 100% reliable.
Diff eren  ally methylated regions between mother and fetus have previously been iden-
 fi ed in several genes. However, this was mainly done by techniques such as cloning, mass 
spectrometry and array. These techniques only produced methyla  on pa  erns without high 
resolu  on since CpG islands were analyzed as a whole (C  et al., 2005; C  et al., 2006; 
B  et al., 2010; D  et al., 2010; P  et al., 2009; P  et al., 2002). As we 
were interested in designing sequence-specifi c primers, we needed to study these methyla-
 on pa  erns at nucleo  de level and therefore decided to perform bisulfi te sequencing. The 
sequences of the BSP primers are located around predicted CpGs and other possible methylat-
ed cytosines (L  et al., 2002). Since these sequences are not infl uenced by bisulfi te conversion, 
it is possible to study diff eren  ally methylated regions, both before and a  er conversion and 
subsequently to design methyla  on specifi c primers for Pyrophosphorolysis-ac  vated Polym-
eriza  on (PAP) (L  et al., 2000; L  et al., 2004; S  et al., 2007). PAP requires an allele specifi c 
oligo with a dideoxyoligonucleo  de block at the 3’end. If and only when the sequence of the 
oligo completely matches the template strand, the dideoxyoligonucleo  de can be removed in 
the presence of pyrophosphate before the oligo can be extended subsequently. We have de-






































































































































































































































































































































































































































































































































































sulfi te conversion. Compared to these fetal sequences, maternal (hypomethylated) sequences 
will diff er quite extensively a  er bisulfi te conversion, resul  ng in several mismatches between 
each primer and the maternal DNA template. This will prevent the PAP reac  on from occuring 
since the 3’ block cannot be removed prior to extension, which makes this assay very specifi c. 
Although many other methods for minority allele enrichment have been described, PAP has 
been described to provide the highest selec  vity (M  et al., 2009). This selec  vity could 
even be enhanced using a bidirec  onal modifi ca  on of two opposing allele-specifi c 3’ dideox-
yoligonucleo  des (M  et al., 2009; L  et al., 2000; L  et al., 2004; S  et al., 2007). The 
mRASSF1A-PAP is based on this bi-direc  onal principle. We previously demonstrated the use 
of PAP for noninvasive fetal sex determina  on using a combina  on of Real-Time PCR and PAP 
for the detec  on of Y-chromosomal sequences (B  et al., 2007). This was successfully vali-
dated in our facility by tes  ng a large amount of samples for noninvasive fetal sexing (n=213), 
resul  ng in a diagnos  c sensi  vity and specifi city of both 100% (95% CI 98.6%-100%) (un-
published data). Samples from the la  er valida  on study were used for this mRASSF1A-PAP 
valida  on study as well. In daily clinical prac  ce, we have also tested the mRASSF1A-PAP by 
using this assay in parallel with rou  ne diagnos  cs for noninvasive fetal sexing. For the cases 
with undetermined results (e.g. no Y chromosomal sequences detected (B  et al., 2007) 
we started out tes  ng the mRASSF1A-PAP in parallel with Real-Time PCR detec  on of a panel 
of 8 high frequency paternal polymorphisms (A  et al., 2002). In some cases, no in-
forma  ve polymorphisms were present that could be used for a diagnos  c conclusion. Thus 
despite using a panel of polymorphisms, the presence of cff DNA in maternal plasma could not 
be confi rmed in 67% of the cases. mRASSF1A-PAP was also performed on these samples. In 
these cases mRASSF1A-PAP results were posi  ve and fetal gender was determined and indeed 
confi rmed as female showing that this assay could serve as a valuable supplemental test in 
diagnos  cs. 
However, there are excep  ons where it is preferable to use paternally inherited poly-
morphisms to confi rm the presence of fetal DNA instead of detec  ng methylated RASSF1A. 
Several recent studies have reported that aberrant methyla  on in the promoter region of 
RASSF1A can also be used as poten  al marker for (early) diagnosis of several types of cancer 
(Z  et al., 2013; M -C  et al., 2013; P  et al., 2013). This could 
mean that there is a poten  al risk for false posi  ve results in the mRASSF1A-PAP assay. Al-
though this risk is considered to be small, given the prevalence of cancer in the reproduc  ve 
age group, it should be taken into account when including women for NIPD. When there is 
a history of cancer, this should be reported to the lab which is tes  ng the samples. In these 
cases, tes  ng of paternally inherited polymorphisms to confi rm the presence of fetal DNA is 
preferable over tes  ng methylated RASSF1A.
Although the percentage cff DNA early in gesta  on diff ers between individuals, most 
reports agree that the fetal contribu  on is around 10% in the fi rst trimester (L  et al., 1998; 
L  et al., 2008a;   O  et al., 2012). On average, we isolate 2-3 ng of total cfDNA 
from maternal plasma, thus expec  ng around 200-300 pg cff DNA as input for the the mRASS-
F1A-PAP assay. Our data show that using PAP, we can reproducibly detect amounts much lower 
than these average expected amounts of fetal DNA, even in the range of a few genome equiva-
lents (30 pg). This demonstrates the extreme sensi  vity of PAP. Using serial dilu  ons, we could 
even detect amounts in the range of only 1-2 genome equivalents (6-15 pg). However, since 
only a few copies of the gene of interest are present, these results were less reproducible. 
We have used this mRASSF1A-PAP assay as a control test in fetal sexing. However, it can also 




using Next Genera  on Sequencing. Since the assay is universal and sex-independent, it can be 
applied to all samples and reliably confi rms the presence of fetal DNA within a sample.
In conclusion, this study confi rmed that methylated RASSF1A sequences can be used 
as informa  ve universal markers for detec  ng the presence of cff DNA in maternal plasma, 
irrespec  ve of fetal sex. Moreover, the PAP technique used provides an extremely sensi  ve 
method for the detec  on of fetal sequences in a large pool of maternal plasma DNA early in 
gesta  on. Therefore, this assay could be of great value as an addi  on to current techniques 
used in noninvasive prenatal diagnos  cs.
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Abstract
Background:  Noninvasive fetal aneuploidy detec  on using free DNA from maternal plas-
ma has recently been shown to be achievable by whole genome shotgun sequencing. The 
high-throughput Next Genera  on Sequencing pla  orms previously tested use a PCR step dur-
ing sample prepara  on, which results in amplifi ca  on bias in GC rich areas of the human ge-
nome. To eliminate this bias, and thereby experimental noise, we have used single molecule 
sequencing as an alterna  ve method. 
Methods:  For noninvasive trisomy 21 detec  on, single molecule sequencing was per-
formed on the Helicos pla  orm using free DNA isolated from maternal plasma from 9 weeks 
of gesta  on onwards. Rela  ve sequence tag density ra  os were calculated and results were 
directly compared to the previously described Illumina GAII pla  orm.
 
Results:  Sequence data generated without an amplifi ca  on step show no GC-bias. 
Therefore, using single molecule sequencing all trisomy 21 fetuses could be dis  nguished 
more clearly from euploid fetuses. 
Conclusion:  This study shows for the fi rst  me that single molecule sequencing is an at-
trac  ve and easy to use alterna  ve for reliable noninvasive fetal aneuploidy detec  on in di-
agnos  cs. Using this approach, previously described experimental noise associated with PCR 





Trisomy 21 (T21) is the most common chromosomal abnormality in live-born children. 
The diagnosis can be made early in pregnancy using invasive tes  ng (e.g. chorionic villus sam-
pling (CVS) or amniocentesis). These invasive procedures however, are associated with a risk 
of miscarriage. Therefore, these tests are commonly only off ered to women at increased risk 
for fetal trisomy. Risk assessment used to be based on maternal age. More recently, this was 
refi ned by adding serum markers for trisomy and ultrasound measurement of the fetal nuchal 
translucency (D  et al., 2009). Current screening programs have detec  on rates for T21 
of around 80% with a false posi  ve rate of 5%, meaning that one in every 20 women screened 
is off ered invasive tes  ng with its inherent risks, while carrying a healthy fetus (W  et al., 
2003; M  et al., 2007).
The discovery of cell-free fetal (cff ) DNA and RNA in maternal plasma opened possibili-
 es for noninvasive prenatal diagnosis (NIPD) (L  et al., 1997). Although cff RNA has been used 
for noninvasive T21 detec  on (L  et al., 2007b; P  et al., 2010; T  et al., 2010; D  
et al., 2011), the majority of approaches use cff DNA for NIPD of T21. In the fi rst trimester, the 
percentage of cff DNA in maternal plasma is on average 1-10% and diff ers quite extensively 
in range depending on gesta  onal age and between individuals (G  et al., 2010; C  et al., 
2011b; L  et al., 1998; L  et al., 2008a; S  et al., 2010; H  et al., 2011). Therefore, 
it remains challenging to detect fetal sequences in a large pool of maternal DNA. Previously, 
several papers have shown that noninvasive T21 detec  on is possible by using single nucleo-
 de polymorphisms (SNPs) (D  et al., 2007; G  et al., 2010) and epigene  cs (O  
et al., 2007; C  et al., 2008; T  et al., 2010b; P  et al., 2011) although these 
methods have a number of limita  ons.
In 2008, noninvasive T21 detec  on by Next Genera  on Sequencing (NGS) was intro-
duced (F  et al., 2008; C  et al., 2008), opening a whole new way of analysis. No longer 
only fetal specifi c sequences were analyzed, but all free DNA in plasma, from both fetal and 
maternal origin, is sequenced with this technique. Two recent papers confi rmed the poten  al 
value of NGS for noninvasive fetal T21 detec  on in mul  plexed plasma DNA samples in a clin-
ical se   ng (E  et al., 2011; C  et al., 2011a). Both the Illumina Genome Analyzer (GA) II 
(F  et al., 2008; C  et al., 2008; F  et al., 2010; E  et al., 2011; C  et al., 2011a) and 
the SOLiD pla  orm (C  et al., 2010) have been used for noninvasive T21 detec  on by NGS. 
These pla  orms use amplifi ca  on steps by polymerase chain reac  on (PCR) which are known 
to introduce preferen  al amplifi ca  on of sequences depending on diff erent GC content (F  
et al., 2008; C  et al., 2009).
In the present study, we have tested single molecule sequencing (tSMS, Helicos Helisco-
peTM Single Molecule Sequencer) for noninvasive T21 detec  on. The Helicos pla  orm u  lizes 
visual imaging across the fl ow cell for direct DNA measurement by recording the incorpora  on 
of fl uorescently labeled nucleo  des (G , 2008; M , 2009). The use of single molecule 
sequencing has been described previously (H  et al., 2008) and this technique should 
largely overcome the limita  ons associated with PCR amplifi ca  on and bias as men  oned 
above. Although the sequencing  me on the Helicos pla  orm is longer compared to the Illu-
mina pla  orm (4 days respec  vely 2 days), Helicos sample prepara  on is simple, 3  mes faster 
(1 day compared to 3 days) and therefore rela  vely cheap. Furthermore, this method requires 




Here, we present a comparison of the applica  on of single molecule sequencing for 
noninvasive T21 detec  on using cff DNA from maternal plasma to the previously described 
PCR-based Illumina NGS pla  orm.
Materials and Methods
Subjects
Pregnant women undergoing prenatal diagnosis were recruited at the Department 
of Obstetrics of the Leiden University Medical Center (LUMC), Leiden, The Netherlands. In-
formed consent was obtained and this study was approved by the Ins  tu  on’s Medical Ethics 
Commi  ee.
Sample Processing and Isola  on
Maternal peripheral blood samples (10-20 mL) were collected in EDTA coated tubes at 
the LUMC and were processed within 24 hrs a  er collec  on. All blood samples were drawn at 
a median gesta  onal age of 12 +2 weeks (range 9 +3 to 16 +6 wks). Preferably blood samples 
were drawn before an invasive procedure, if this was not possible samples were drawn at least 
5 days a  er the invasive procedure to minimize any disturbance with fetal material due to this 
procedure.
Blood was centrifuged at 1200g (without brake) for 10 min at room temperature. Plas-
ma was transferred to 15 mL micro centrifuge tubes and centrifuged at 2400g for 20 min (with 
brake) at room temperature to remove residual cells. Cell-free plasma was divided into 800 μL 
aliquots and stored at -80⁰C un  l further processing.
Because both sequencing pla  orms require diff erent amounts of input DNA, cell-free 
DNA was isolated from plasma with the EZ1 Virus Mini Kit v2.0 on the EZ1 Advanced (QIAGEN, 
Venlo, The Netherlands; www.qiagen.com) for Helicos sample prepara  on or manually with 
the QiaAmp MinElute Virus Spin Kit (QIAGEN) for Illumina sample prepara  on according to the 
manufacturer’s instruc  ons.
To verify fetal gender and to measure the total quan  ty of cell-free DNA, we respec  ve-
ly performed a pyrophosphoryla  on-ac  vated polymeriza  on assay on the Y chromosome 
(Y-PAP) and a Real-Time Taqman PCR assay on CCR5 for quality control purposes as described 
previously (B  et al., 2007). In addi  on, for male fetuses we es  mated the percentage 
of cff DNA based on sequencing data of chromosome X (F  et al., 2008) and by Real-Time 
Taqman PCR assay on SRY, for which we used a standard curve from male genomic DNA to 
determine the range of cff DNA percentages in maternal plasma. Percentages were es  mated 
by dividing the amount of SRY (pg/μL) by the maternal frac  on of CCR5 from 1 allele (SRY/
(0.5*CCR5total – SRY)), taken into account that the PCR effi  ciency of both genes is similar. 
Library prepara  on and sequencing 
A total of 24 plasma samples was included in this retrospec  ve study, containing 20 
samples from singleton pregnancies, of which 11 cases (5 female and 6 male fetuses) of T21, 
9 cases of disomy (D21) pregnancies (1 female and 8 male fetuses) and 4 plasma control sam-
ples from anonymous adult male blood donors. All samples were de-iden  fi ed to the inves-
 gators before sample prepara  on and data analysis. These results were not revealed to the 
inves  gators un  l a  er data analysis. Material from the invasive procedure was sent to the 
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Cytogene  cs Lab for full karyotyping. Fetal gender was confi rmed by karyotype or a  er birth. 
All cell-free plasma DNA samples were sequenced on both the Helicos (Helicos Bio-
Sciences Corpora  on, Cambridge, MA, USA, www.helicosbio.com) and the Illumina (Illumina 
Inc., San Diego, CA, USA, www.illumina.com) GA II pla  orm. Owing to the rela  vely short 
length  (F  et al., 2008) and fragmented nature of free DNA in plasma, no addi  onal shearing 
step was performed during library prepara  on.
Helicos sample prepara  on was performed according to the manufacturer’s ChIP-Seq 
Direct Tailing Procedure with an input of 400 μL plasma for DNA isola  on with the EZ1 (QIA-
GEN) and the maximum amount of input for tailing. As a quality control, size of the fragments 
and template size distribu  on were determined by running a High Sensi  vity DNA chip on the 
Agilent Technologies 2100 Bioanalyzer. A standard 120-cycle run was performed on the Helis-
copeTM Single Molecule Sequencer, which resulted in an average read length of 35 nucleo  des. 
Illumina sample prepara  on was performed according to the manufacturer’s ChIP-Seq 
protocol with an input of 1600 μL plasma per sample per column for manual DNA isola  on 
and a maximum amount of input for this protocol. Sixteen out of 24 samples were sequenced 
in a duplex assay (T21 n=7, D21 n=7 and male plasma controls n=2). For this, unique synthet-
ic 6 nucleo  de barcodes (indexes) were used. The barcode was ligated to the plasma DNA 
molecule prior to the PCR amplifi ca  on step. Indexed samples were addi  onally purifi ed on a 
3% TAE Agarose gel prior to the quality control run on the Bioanalyzer as men  oned above. A 
36-cycle run was performed on the Illumina GA II.
Data analysis
Helicos sequencing data were analyzed with the Helicos Helisphere resequencing pipe-
line using default se   ngs. Data were aligned against hg19 and gaps and repeats were fi ltered 
out. Filtered data were sorted and binned per 50 kb.
Illumina raw data from duplexed samples were pre-analyzed by spli   ng the data per 
indexed barcode with in-house Linux command lines. Sequencing data were analyzed with 
NextGENe so  ware (So  Gene  cs, State College, PA, USA, www.so  gene  cs.com). Data were 
mapped to the annotated Human Genome GFCh37-dbSNP 131(4/14/2010) (hg19) for Illumina 
data compa  ble with NextGENe so  ware. Expression reports per 50 kb were created. Only 
unique reads with at most 1 mismatch, which could be aligned to the reference genome, were 
used for calcula  ons.
For all samples (both T21 and D21) used for noninvasive fetal trisomy 21 detec  on in 
maternal plasma, ra  os of rela  ve sequence tag density (RSTD) were calculated. First, for each 
sample the total number of reads was calculated per chromosome, by summing the read 
counts of all 50 kb bins belonging to a par  cular chromosome. Second, for each sample, the 
total summed number of reads was normalized by the median value of the autosomes. Finally, 
ra  os of RSTD were calculated by dividing these normalized values by the averaged normal-
ized value of the disomy samples (F  et al., 2008) or, in addi  on, by the normalized average 
of male plasma control samples. As the data were obtained by two separate runs for both 
sequencing technologies, ra  os were determined for each run separately.
Sta  s  cal analysis
Sta  s  cal analysis was conducted with PASW Sta  s  cs version 17.0 (SPSS Inc., Chicago 
IL, USA, www.spss.com), Prism 5 (version 5.00, GraphPad So  ware, Inc. La Jolla CA, USA, www.
graphpad.com) and R version 2.13 (R Development Core Team (2011)). R: A language environ-
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3-900051-07-0, www.R-project.org). Diff erences between the numbers of uniquely mapped 
reads between groups were determined by independent samples T-test. Correla  on between 
the number of reads and RSTD were determined by non-parametric Spearman correla  on. P 
values of less than 0.05 are considered sta  s  cally signifi cant. 
Results
Included samples
A total of 20 maternal plasma samples were included in this study and were taken at a 
median gesta  onal age of 12 +2 weeks (range 9 +3 to 16 +6 weeks). In 4 out of 20 cases blood 
samples were drawn a  er the invasive procedure (on average > 1 week a  erwards). No cor-
rela  on between the  me of sampling (before or a  er the invasive procedure) and the ra  os 
was observed. All details on the included samples are depicted in Table 1. For the noninvasive 
detec  on of fetal T21, DNA isolated from 20 maternal plasma samples and 4 anonymous male 
plasma controls were sequenced on both the Helicos and the Illumina GA II pla  orm. One D21 
sample, that did pass the quality controls prior to sequencing, failed the quality controls a  er 
sequencing for both pla  orms. For this sample hardly any reads were obtained for the Helicos 
pla  orm and sequencing results from the Illumina pla  orm showed preferen  al amplifi ca  on 
of only a few regions. This sample was therefore excluded for further analysis.
Figure 1: Ra  os of normalized rela  ve sequence tag density (RSTD) from all autosomes. 
Ra  os are calculated against averaged normalized read counts from male plasma controls. Data are shown for each 
Next Genera  on Sequencing pla  orm (T21 n=11 and D21 n=8). Chromosomes are ordered by increasing GC content. 




Sample sta  s  cs
For each NGS pla  orm, the mean number of raw reads, the percentage of fi ltered reads 
and the mean and median number of uniquely mapped reads are depicted in Table 2. For 
Helicos, our data show one D21 sample with the overall lowest amount of reads, to have the 
lowest RSTD ra  o, but overall we observed no correla  on between RSTD ra  o and the amount 
of uniquely mapped reads for both pla  orms (Helicos, Spearman r = -0.088, 95%CI [-0.532-
0.394], P = 0.7210 and Illumina, Spearman r = -0.232, 95% CI [-0.629, 0.263], P = 0.3401). Fur-
thermore, the number of uniquely mapped reads between T21 and D21 was similar (Helicos 
P = 0.128 and Illumina P = 0.810). When looking at the duplexed Illumina samples (n=16), no 
bias in read counts was observed towards any specifi c barcode a  er spli   ng (P= 0.9551).
The percentage of cff DNA in maternal plasma was calculated using 2 diff erent methods. 
When using the method based on Illumina sequence data from chromosome X by the group 
of Fan et al. (F  et al., 2008), we es  mated the percentage of fetal DNA for male pregnancies 
(n=6) to be on average ~7% (range 1-18%). Concordant results were obtained by Real-Time 
PCR on the SRY  gene (average ~9%, range 3-18%).
Figure 2: Normalized total number of reads per chromosome against GC content. 
Normalized reads are shown in order of GC content per chromosome (upper panel) and by GC percentage (lower 
panel) for both the Helicos (le  ) and Illumina (right) pla  orm. Chromosomes subject to possible GC bias because of 
high GC content are depicted within dashed lines (upper and lower panel).
Noninvasive T21 detec  on
For the detec  on of noninvasive fetal T21, RSTD ra  os for all 19 maternal plasma sam-
ples are shown per chromosome for each NGS pla  orm (Fig. 1). The autosomes were ordered 
by increasing GC content (Fan et al., 2008). The overall distribu  on of reads across the genome 
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is similar between both pla  orms and seems independent of GC content (data not shown). 
However, our data show a clear diff erence in read coverage between pla  orms. For Helicos, 
the RSTD ra  os for all chromosomes (Fig. 1), the normalized total number of reads per chro-
mosome (Fig. 2) and the average amount of reads per bin (Fig. 3) were quite uniform between 
samples and virtually independent of GC content of the chromosome, while as reported be-
fore (F  et al., 2008), Illumina results showed increased read density  in GC rich areas of the 
genome (Fig. 1-3).
Figure 3. Average read count per 50 kb bin against GC content. 
For both pla  orms, the average number of reads per bin was determined by dividing the summed total number of 
reads by the number of bins. Chromosomes are ordered by GC content. 
Our data show RSTD ra  os for T21 samples in a range of 1.04-1.11 for Helicos and a 
range of 1.03-1.12 for Illumina. For D21 samples we obtained RSTD ra  os from 0.98-1.01 and 
0.99-1.01 respec  vely (Fig. 4). Our data show a clear dis  nc  on between plasma samples from 
women carrying a T21 fetus and woman carrying a D21 fetus for both pla  orms when looking 
at the overrepresenta  on of the aff ected chromosome (Fig. 4). All maternal plasma samples 
of women carrying a fetus with Down syndrome were correctly classifi ed as T21 (n=11). In ad-
di  on, all euploid samples (n=8) were correctly iden  fi ed as D21, resul  ng in a sensi  vity and 
specifi city of both 100% (95% CI [87.0-100]). When construc  ng a 99% confi dence interval of 
the distribu  on of RSTD from all D21 samples, all T21 samples lie outside the upper boundary 
of 1.01 and all D21 samples on or below this boundary. Overall, we show that noninvasive 
detec  on of T21 can be performed on both NGS pla  orms, although Helicos results show a 




Table 2: Overview of mean and median number of uniquely mapped readsA.
Table 2: A Results are indicated by Next Genera  on Sequencing Pla  orm. Data for each pla  orm are represented as 
mean (SD) for n=23 samples. BFor the Illumina pla  orm, the mean number of raw reads and % fi ltered reads is depict-
ed for the duplexed samples n=15 (T21 n=7, D21 n=6, male plasma control n=2).
Calcula  on methods
We have based our calcula  ons on the method of Fan et al. (F  et al., 2008), which 
uses read counts to calculate ra  os of RSTD. Samples can be normalized against averaged 
normalized RSTD from both adult male plasma controls (Fig. 1) or disomy samples (Fig. 4). 
Our results look similar when applying either one of these methods to data from both NGS 
pla  orms. Recently, a new calcula  on method for the detec  on of fetal chromosomal abnor-
mali  es was published by the group of Sehnert et al. (S  et al., 2011). With this method, 
samples can be classifi ed as aff ected (i.e. aneuploid for that chromosome) or unaff ected by 
calcula  ng a normalized chromosome value (NCV) using data from a previously analyzed train-
ing set consis  ng of unaff ected samples (i.e. maternal plasma samples from women carrying 
a euploid fetus). When applying this new calcula  on method to our Illumina data, all Illumina 
samples were again correctly classifi ed as either T21 or D21, within the criteria as described 
(See Supplemental Figure S1) (S  et al., 2011). Since these criteria are only determined 
for Illumina data, they are not applicable on our Helicos results and thus fi rst need to be es-
tablished.
a
Figure 4. Ra  os of normalized rela  ve sequence tag density (RSTD) from chromosome 21. 
Ra  os are calculated against averaged normalized read counts from disomy samples. Data are shown for each Next 
Genera  on Sequencing pla  orm (T21 n = 11 and D21 n = 8).
Pla  orm Mean # of raw reads % of fi ltered 
reads
Mean # of alligned 
reads
Median # of 
alligned reads
Helicos 1.06 x 107 (0.46 x 107) 35.09 (1.52) 4.65 x 106 (3.6 x 106) 2.65 x 106




Noninvasive fetal aneuploidy detec  on using free DNA from maternal plasma has 
evolved drama  cally the past few years with the introduc  on of NGS. The majority of studies 
use the Illumina GA II pla  orm for whole genome shotgun detec  on of T21. Data obtained in 
these studies have shown that limita  ons due to low percentages of cff DNA in maternal plas-
ma, no longer seem to be a major problem. However, the Illumina pla  orm is PCR-based and 
the amplifi ca  on step could ini  ate several nega  ve side eff ects, such as read density bias in 
GC rich areas of the genome.
In this study, we show successful fetal T21 detec  on using free DNA from maternal 
plasma by single molecule sequencing on the Helicos pla  orm and compared it to the Illumi-
na GA II pla  orm (F  et al., 2008; C  et al., 2008; E  et al., 2011; C  et al., 2011a). 
For Illumina, we could confi rm previously described fi ndings (F  et al., 2008). Moreover, we 
demonstrate a more dis  nct separa  on between T21 and D21 samples in Helicos data versus 
Illumina. We show that as early as 9 +3 wks of gesta  onal age, cff DNA samples from maternal 
plasma can be classifi ed correctly with high sensi  vity and specifi city. Because for single mol-
ecule sequencing only small amounts of free DNA are required as input for sample prepara-
 on and direct sequencing is performed, we hypothesize that this method might therefore be 
more suitable for early noninvasive aneuploidy detec  on.  
Also, our study confi rms that data obtained on the Helicos pla  orm is not biased in GC 
rich areas, leading to an increased accuracy of analysis. Previously, a strong correla  on be-
tween GC rich areas and read coverage was observed on the Illumina pla  orm, with increased 
number of reads in areas containing elevated GC content (D  et al., 2008; H  et al., 
2008; F  et al., 2008). There has been discussion whether this is a biological eff ect rela  ng 
to chroma  n structure or originates from PCR ar  facts introduced during sample prepara  on, 
cluster forma  on or the sequencing process itself. Since GC bias is not observed in single mol-
ecule sequencing it is less likely that this is a true biological eff ect or be due to the sequencing 
process. We therefore hypothesize that it is introduced in the pre-amplifi ca  on step for DNA 
enrichment or during local amplifi ca  on for cluster forma  on on the fl ow cell. The exact rea-
son, however, remains to be elucidated.
Before implemen  ng noninvasive trisomy detec  on into rou  ne diagnos  cs several 
quality controls criteria need to be determined and validated. The QUADAS criteria can be 
applied, which take into account the experimental bias and varia  on (W  et al., 2003). 
Equally important are the quality controls before and during sample prepara  on. Since the 
percentage of cell free DNA in maternal plasma diff ers between samples and at diff erent  mes 
of gesta  on (L  et al., 1998; L  et al., 2008a), it is diffi  cult to determine the most appropri-
ate  me of gesta  on for tes  ng. However, for diagnos  cs inclusion criteria including  me 
of gesta  on need to be determined. Measurement of the amount of cff DNA and its correla-
 on to reliable diagnosis and  me of gesta  on needs to be studied more thoroughly in large 
valida  on studies. Before sequencing isolated free DNA, combined Real-Time PCR results on 
CCR5 and SRY could help es  mate the ra  o of maternal and fetal DNA in maternal plasma, 
the percentage of fetal DNA and the quality of DNA as shown in our data. A  er sequencing, 
percentages of cff DNA can then be verifi ed by using data from chromosome X as described 
previously (F  et al., 2008). Both methods however are limited to male pregnancies only. 
When encountering samples containing low percentages of fetal sequences or large amounts 
of contamina  ng maternal sequences, restric  ons for the detec  on limit should be taken into 




gene  c diff erences could be used for quan  fi ca  on (N  et al., 2010), although it needs to 
be established whether diff erences in methyla  on are stable and comparable between indi-
viduals to be used reliably in diagnos  cs. 
Another issue that should be taken into account are maternal copy number varia  ons 
(CNVs). These can be of par  cular interest for the interpreta  on of trisomy detec  on using 
NGS data in diagnos  cs. Pre-determina  on of CNVs in the maternal genome could be an use-
ful control in diagnos  cs, because these fi ndings may infl uence the interpreta  on of data 
when looking at the overrepresenta  on of a specifi c chromosome, regardless the NGS plat-
form used. 
In summary, this study shows for the fi rst  me that single molecule sequencing can 
be a reliable and easy-to-use alterna  ve for noninvasive T21 detec  on in diagnos  cs. By us-
ing single molecule sequencing, previously described experimental noise associated with PCR 
amplifi ca  on, such as GC bias, can be overcome. This method is therefore not only promising 
for noninvasive T21 detec  on, but is poten  ally also useful for the detec  on of other aneu-
ploidies.
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Supplemental fi gure S1. Normalized Chromosome Value for Chromosome 21. 
Normalized Chromosome Value (NCV) for chromosome 21 was calculated according to the method described in Seh-
nert et al. (S  et al., 2011). An NCV > 4.0 was used to classify the sample as aneuploid for chromosome 21 and 
an NCV < 2.5 to classify a chromosome as unaff ected. Samples with an NCV between 2.5 and 4.0 were classifi ed as 
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Abstract
Background:  Noninvasive trisomy 21 detec  on using massively parallel sequencing is 
achievable with high diagnos  c sensi  vity and low false posi  ve rates. Detec  on of fetal tri-
somy 18 and 13 has been reported as well, but seems to be less accurate using this approach. 
Reduced accuracy can be explained by PCR introduced guanine-cytosine (GC) bias infl uencing 
sequencing data. Previously, we demonstrated that sequence data generated by single mol-
ecule sequencing show virtually no GC bias and result in a more pronounced noninvasive de-
tec  on of fetal trisomy 21. In this study, single molecule sequencing was used for noninvasive 
detec  on of trisomy 18 and 13. 
Methods: Single molecule sequencing was performed on the Helicos pla  orm using 
free DNA isolated from maternal plasma from 11 weeks of gesta  on onwards (n=17). Rela  ve 
sequence tag density ra  os were calculated against male control plasma samples and results 
were compared to those of previous karyotyping.
Results: All trisomy 18 fetuses were iden  fi ed correctly with a diagnos  c sensi  vity 
and specifi city of 100%.  However, low diagnos  c sensi  vity and specifi city was observed for 
fetal trisomy 13 detec  on.
Conclusions:   We successfully applied single molecule sequencing in combina  on with 
rela  ve sequence tag density calcula  ons for noninvasive trisomy 18 detec  on using free 
DNA from maternal plasma. However, noninvasive trisomy 13 detec  on was not accurate and 
seemed to be infl uenced by more than just GC content.
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Recent large studies have confi rmed that noninvasive prenatal diagnosis (NIPD) for fe-
tal aneuploidies is achievable (F  et al., 2008; C  et al., 2008; C  et al., 2011a; E  
et al., 2011; P  et al., 2011; L  et al., 2012a; B  et al., 2012). Using massively 
parallel sequencing (MPS) and subsequent quan  fi ca  on of chromosome specifi c sequences, 
overrepresenta  on of a specifi c chromosome can be determined with high diagnos  c accu-
racy. Successful detec  on of fetal trisomy 21 (T21) in maternal plasma was shown in several 
clinical valida  on studies (C  et al., 2011a; P  et al., 2011; E  et al., 2011; L  
et al., 2012a; B  et al., 2012). For noninvasive detec  on of trisomy 18 (Edwards Syn-
drome, T18) and trisomy 13 (Patau Syndrome, T13), however, it seems to be more diffi  cult 
to achieve similar results (C  et al., 2011; L  et al., 2012a; P  et al., 2012; B  
et al., 2012). Although theore  cally molecules from diff erent regions of a genome should be 
sequenced uniformly by MPS, preferen  al amplifi ca  on of sequences, depending on diff erent 
guanine-cytosine (GC) content, has been observed (D  et al., 2008; F  et al., 2008;  
 O  et al., 2012). In contrast to an average GC content of chromosome 21, chromo-
somes 13 and 18 have a rela  vely low GC content (F  et al., 2008;   O  et al., 
2012). Therefore, non-uniform amplifi ca  on of these chromosomes could occur on PCR based 
MPS pla  orms. As a result, several studies have used specifi c algorithms or internal references 
to correct for GC content to op  mize noninvasive detec  on rates for T18 and T13 (C  et al., 
2011; P  et al., 2012; S  et al., 2012a; L  et al., 2012b). 
We previously demonstrated that sequence data generated by single molecule se-
quencing show virtually no GC bias (   O  et al., 2012). This specifi c method of se-
quencing requires no PCR amplifi ca  on step during sample prepara  on or during fl ow cell 
processing and results in a more pronounced noninvasive detec  on of T21. Therefore, this 
approach could also be applicable for the detec  on of other common fetal aneuploidies such 
as T18 and T13. 
To test this hypothesis, a retrospec  ve study was performed on fi rst and second tri-
mester pregnant women with an increased risk for fetal aneuploidy based on previous serum 
screening and/or ultrasound results. Maternal peripheral blood samples were collected in 
EDTA coated tubes and processed within 24 hrs a  er collec  on. All blood samples were drawn 
at a median gesta  onal age of 12 weeks + 6 days (range 11w +4d to 22w +1d, see Table 1) prior 
to an invasive procedure, except for one sample, which was obtained 6 days a  er amniocen-
tesis. Plasma was obtained by double centrifuga  on of the blood samples and stored at -80⁰C 
un  l further processing. Material from all invasive procedures was sent to our cytogene  cs 
laboratory for karyotyping as the gold standard. 
A total of 21 plasma samples were used in this study. Four plasma control samples from 
anonymous male blood donors and 17 samples of singleton pregnancies (Table 1), consis  ng 
of 9 cases of T18 (2 female and 7 male fetuses), 4 cases of T13 (2 female and 2 male fetuses), 
and 4 euploid pregnancies (all male fetuses) were included. All maternal blood samples were 
processed within 24 hrs a  er collec  on. Cell-free DNA was isolated from plasma using the EZ1 
Virus Mini Kit v2.0. For quality control purposes, fetal sex and the total amount of free DNA in 
maternal plasma were determined by Real-Time Taqman PCR assays as described previously 
(B  et al., 2007;   O  et al., 2012). In addi  on, using this data, the percentage of 
cell-free fetal DNA (cff DNA) for male pregnancies was es  mated (   O  et al., 2012). 
All samples were de-iden  fi ed to the inves  gators before sample prepara  on and data anal-
ysis. Libraries were prepared according to manufacturer’s ChipSeq protocol and a standard 





Figure 1. Ra  os of normalized Rela  ve Sequence Tag Density for noninvasive fetal aneuploidy detec  on.
Ra  os were calculated against anonymous male plasma controls (n=4). Samples are divided in either disomic (closed 
symbols) or trisomic (open symbols) for that specifi c chromosome. Chromosome 21 is displayed as circles, chromo-
some 18 as triangles and chromosome 13 as diamonds. 99% Confi dence intervals for disomic samples were calculated 
for each chromosome and upper boundaries are depicted in the graph as a line. Euploid fetuses (n=4), T18 fetuses 
(n=9), T13 fetuses (n=4). ND: Not determined.
Raw data analysis was performed with the HeliSphere so  ware package. Ra  o calcu-
la  ons and sta  s  cs were executed as described previously (   O  et al., 2012). In 
short, for fetal trisomy detec  on, ra  os of rela  ve sequence tag density (RSTD) were calculat-
ed by dividing the normalized total summed number of reads for each sample by the normal-
ized mean of male plasma controls for each chromosome of interest. A  er alignment against 
hg19 reference genome and fi ltering of gaps and repeats a mean of 1.21x106 + 0.69x106 (SD) 
reads, with a median of 1.12x106, were obtained per sample. In 11 maternal plasma samples 
from women carrying a male fetus, the percentage of cff DNA was es  mated, resul  ng in a 
mean percentage of 11 % (Table 1).
For noninvasive T18 detec  on we showed that using RSTD calcula  ons for chromosome 
18, all T18 samples (n=9) were correctly iden  fi ed as being aneuploid and all euploid controls 
and T13 samples as being disomic for chromosome 18. When construc  ng a 99% confi dence 
interval from all samples disomic for chromosome 18 (n=8), all T18 samples were outside the 
upper boundary of the 99% CI [0.991, 1.016], while all euploid controls and T13 samples were 
on or below this upper boundary (Fig. 1). For noninvasive T13 detec  on, only 1 out of 4 T13 
samples was correctly iden  fi ed. False posi  ve results (4/13) were observed in both euploid 
(n=2) and T18 (n=2) samples when using RSTD ra  o and 99% CI calcula  ons for chromosome 
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13, resul  ng in a diagnos  c sensi  vity and specifi city of 25% and 69% respec  vely (Fig. 1). As 
a control we calculated RSTD ra  os for chromosome 21 for all samples tested in this study 
(n=17) using the 99% CI previously published (   O  et al., 2012). All samples tested 
in this study were indeed iden  fi ed as disomic for chromosome 21 (Fig 1). When calcula  ng 
a 99% CI using RSTD results from this study a similar upper boundary was obtained, thus con-
fi rming this result.
As a follow up on noninvasive T21 detec  on using single molecule sequencing, in the 
present study we demonstrated successful noninvasive detec  on of T18 (100% diagnos  c 
sensi  vity and specifi city) using free DNA from maternal plasma from 11w + 4d of gesta  on 
onwards. The mean percentage of cff DNA in maternal plasma in the fi rst trimester was 4.03% 
and we observed an increase in fetal frac  on during the second trimester, with a mean per-
centage of 21.1%. This observa  on is concordant with previous reports (L  et al., 2008a; 
L  et al., 1998). Even though the percentage increased, we s  ll observed quite a large range 
between individuals with an approximate 4-fold change for the second trimester pregnancies, 
up to a 13-fold diff erence between fi rst trimester samples. 
Compared to noninvasive detec  on of T18, our data showed low diagnos  c sensi  vity 
and specifi city for detec  on of T13 using single molecule sequencing. Previous publica  ons 
from other groups also reported reduced diagnos  c sensi  vity and/or specifi city for noninva-
sive T13 detec  on (C  et al., 2011; L  et al., 2012b; P  et al., 2012; B  et al., 
2012). However, the values were not as low as observed in this study. Furthermore, in these 
cases it was thought to be related to the GC content of chromosome 13 given that PCR based 
Next Genera  on Sequencing (NGS) pla  orms were used. As shown in our previous study, data 
for chromosome 13 are biased on such pla  orms (   O  et al., 2012). Chromosome 
13, compared to 18 and 21, has the lowest GC content of all three (38.5%) (D  et al., 
2004). This low GC content could be reason for a misrepresenta  on of the amount of sequenc-
ing reads coming from these PCR based NGS pla  orms. However, in the current study, single 
molecule sequencing results were not infl uenced by a chromosome’s GC content, implying 
that other factors might be involved in lowering the diagnos  c sensi  vity and specifi city for 
noninvasive trisomy 13 detec  on. 
The fetal contribu  on of free DNA in maternal plasma is derived from syncy  otropho-
blasts undergoing apoptosis (A  et al., 2007). Placental apoptosis is a naturally occurring 
process during gesta  on in both normal and abnormal pregnancies, resul  ng in fragmented 
fetal DNA circula  ng in the maternal circula  on (H  et al., 2008; A  et al., 2007). 
Some studies have demonstrated the diff erence in size between fetal and maternal free DNA 
fragments and have even shown that the en  re fetal genome is present (L  et al., 2010). How-
ever, virtually no studies have considered that fetal DNA from chromosomes of diff erent sizes 
and/or those of diff ering GC contents may fragment at diff erent rates. Considering that chro-
mosome 13 is the largest acrocentric chromosome with the lowest gene density among all 
human chromosomes (D  et al., 2004), its stability may diff er from chromosome 18 and 
21. A less stable chromosome is hypothesized to degrade faster, which could lead to a skewed 
number of DNA fragments from this par  cular chromosome in maternal plasma. Also, several 
segmental duplica  ons with at least 90% homology and regions with a high SNP density due to 
the presence of paralogous sequence variants have been shown for chromosome 13 (D  
et al., 2004). This may infl uence data analysis, resul  ng in improper assignment of reads to 
a certain chromosome during alignment. Which factors exactly play a role is not clear at this 
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data are infl uenced by more than just GC content alone. Data analysis for noninvasive fetal 
trisomy 13 detec  on may therefore require a diff erent approach.
In summary, we demonstrate successful noninvasive T18 detec  on using a combina  on 
of single molecule sequencing and rela  ve sequence tag density ra  o calcula  ons, while non-
invasive T13 detec  on is not accurate using this approach.
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The challenge in noninvasive prenatal diagnosis (NIPD) for monogenic disorders lies in 
the detec  on of low levels of fetal variants in the excess of maternal cell-free plasma DNA. 
Next Genera  on Sequencing (NGS), which is the main method used for noninvasive prenatal 
tes  ng and diagnosis, can overcome this challenge. However this method may not be acces-
sible to all gene  c laboratories. Moreover, shotgun NGS as for instance currently applied for 
noninvasive fetal trisomy screening may not be suitable for the detec  on of inherited muta-
 ons. We have developed a sensi  ve, muta  on specifi c and fast alterna  ve for NGS-mediated 
NIPD using PCR methodology. For this proof of principle study, noninvasive fetal paternally 
inherited muta  on detec  on was performed using cell-free DNA from maternal plasma. Pref-
eren  al amplifi ca  on of the paternally inherited allele was accomplished through a personal-
ized approach using a blocking probe against maternal sequences in a high resolu  on mel  ng 
curve analysis (HR-MCA) based assay. Enhanced detec  on of the fetal paternally inherited 
muta  on was obtained for both an autosomal dominant and a recessive monogenic disorder 




Since the successful introduc  on of noninvasive prenatal tes  ng for fetal trisomy 
screening, there has also been a growing request to expand the repertoire for noninvasive 
prenatal diagnos  cs (NIPD). NIPD can be performed on small fragments of cell-free fetal DNA 
(cff DNA) that are present in maternal plasma (L  et al., 1997). On average, from about 7-9 
weeks in gesta  on the amount of cff DNA is suffi  cient to be detected noninvasively in maternal 
plasma (H  et al., 2010). Current clinical applica  on of NIPD include fetal sex determina  on, 
fetal Rhesus D (RhD) determina  on and the diagnosis of several monogenic disorders. For the 
la  er, NIPD can be applied in both autosomal dominant and recessive cases, most effi  ciently 
when the mother does not carry the mutant allele and/or carries a diff erent muta  on com-
pared to the father respec  vely (D  et al., 2014; B -A  et al., 2012).
One of the biggest challenges of noninvasive detec  on of paternally inherited sequenc-
es in the fetus, is the excess of maternal cell-free DNA (cfDNA) in plasma. Here a parallel 
can be drawn towards cancer gene  cs, which faces similar challenges in the need to detect 
mosaic or low level soma  c muta  ons in the presence of excess wild-type sequences (O  
et al., 2010). Deep sequencing approaches using various Next Genera  on Sequencing (NGS) 
pla  orms can be used to overcome these challenges for both NIPD and cancer gene  cs (e.g. 
targeted NGS approaches for both cancer detec  on and therapy) (C  et al., 2013; H -
 et al., 2013; L  et al., 2010). Even though the applica  on of NGS for both these purpos-
es is expanding, currently implementa  on and proper valida  on of novel applica  ons for NGS 
in diagnos  cs is s  ll quite expensive, especially when this method is applied for the detec  on 
of merely 1 or 2 variants. Moreover, NGS may be less suitable for the detec  on of variants in 
certain regions of the genome, such as GC rich regions and repeat areas and may therefore not 
be the most eligible method of choice for muta  on detec  on. Therefore this study is aimed to 
develop an alterna  ve noninvasive paternal muta  on detec  on method that does not require 
NGS. Such an alterna  ve needs to be accessible for gene  c diagnos  c laboratories and needs 
to be sensi  ve enough to detect the low levels of fetal sequences in maternal plasma.
High-resolu  on mel  ng curve analysis (HR-MCA) is a rela  vely simple, fast and low-cost 
technique for genotyping and muta  on scanning and is frequently used in rou  ne molecular 
and cancer diagnos  cs (M  et al., 2007; O  et al., 2010; A  et al., 2009;  
 S  et al., 2009). It combines (asymmetric) PCR with a short post-PCR mel  ng step to 
detect sequence varia  ons using a satura  ng double-stranded DNA binding dye (Montgomery 
et al., 2007). Although HR-MCA is a rela  vely sensi  ve technique, the detec  on of mosa-
ic or low level muta  ons may s  ll be challenging and variant dependent (O  et al., 2015). 
Therefore, varia  ons in tradi  onal HR-MCA methods have been developed to overcome this 
challenge (C  et al., 2005; O  et al., 2010; L  et al., 2010; W  et al., 2011; 
M  et al., 2012). The majority of these studies describe the use of either pep  de nucleic 
acid (PNA) or locked nucleic acid (LNA) probes. Addi  on of such probes to the PCR reac  on re-
sults in clamping or blocking specifi c undesired PCR products by inhibi  ng amplifi ca  on (C  
et al., 2005; O  et al., 2010; L  et al., 2010; W  et al., 2011). LNA is a bicyclic 
high affi  nity nucleic acid analogue that contains a ribonucleoside link between the 2’-oxygen 
and the 4’-carbon atoms with a methylene unit (2’-O,4’-C-methylene bridge) (M  et 
al., 2003; W  et al., 2011). The thermal stability, binding capacity and affi  nity of LNA 
to complementary DNA increases substan  ally with each LNA base incorporated, resul  ng in 
suppressed amplifi ca  on of these complementary sequences (M  et al., 2003; W -
 et al., 2011). More importantly, in case of a mismatch, the LNA probe does not bind 
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to the template with high affi  nity, enabling primer extension and preferen  al amplifi ca  on of 
the allele of interest. This principle of allele specifi c blocking could be of use in NIPD to ob-
tain preferen  al amplifi ca  on of the paternally inherited allele through targeted blocking of 
the maternal allele. By fi rst determining both parental genotypes, target specifi c LNA probes 
against maternal sequences could be designed, enabling preferen  al amplifi ca  on and specif-
ic detec  on of the paternally inherited muta  on in maternal plasma.
In this proof of principle study we describe a fast and sensi  ve alterna  ve for NGS-me-
diated NIPD using a PCR-based methodology. We have explored the use of HR-MCA in combi-
na  on with target specifi c blocking LNA probes to obtain allele specifi c blocking of maternal 
sequences for the enhanced detec  on of the fetal paternally inherited allele in maternal plas-
ma. We show that this novel approach for NIPD can be applied in both an autosomal dominant 
and recessive monogenic disorder. 
Methods
Pa  ents 
Two couples who opted for prenatal diagnosis visited the department of Clinical Genet-
ics. Both mothers underwent an invasive procedure (chorionic villus sampling (CVS)) for pre-
natal diagnosis to determine fetal genotype for a familial muta  on. In case 1, the father was a 
carrier of a pathogenic BRCA2 muta  on (c.5682C>G, p.Tyr1894*). In case 2, both parents were 
carriers of a diff erent heterozygous muta  on in the HBB gene. The mother was heterozygous 
for the HbC muta  on (c.19G>A, p.Glu7Lys) and the father was heterozygous for the HbS muta-
 on (c.20A>T, p.Glu7Val). A previous child was also shown to be a carrier of the HbS muta  on. 
Maternal blood withdrawal was performed at 10+6 and 11+1 weeks of gesta  on for case 1 
and 2 respec  vely a  er informed consent was obtained.
Sample processing 
Maternal (n=2) and paternal (n=1) plasma (input 800 μL) was isolated, processed and 
measured as previously described (   O  et al., 2012). Isolated plasma DNA was con-
centrated to 20 μL using the Zymo Clean & Concentrator™ -5 kit (Zymo Research, Irvine, USA). 
As a control, the total amount of cell-free DNA (fetal + maternal) was determined by Real Time 
PCR detec  on of CCR5 as previously described (B  et al., 2007). A total concentra  on of 
112 pg/μL and 350 pg/μL was obtained for the BRCA2 and HBB case respec  vely. Genomic 
DNA (gDNA) from all parents was isolated from peripheral blood cells using automated iso-
la  on (QIAGEN, Venlo, the Netherlands). Fetal gDNA was isolated from CVS on the QIAcube 
according to manufacturer’s instruc  ons (QIAGEN, Venlo, the Netherlands).
Control samples 
Several posi  ve and nega  ve control samples (gDNA and freshly isolated anonymized 
wild type (WT) plasma DNA) were used to op  mize the assay. All control samples were iso-
lated similarly to the parental DNA samples. For BRCA2 a total of n= 20 control samples were 
analyzed: anonymized WT plasma DNA (n=12), WT gDNA (n=6) and gDNA from individuals 
heterozygous for the BRCA2 muta  on (n=4). For HBB a total of n=23 control samples were 
analyzed: anonymized WT plasma DNA (n=12), WT gDNA (n=4), gDNA heterozygous for HbC 
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(n=2), gDNA heterozygous for HbS (n=2), gDNA homozygous for HbC (n=1), gDNA homozygous 
for HbS (n=1) and gDNA from an individual compound heterozygous for HbC/HbS (n=1).
Assay design 
PCR for HR-MCA was performed using target specifi c primers and a muta  on specifi c 
unlabeled detec  on probe (from now on referred to as “muta  on detec  on probe”) with a 3’ 
C3-spacer (Biolegio, Nijmegen, the Netherlands) and was executed both with and without the 
addi  on of a target specifi c blocking LNA probe (from now on referred to as “target blocking 
probe”) (Exiqon, Vedbaek, Denmark) that binds to the WT or mutant maternal allele. Primer/ 
probe design was based on parental Sanger sequencing results of the region of interest (Table 
1). Amplicons of 117 bp and 115 bp were designed for the detec  on of the familial BRCA2 and 
HBB muta  ons respec  vely using LightScanner Primer Design (Idaho Tech/ BioFire Diagnos-
 cs, Salt Lake City, USA). In both cases, muta  on detec  on probes were designed against the 
forward strand. Target blocking probes were designed against maternal templates in the same 
region as the muta  on detec  on probes and were directed to the reverse strand. 
PCR and HR-MCA 
PCR and HR-MCA without target blocking probe were performed as previously de-
scribed (   S  et al., 2009; A  et al., 2009). In short, asymmetric PCR (to 
preferen  ally amplify the forward strand) was performed in 96-well non-transparent plates 
(Framestar, 4  tude, Surray, United Kingdom) in a total reac  on volume of 10 μL containing 
1x LightScanner Master mix (Idaho Tech/ BioFire Defense), 5 pmol forward primer, 1 pmol 
reverse primer, 5 pmol muta  on detec  on probe and 2 ng gDNA template. Primer specifi c 
op  mal annealing temperature (Ta) for both primer sets was determined using a PCR gradient 
(58-64°C). Asymmetric PCR was performed with a reverse primer, forward primer and muta-
 on detec  on probe ra  o at 1:5:5 respec  vely. All samples were tested in duplicate. A range 
from 50 to 98°C was used for HR-MCA mel  ng. Melt temperature (Tm) of normalized mel  ng 
peaks was determined using the unlabeled probe genotyping analysis tool of the LightScan-
ner so  ware (Idaho Tech/ BioFire Diagnos  cs, Salt Lake City, USA). Target blocking probe was 
 trated into each reac  on in a muta  on detec  on probe to target blocking probe ra  o from 
1:1 to 1:10 (i.e. 5-50 pmol/reac  on) and op  mized for each set. Cycling protocol for tes  ng 
the target blocking probe was 95°C for 5 min, 50 cycles of 10 s at 95°C, 20 s at 72°C and 30 s at 
the primer specifi c Ta of 58°C or 63°C for BRCA2 and HBB respec  vely to obtain target blocking 
probe binding prior to amplifi ca  on (modifi ed from Oh et al.) (O  et al., 2010).
Determining the detec  on limit of the assay 
As a control, the detec  on limit of the assay was determined using a mix of paternal 
gDNA (muta  on carrier (MUT)) heterozygous for the familial muta  on and maternal gDNA for 
each case, mimicking an ar  fi cial pregnancy (with the paternal gDNA represen  ng the fetus). 
A rela  ve serial dilu  on range from 33% to 1% paternal gDNA mixed into maternal gDNA was 
created using a total amount of ~425 pg mixed gDNA (maternal and paternal) per reac  on. 
Both parental samples were also tested separately (100% paternal or 100% maternal gDNA). 
All samples were tested in duplicate using the op  mal ra  o of muta  on detec  on probe to 
target blocking probe of 1:5 and 1:2 for BRCA2 and HBB respec  vely in each PCR reac  on.
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Condi  ons for tes  ng maternal plasma samples 
Maternal plasma samples were tested together with corresponding parental gDNA, 
CVS gDNA and several posi  ve and nega  ve controls (see Control samples) using the cycling 
protocol for target blocking probes. When tes  ng plasma samples total reac  on volume was 
increased 1.5x enabling an input of 7.5 μL of concentrated plasma DNA template per reac  on. 
Plasma samples were tested at least in duplicate. Total gDNA input per reac  on for control 
samples was 2 ng. Results were confi rmed in at least 2 independent tests.
Results
Op  miza  on of HR-MCA 
To op  mize parameters for HR-MCA muta  on scanning using a muta  on detec  on 
probe, DNA samples from all parents and several controls with known genotypes (anonymized 
plasma DNA and gDNA) were u  lized. With the op  mal Ta for the primers determined (i.e. 
58°C or 63°C for BRCA2 and HBB respec  vely), the target blocking probes specifi c for the 
maternal allele(s) were tested subsequently, together with the muta  on detec  on probe. The 
selected PCR condi  ons used for tes  ng the target (WT) specifi c blocking LNA probes enabled 
binding of the target blocking probe to unwanted target sequences prior to primer extension 
(Fig. 1). To determine op  mal concentra  ons, target blocking probe was  trated into each PCR 
reac  on, resul  ng in op  mal ra  os of muta  on detec  on probe to WT target blocking probe 
of 1:5 and 1:2 for BRCA2 and HBB respec  vely. 
Figure 1: Principle of target blocking LNA probe binding in HR-MCA. 
Target blocking probes designed against maternal wild type (WT) sequences are able to bind denatured single stranded 
WT sequences. No primer extension and amplifi ca  on can occur (blue arrow, red cross). In case of a muta  on (*) target 
blocking probes will not bind to paternal mutant (MUT) sequences (blue cross), enabling primer extension and amplifi -
ca  on. 
Next, we determined the detec  on limit of this assay. For each case, paternal (MUT) 
gDNA was mixed into maternal gDNA mimicking an ar  fi cial pregnancy using amounts of 
gDNA resembling the quan   es of cfDNA found in maternal plasma early in gesta  on. With-
out the addi  on of a target blocking probe, a dilu  on eff ect is observed in the detec  on signal 
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of the MUT allele, while the detec  on signal of the WT specifi c mel  ng peak was increased 
because of the high background of WT sequences (Fig. 2A). Without blocking, the mutant 
allele could no longer be detected in a rela  ve paternal gDNA percentage of ~16% and lower 
(i.e. ~10 genome equivalents (GE), based on a conversion factor of 6.6 pg of DNA per cell). 
However, addi  on of a target blocking probe directed against maternal sequences resulted 
in preferen  al amplifi ca  on and enhanced detec  on of the paternal muta  on at ~1% - 2% 
paternal gDNA (i.e. ~0.5-2 GE) in a background of maternal sequences. 
Figure 2: HR-MCA results using the BRCA2 muta  on detec  on probe. 
Panel A: Without target blocking LNA probe: Gray: Wild type (WT) plasma DNA; Red: heterozygous paternal gDNA; 
Blue: control paternal gDNA (25%) diluted in WT maternal gDNA. Panel B: With target blocking LNA probe: WT signal 
is blocked (arrow). Gray: maternal WT gDNA; Red: heterozygous CVS gDNA; Blue: heterozygous paternal gDNA; Green: 
maternal plasma. 
Tes  ng maternal plasma samples 
Paternal muta  on detec  on was performed on total cfDNA from maternal plasma using 
a muta  on detec  on probe and target blocking probe(s) for selec  ve blocking of maternal 
template amplifi ca  on during PCR amplifi ca  on. 
For case 1, results from WT plasma DNA show that with the use of only the BRCA2 
muta  on detec  on probe, one WT specifi c normalized mel  ng peak is present in HR-MCA, 
as expected in a WT individual, with a Tm calling at around 66°C (Fig. 2A, gray line). Paternal 
gDNA shows two mel  ng peaks, with a Tm calling at 66°C for the WT and 72° for the BRCA2 
MUT specifi c peak respec  vely, as expected for an individual heterozygous for this muta  on 
(Fig. 2A, red line). Similar results were obtained for paternal plasma (data not shown). As a 
control we mixed heterozygous paternal gDNA with maternal WT gDNA (25% paternal gDNA 
in 100% maternal gDNA). As expected, without the use of a target blocking probe a dilu  on 
eff ect of the MUT specifi c mel  ng peak was observed (Fig. 2A, blue line). The detec  on signals 
were skewed towards detec  on of the WT specifi c mel  ng peak as also previously observed 
in the aforemen  oned serial dilu  on range of mixed parental gDNA. To improve paternal mu-
ta  on detec  on, we used a WT target blocking probe together with the BRCA2 muta  on de-
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tec  on probe, resul  ng in inhibi  on of amplifi ca  on of the WT BRCA2 allele during PCR (Fig. 
2B, arrow). As a result, the BRCA2 muta  on detec  on probe can no longer detect a WT PCR 
product in HR-MCA as shown for WT maternal gDNA (Fig. 2B, gray line). In CVS (red line) and 
paternal (blue line) gDNA samples heterozygous for the BRCA2 muta  on, only the BRCA2 MUT 
specifi c normalized mel  ng peak could be detected (Fig. 2B). In the maternal plasma sample, 
the paternally inherited muta  on in the fetus could only be detected when the maternal WT 
template was blocked, showing that for this muta  on, the addi  on of a single target specifi c 
blocking LNA probe is suffi  cient to enhance the detec  on of the paternally inherited BRCA2 
muta  on (Fig.2B, green line).
Figure 3: Representa  on of the HR-MCA mel  ng peak pa  erns for HBB from controls, parents and fetus using the 
HbS muta  on detec  on probe. 
Panel A: Selec  on of the posi  ve and nega  ve controls scanned for op  miza  on of se   ngs for HR-MCA tested with-
out a target blocking LNA probe. Gray: Wild type (WT); Dark blue: control homozygous for HbS; Red: control homozy-
gous for HbC; Light blue: control compound heterozygous for HbS/HbC. Panel B: Mel  ng peak pa  erns of maternal 
(red; heterozygous for HbC), paternal and CVS gDNA (blue; both heterozygous for HbS), without addi  on of a target 
blocking LNA probe to the PCR reac  on. Panel C: Samples tested with WT target blocking LNA probe directed to block 
only the maternal WT sequences (arrow). Gray: WT gDNA; Blue: paternal gDNA heterozygous for HbS; Red: maternal 
gDNA heterozygous for HbC; Green: maternal plasma. Panel D: Addi  onal blocking with an HbC target blocking LNA 
probe directed to the maternal HbC allele together with a WT blocking LNA probe (arrows). Gray: maternal gDNA 
heterozygous for HbC; Blue: paternal gDNA heterozygous for HbS; Green: maternal plasma. 
For case 2, the situa  on is more challenging. In this case both parents carry a diff erent 
muta  on in the HBB gene. These muta  ons even aff ect the same codon and the posi  on of 
the muta  ons is only 1 bp apart. As a result, the template region covered by the paternal HbS 
muta  on detec  on probe, also covers the adjacent maternal HbC muta  on. When using only 
this HbS muta  on detec  on probe (Fig. 3A and 3B, without LNA), results from parental, CVS 
and control gDNA samples show a specifi c normalized mel  ng peak pa  ern in the HR-MCA as-
say for all 3 diff erent alleles (HbC, WT and HbS with Tm calling at 62, 66 and 70°C respec  vely
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Figure 4: Family pedigrees from par  cipa  ng couples. 
Panel A: Case 1: Both father and fetus are heterozygous for BRCA2 muta  on c.5682C>G, p. Tyr1894*. Panel B: Case 2: 
Both parents are heterozygous for a diff erent muta  on in the HBB gene. Mother is heterozygous for c.19G>A, p.Glu-
7Lys (HbC), while father, daughter and the fetus are heterozygous for c.20A>T, p.Glu7Val (HbS).
(Fig. 3A and 3B). As expected, maternal gDNA shows a mel  ng peak for the HbC and WT allele, 
since mother is heterozygous for HbC muta  on (Fig. 3B, red line). Results from paternal gDNA 
(heterozygous for the HbS muta  on) show two peaks for both the WT and HbS allele respec-
 vely (Fig. 3B, blue line). CVS gDNA displays a pa  ern similar to father (Fig. 3B, blue line). 
Table 1: Primer and probe sequences.
Table 1: Primer and probe sequences used for PCR and HR-MCA. 
Forward (F) and reverse (R) primers are depicted for both cases. Muta  on detec  on probes (P) contain a 3’ C3-spacer 
(Me*). LNA (locked nucleic acid) modifi ed bases in the target blocking probes are depicted with + prior to the base. 
Target blocking probes were designed to perfectly match maternal sequences. Posi  on of the altered nucleo  de is 
underlined. 
The addi  on of a WT target (HBB) blocking probe to the PCR reac  on, completely blocked 
amplifi ca  on of the WT HBB allele. As expected, no PCR product can be detected by the HbS 
muta  on detec  on probe in WT control plasma DNA (data not shown) and WT gDNA (Fig. 3C, 
gray line and arrow), while in heterozygous maternal and paternal gDNA only the HbC and HbS 
MUT peaks are visible (Fig. 3C, red line (HbC) and blue line (HbS) respec  vely). More impor-
tantly, results from maternal plasma show that blockage of only the maternal WT HBB allele 
is not suffi  cient to detect the fetal paternally inherited HbS muta  on (Fig. 3C, green line). In 
maternal plasma only the maternal HbC specifi c mel  ng peak is visible, since the excess of 
HbC allele is not blocked by the WT HBB target blocking probe (Fig. 1). Hence, an HbC target 
Descrip  on Sequences 5’- 3
BRCA2_NIPD_MCA_F 5’-CAA CGA GAA TAA ATC AAA AAT TTG-3’
BRCA2_NIPD_MCA_R 5’-TGC GTG CTA CAT TCA TCA TTA-3’
BRCA2_NIPD_MCA_P_Me* 5’-CCG TCC AAC AAT CCT CCG TAA CCT-3’
BRCA2_LNA (WT) 5’-T+T+G+T+TA+C+G+A+G+GC-3’
HBB_NIPD_MCA_F 5’-GAC ACA ACT GTG TTC ACT AGC A-3’
HBB_NIPD_MCA_R 5’-CCA CCA ACT TCA TCC ACG TTC A-3’
HBB_NIPD_MCA_P_Me* 5’-GCA GAC TTC TCC ACA GGA GTC AG-3’
HBB_LNA1 (WT) 5’-+T+G+A+C+TC+C+T+G+A+G-3’
HBB_LNA2 (HbC) 5’-C+T+C+C+T+A+A+G+G+A+G-3’
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blocking probe was designed and addi  onally  trated into the PCR reac  ons together with 
both the HbS muta  on detec  on probe and the WT (HBB) target blocking probe. The op  mal 
ra  o between HbS muta  on detec  on probe, WT target blocking probe and HbC target block-
ing probe per reac  on was shown to be 1:2:2 respec  vely. As expected, no signal is detected 
in maternal gDNA (Fig. 3D, gray line) when simultaneously blocking WT and HbC templates 
(Fig. 3D, arrows). In paternal gDNA only the HbS peak is visible (Fig. 3D, blue line). Subsequent-
ly, in maternal plasma the paternally inherited HbS muta  on in the fetal cfDNA can now be 
detected a  er simultaneously blocking amplifi ca  on of both maternal WT HBB and HbC allele 
(Fig. 3D, green line). 
For both case 1 and case 2, successful detec  on of the fetal paternally inherited muta-
 on in maternal plasma was achieved using this LNA-mediated targeted blocking approach in 
HR-MCA for NIPD. In case 1 this meant that the fetus would be aff ected and in case 2 the fetus 
would either be a carrier or aff ected with the disease. All results were concordant to Sanger 
sequencing results from CVS derived gDNA obtained a  er invasive procedures. (Fig. 4). 
Discussion
The use of cff DNA isolated from maternal plasma for prenatal molecular tes  ng or di-
agnos  cs has increased rapidly. Noninvasive prenatal tes  ng (NIPT) for fetal trisomy screening 
has been introduced successfully in the past few years. Maternal plasma is easily obtainable 
and very early in pregnancy suffi  cient amounts of cff DNA are present. All this, together with 
the low risk for the fetus and con  nuous improvements of detec  on methods, have provided 
many advances for the use of NIPD in favor of invasive tes  ng procedures early in gesta  on 
(D  et al., 2014).
Advantage and applica  on of the HR-MCA approach in NIPT
In this proof of principle study, we demonstrate the use of LNA target specifi c block-
ing probes in HR-MCA. These target blocking LNA probes are directed against maternal back-
ground sequences in order to enhance the detec  on of fetal paternally inherited muta  ons 
in maternal plasma DNA. We choose to explore this approach since this methodology is sen-
si  ve, muta  on specifi c and has a short turnaround  me. Moreover, HR-MCA is easy to im-
plement in diagnos  cs and also equipment that is required to perform HR-MCA is rela  vely 
inexpensive. This makes this method more manageable for gene  c laboratories rather than 
for example an NGS mediated approach. 
High throughput whole genome shotgun sequencing as currently performed for NIPT 
is not effi  cient for the detec  on of a single paternally inherited muta  on since this method 
will require a much higher ver  cal coverage of the data than currently is obtained. Targeted 
sequencing may be a good alterna  ve NGS method to use for muta  on detec  on since good 
ver  cal coverage can be obtained. Pooling of mul  ple samples is required to obtain cost re-
duc  on. However, in case of prenatal tes  ng, a short turnaround  me is demanded. Therefore 
batching of samples might not always be feasible because of insuffi  cient sample number. The 
advantage of HR-MCA is that it can always be performed within a short turnaround  me re-
gardless of the sample number.
When performing paternally inherited muta  on detec  on using this novel HR-MCA 
based approach in NIPD, for autosomal dominant disorders it is restricted to cases where the 
mother does not carry the muta  on, while for autosomal recessive disorders mother and 
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father should carry diff erent muta  ons (D  et al., 2014). In this proof of principle study, we 
have pursued a personalized approach and we have used these diff erences in parental geno-
type to design target blocking LNA probes for use in HR-MCA which are specifi cally directed 
against the maternal sequences. This way, amplifi ca  on of maternal cfDNA in plasma, includ-
ing the maternally inherited fetal allele, will be blocked, providing enhanced sensi  vity and 
specifi c detec  on of paternally inherited muta  ons by muta  on specifi c detec  on probes. 
Such an approach could be a fi rst step towards expanding the current repertoire for NIPD to-
wards a more general applica  on by detec  ng recurrent pathogenic muta  ons or genotypes 
linked to a pathogenic haplotype.
Detec  on of paternally inherited muta  ons in maternal plasma DNA using HR-MCA. 
In this study, we describe the applica  on of this approach for 2 diff erent cases; one 
autosomal dominant (BRCA2) and one autosomal recessive monogenic disorder (HBB). While 
for case 1 (BRCA2) maternal sequences could be blocked with the use of only a single blocking 
LNA probe, for case 2 (HBB) the situa  on was more challenging. Both parents were heterozy-
gous for a diff erent muta  on in the HBB gene and these muta  ons involved the same codon/
amino acid by aff ec  ng a bp subs  tute 1 bp apart. Therefore, the template region covered by 
the HbS specifi c detec  on probe and the WT specifi c blocking LNA probe, also covered the 
adjacent maternal HbC muta  on. Consequently, this implicated that the WT specifi c blocking 
LNA probe would have a mismatch on the other maternal (HbC) allele and amplifi ca  on of 
this HbC allele could therefore s  ll occur. Blocking only the maternal WT allele in this case ap-
peared insuffi  cient for selec  ve detec  on of the paternally inherited muta  on because of the 
excess of amplifi ed HbC specifi c template in maternal plasma a  er PCR. Both the maternal WT 
and HbC alleles needed to be blocked simultaneously to provide enough background reduc-
 on of maternal cfDNA to detect the paternally inherited muta  on in the fetus. Considering 
the recessive inheritance of the disease, addi  onal confi rma  on of the actual fetal genotype 
through an invasive procedure was s  ll required for this case, to determine whether the fetus 
would be aff ected or a carrier of the disease. Nevertheless, in cases where the paternally in-
herited muta  on is excluded an invasive procedure could be avoided using this approach (in 
~ 50% of the cases).
Applying HR-MCA method in NIPD. 
As shown in this study, this method can be used successfully for NIPD. Do note that ad-
di  onal controls to confi rm the presence of cff DNA in plasma are essen  al in NIPD to exclude 
false nega  ve results, especially when no paternally inherited muta  on was detected (B  
et al., 2007;   O  et al., 2013). Due to the fragmented nature of circula  ng cfDNA, 
there is a restric  on for designing primers and probes. Fetal cfDNA is on average around 143-
146 bp in size, which limits amplicon size for PCR (L  et al., 2010).
HR-MCA has previously been proposed as a useful method for NIPD (Y  et al., 
2013; M  et al., 2012; P  et al., 2012). In these studies no blocking LNA probe was 
used. The use of a blocking LNA probe could however be essen  al for the detec  on of fetal 
muta  ons in case of low fetal frac  on or for the detec  on of more challenging muta  ons. In 
the study of Yenilmez and colleagues HR-MCA without a blocking LNA probe was performed 
and was not successful in case of early gesta  on (Y  et al., 2013). Levels of cff DNA 
may diff er extensively between individuals and have been described to increase as gesta  on 
progresses (L  et al., 1998; L  et al., 2008a). Early in gesta  on, fetal paternally inherited 
variants may not be dis  nguished from the maternal background, since the levels of cff DNA 
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are too low to detect. We have previously shown  that the lowest detectable frac  on of a var-
iant or mosaic by a conven  onal HR MCA approach (without a blocking probe) is very variant 
dependent and can be limited to only 25% (O  et al., 2015) Therefore, it will be par  cularly 
challenging for some variants to be detected at low levels of template DNA, not only in gDNA 
but especially in plasma DNA. For future NIPD, the use of target blocking probes to block the 
amplifi ca  on of undesired PCR products may therefore be extremely useful for muta  on de-
tec  on early in gesta  on, if not essen  al. 
In summary, in this proof of principle study we have successfully demonstrated a PCR-
based target specifi c detec  on HR-MCA approach that is suitable for the detec  on of pater-
nally inherited muta  ons in cff DNA from maternal plasma by making use of a target specifi c 
LNA blocking probe. We have used a personalized approach by designing primers, paternal 
allele specifi c muta  on detec  on probes and maternal allele specifi c target blocking probes 
based on parental sequences. The applica  on of this method was shown for NIPD in both an 
autosomal dominant and recessive monogenic disorders and can be used as a sensi  ve and 
fast alterna  ve for NGS-based approaches.
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Abstract
Objec  ve:  With a shi   towards noninvasive tes  ng, we have explored and validated the 
use of noninvasive prenatal diagnosis (NIPD) for Hun  ngton disease (HD).
Methods: Fi  een couples have been included, assessing a total of n=20 pregnancies. 
Fetal paternally inherited CAG repeat length was determined in total cell-free DNA from ma-
ternal plasma using a direct approach by PCR and subsequent fragment analysis.
Results: All fetal HD (n=7) and intermediate (n=3) CAG repeats could be detected in 
maternal plasma. Detec  on of repeats in the normal range (n=10) was successful in n=5 cases 
where the paternal repeat size could be dis  nguished from maternal repeat pa  erns a  er 
fragment analysis. In all other cases (n=5) the paternal peaks coincided with the maternal 
peak pa  ern. All NIPD results were concordant with results from rou  ne diagnos  cs on fetal 
genomic DNA from chorionic villi.
Conclusion: In this valida  on study we demonstrated that all fetuses at risk for HD could 
be iden  fi ed noninvasively in maternal plasma. Addi  onally, we have confi rmed results from 
previously described case reports that NIPD for HD can be performed using a direct approach 
by PCR. For future diagnos  cs, parental CAG profi les can be used to predict the success rate 




Hun  ngton disease (HD, OMIM #143100) is an autosomal dominant progressive neuro-
degenera  ve disorder, characterized by irrepressible motor symptoms, cogni  ve impairment 
and psychiatric disturbances (L  et al., 2004). HD is caused by the expansion of a poly-
morphic trinucleo  de (CAG)n repeat in exon 1 of the hun  ng  n (HTT) gene (previously known 
as IT15) which is located on chromosome 4p16.3 (T  H ’  D  C  
R  G , 1993). CAG repeats are classifi ed in 3 major categories: Alleles < 27 CAG re-
peats are classifi ed as normal, the range between 27 and 35 as intermediate and > 36 repeats 
as causing HD. Repeats in the intermediate range can be unstable and may expand into the 
aff ected range over genera  ons, predominantly upon paternal germline transmission (S  
et al., 2010). As a consequence, the off spring is at risk for developing HD.
Prospec  ve parents in families with HD may opt for prenatal tes  ng which can be ac-
complished via in vitro fer  liza  on (IVF) in combina  on with preimplanta  on gene  c diagno-
sis (PGD) or prenatal molecular tes  ng. The la  er op  on can be performed either by means of 
a direct approach, tes  ng the expanded CAG repeat and/or by linkage analysis of informa  ve 
markers (  D -S  et al., 2013). In contrast to PGD, prenatal molecular tes  ng is of-
fered by many labs (  D -S  et al., 2013). Prenatal diagnosis for HD, as for many other 
gene  c disorders, is performed on fetal DNA derived from invasive procedures such as chori-
onic villus sampling (CVS) or amniocentesis. These procedures are associated with a small but 
signifi cant procedure-related risk of fetal loss of ~0.5-1% (N  et al., 1994; T  et al., 
2010). A  er the discovery of the presence of circula  ng cell-free fetal DNA (cff DNA) in mater-
nal plasma, a shi   towards noninvasive prenatal diagnosis (NIPD) occurred as an alterna  ve 
for prenatal tes  ng (L  et al., 1997). Several NIPD studies have since been incorporated into 
daily clinical prac  ce, including fetal sex determina  on, fetal Rhesus D (RHD) determina  on 
and the diagnosis of monogene  c disorders caused by single muta  ons or small duplica  ons/
dele  ons (D  et al., 2014;   O  et al., 2013). However, only a few case studies 
have been repor  ng on disorders caused by the expansion of large polymorphic trinucleo  de 
repeats. Four previous papers from one group describe NIPD for a total of 7 unique cases of 
fetuses at risk for HD (G -G  et al., 2003a; G -G  et al., 2003b; 
G -G  et al., 2008; B -A  et al., 2012). In these studies a direct 
approach for NIPD was used by determining paternally inherited fetal CAG repeat length in 
maternal plasma using (semi-)quan  ta  ve fl uorescent polymerase chain reac  on. In 5 out of 
these 7 cases this direct approach was applied successfully.
All diagnos  c tes  ng for HD in the Netherlands is performed in our facility. Due to a 
general shi   towards less invasive sampling techniques in the Netherlands, there is also an 
appeal for NIPD for HD. Here we describe a valida  on study for the detec  on of the paternally 
inherited CAG repeat in maternal plasma for fetuses at risk for HD.
Pa  ents and Methods
Pa  ents 
From 2010 onwards, pregnant couples of which the male was at risk for developing HD 
and op  ng for prenatal diagnosis, were asked to par  cipate in this study and to provide ad-
di  onal blood samples for NIPD. Inclusion criteria for this study were (1) only the prospec  ve 
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father is a carrier for a CAG repeat in the intermediate or HD range, (2) a singleton pregnancy 
with a gesta  onal age from 8 weeks onwards and (3) signed informed consent. Exclusion cri-
teria for par  cipa  on were (1) invasive procedure performed prior to blood sampling, (2) fetal 
demise at the  me of blood sampling, (3) inability to understand the study informa  on and (4) 
age at  me of sampling < 18 yrs. Sixteen couples directly met all inclusion criteria men  oned 
above. Two cases were excluded a  erwards: one pregnancy resulted in early fetal demise af-
ter blood sampling and subsequent karyotyping revealed triploidy. The blood sample from the 
other pregnancy did not contain fetal DNA. One couple was included later in pregnancy. In this 
case, a period of > 4 wks between the invasive procedure and blood sampling was considered 
suffi  cient to exclude procedure related eff ects on cff DNA levels in maternal plasma. In total 15 
couples were included in this study assessing 20 plasma samples from singleton pregnancies 
(Table 1). For 14 couples, full CAG repeat profi les from genomic DNA (gDNA) analysis were 
available for both parents. For 1 couple only the maternal profi le was known. The father was 
at 50% risk for developing HD and at the  me of prenatal diagnosis he refrained from molec-
ular gene  c tes  ng. Wri  en informed consent was obtained for all cases and all procedures 
were approved by the ethical standards of the Medical Ethics Commi  ee (METC) of the Leiden 
University Medical Center. 
Sample prepara  on 
Maternal blood withdrawal was performed from 8 weeks of gesta  on onwards (range 
7+6 – 16+1 wks+days, see Table 1). Maternal plasma was processed within 24 hrs a  er with-
drawal and total cell-free DNA from plasma (input 800 μL) was isolated as previously described.
(   O  et al., 2012) Isolated cell-free DNA was concentrated to 20 μL using the Zymo 
Clean & Concentrator™-5 kit (Zymo Research, USA). Paternal plasma (n=4) was obtained and 
processed similar to maternal plasma and was used as a control during op  miza  on. Paren-
tal gDNA was isolated from peripheral blood cells using automated isola  on (QIAGEN, the 
Netherlands). Fetal gDNA from CVS was isolated on the QIAcube according to manufacturer’s 
instruc  ons (QIAGEN, the Netherlands). 
PCR amplifi ca  on and fragment analysis: 
A combina  on of PCR and subsequent automated fragment analysis was used to de-
termine CAG repeat size. PCR for NIPD was performed in a fi nal reac  on volume of 25 μL 
containing 5 μL of concentrated plasma DNA, 5 pmol of each primer (modifi ed from Warner 
et al. (W  et al., 1993); Fw (HD1*): 5’ 6-FAM*-ATG AAG GCC TTC GAG TCC CTC AAG TCC 
TTC-3’ and Rev (HD3): 5’-GGC GGT GGC GGC TGT TGC TGC TGC-3’ (Biolegio, the Netherlands)) 
and 12.5 μL OneTaq Hot Start 2x Master Mix with GC buff er (New Engeland Biolabs, USA). 
Cycling condi  ons were 94°C for 5 min, 40 cycles of 94°C 30 sec, 63°C 1 min and 68°C 2 min, 
followed by a fi nal extension at 68°C for 5 min. Each maternal plasma sample was tested in 
duplicate. In case of inconclusive results (i.e. no paternally inherited allele was detected), the 
test was repeated. Subsequent automated fragment analysis was performed on the 3130XL 
Gene  c Analyzer (Applied Biosystems, USA) using Gene Scan™ 500 LIZ Size Standard (Applied 
Biosystems) and data was analyzed with GeneMarker So  ware version 2.4.0 (So  gene  cs, 
USA) using an empirical determined and validated panel to convert fragment length (bp) into 
the number of CAG repeats. Fetal gDNA from CVS and parental gDNA samples (input 1 ng 
gDNA per reac  on) were also tested with this NIPD protocol as addi  onal controls. Findings 
from NIPD on maternal plasma were compared to results from rou  ne prenatal diagnosis 
using fetal gDNA from CVS. All diagnos  c tes  ng for HD in our facility is performed under the 
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guidelines of the European Molecular Gene  cs Quality Network and the Clinical Molecular 
Gene  cs Society (EMQN/CMGS).
Figure 1: Representa  ve results for direct CAG repeat analysis on maternal plasma for 3 diff erent pregnancies. 
In each panel, the top part represents the result from maternal gDNA. The bo  om part represents results from mater-
nal plasma with the fetal paternally inherited repeat size indicated with *. Panel A: Family 78457; Fragment analysis 
on maternal plasma shows maternal CAG repeat of 17 and 22 together with the fetal paternally inherited repeat of 
40 CAG repeats (insert). Panel B: Family 56092; The maternal profi le of 18 and 20 CAG repeats is shown with a third 
dis  nct peak at 15 CAG repeats corresponding to the paternally inherited allele of the fetus. Panel C: Family 8062; 
Results show a maternal CAG repeat of 17 and 23. The paternally inherited fetal repeat of 15 CAG repeats coincides 
with the maternal stu  er peak pa  ern and could not be confi rmed.
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All fetal paternally inherited HD (n=7) and intermediate (n=3) CAG repeats could be de-
tected in one or more replicates in maternal plasma (Table 1, Figure 1A). In our study, the CAG 
repeat had contracted upon transmission in two cases and expanded in two cases. The longest 
fetal repeat present in this cohort was 70 CAG repeats (Table 1). Transmission of repeats in the 
normal range could be detected in 50% of the cases (n=5). These repeat sizes were either at 
least 2 repeats larger or 3 repeats smaller than the nearest maternal CAG repeat (Figure 1B). In 
all other cases (n=5) results were inconclusive because either both parents shared a par  cular 
repeat size or the paternally inherited peak coincided with the maternal stu  er peak profi le in 
fragment analysis and could therefore not be dis  nguished (Figure 1C). All NIPD results were 
concordant to results obtained in rou  ne prenatal diagnosis using fetal gDNA from CVS. The 
accuracy of this NIPD test is 100%, provided this test is performed in duplo or triplo.
Discussion and Conclusions
In the past few years, the use of NIPD in a clinical se   ng has already been established 
for applica  ons such as fetal sexing and RhD detec  on. Nevertheless, li  le is known yet about 
NIPD for disorders caused by polymorphic repeat expansions, such as HD. In this valida  on 
study for NIPD of HD, we show that we can indeed detect paternally inherited CAG repeats in 
maternal plasma. We have hereby not only confi rmed the results from previously described 
case studies reported by González-González et al. and Bustamante-Aragones et al., we have 
also extended the number of cases tested (G -G  et al., 2003a; G -G -
 et al., 2003b; G -G  et al., 2008; B -A  et al., 2012). 
Moreover, we show that NIPD for HD can also be used for successful detec  on of interme-
diate repeats in addi  on to normal and HD repeats. We did experience the same technical 
limita  ons for the detec  on of extremely large HD repeats and repeats in the normal range as 
previously described.
The success of detec  ng the paternal repeat in maternal plasma is infl uenced by sev-
eral factors. Detec  on depends on the diff erence in size between the paternal and maternal 
repeats. Irrespec  ve of the size range of the transmi  ed repeat (e.g. normal, intermediate 
or HD), our study shows that the paternal repeat can be detected in maternal plasma when 
there was a suffi  cient diff erence in size between paternal and maternal repeats. With respect 
to par  ally informa  ve couples (i.e. parents share an allele size), this would mean that in NIPD 
only the extended paternal allele can be discriminated from the maternal profi le. In case of 
informa  ve couples (i.e. parents have 4 diff erent CAG repeats) on the other hand, the ter-
minology “informa  ve” may be misleading in some cases. Even though in theory 4 diff erent 
parental repeat sizes imply a high detec  on rate, results from NIPD may not always be inform-
a  ve when the paternal peak coincides with the stu  er peak pa  ern of the maternal profi le. 
Stu  er peaks are a known phenomenon in repeat amplifi ca  on (W  et al., 1996). Each 
peak in the stu  er lacks one core repeat unit rela  ve to the main peak. When the paternal 
CAG repeat size is directly adjacent to the maternal CAG repeat size, it may be very diffi  cult 
to dis  nguish the signals. Therefore, the use of both parental gDNA profi les as a reference is 
very helpful in fragment analysis since pa  erns observed in gDNA are quite similar to pa  erns 
observed in plasma DNA. In our study, one family (#68395) was included in which the paternal 
genotype was unknown at the  me of maternal blood sampling. Results from NIPD showed 
NIPD for Hun  ngton disease
6
90
the father had transmi  ed a CAG repeat in the normal range, that could clearly be dis  n-
guished from the maternal profi le. Shortly a  er fetal results from rou  ne prenatal diagnos  cs 
were reported, he had his genotype determined. Outcome showed he actually had two CAG 
repeats in the normal range and both these repeats diff ered suffi  ciently from both the ma-
ternal repeats. This also illustrates that future cases where the father does not want to have 
his profi le determined can indeed be included for NIPD. However, it may be more challenging 
to dis  nguish between a true or false nega  ve result and couples should be informed about 
the limita  ons of performing NIPD without the accessibility of a paternal reference profi le. 
Preferably, profi les of both parents should be available prior to the start of NIPD to determine 
whether couples are eligible for this test and to es  mate the success rate of NIPD based on 
CAG repeat size diff erences. 
Besides the diff erence in repeat sizes between both parents, also repeat size itself can 
be of infl uence for the success of direct analysis for NIPD. With an average size of ~143 bp, the 
fragmented nature of cff DNA indeed makes the detec  on of expanded repeats in the fetus 
more challenging (C  et al., 2004; L  et al., 2010). Expanded repeats can be unstable. When 
the inherited paternal allele is expanded upon transmission, there is a possibility that it be-
comes too large to be detected in fragmented cff DNA. Flanking primers used for detec  on of 
the CAG repeat may not be able to bind both sides of the fragment and thus amplifi ca  on will 
be hampered. The longest repeat size described in the study by the group of Bustamante-Arag-
ones et al. was 114 repeats and could not be detected (B -A  et al., 2008), 
while in our study the largest fetal CAG repeat was 70 (represen  ng a PCR product of ~245 bp) 
which could be detected with NIPD. In this study we could detect all HD repeats, however such 
long repeats were not detected in every replicate. We therefore strongly advice to perform 
the test in duplo or triplo to obtain a more accurate and robust test result. Preferen  al am-
plifi ca  on of small repeats (i.e. repeats in the normal range) is o  en observed a  er fragment 
analysis. As a consequence, there can be a large diff erence in the intensity of signals between 
diff erent HD repeat ranges. The signal intensity of long CAG repeats is o  en much lower com-
pared to the signal of smaller repeats and this phenomenon is observed in both gDNA as well 
as plasma DNA. In maternal plasma, the fetal contribu  on to the total amount of cell-free DNA 
is on average only ~10% in the fi rst trimester, however this percentage may diff er quite exten-
sively between individuals (L  et al., 1998; L  et al., 2008a). The group of Chan et al. report 
in their study only 20% of the total amount of fetal sequences in maternal plasma have a size 
>193 bp and this percentage decreases when fragments are even larger (C  et al., 2004). 
The low signal intensity of long CAG repeats together with the low amount of fetal sequences 
in these size ranges may explain why such long fetal repeats are not detected in every plasma 
DNA replicate.
Another factor to consider, especially when sampling very early in gesta  on, is a low 
amount of cff DNA in maternal plasma itself. Very low levels of cff DNA may lead to inconclusive 
results. In case of inconclusive results, a second blood sample could be requested to retest lat-
er in pregnancy. Nevertheless, for all inconclusive results prenatal tes  ng through an invasive 
procedure is recommended. 
In summary we show that in this study all fetuses at risk for HD could be iden  fi ed 
noninvasively in maternal plasma. Moreover, we have hereby confi rmed the results from pre-
viously published cases for NIPD of HD in a larger cohort. Our data also illustrates that when 
a paternally inherited allele in the normal range is transmi  ed to the fetus, the detec  on rate 
strongly depends on the size diff erence between paternal and maternal CAG repeats. With 
this valida  on study we show that NIPD for HD can indeed be performed through direct test-
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ing of paternally transmi  ed repeats in maternal plasma, although not every couple will be 
good candidates for this test. However, prior to tes  ng, parental CAG profi les can be used to 
determine whether a couple is actually eligible for NIPD. In conclusion, we consider the ap-
proach of detec  ng the paternally inherited repeat in maternal plasma by means of PCR and 
subsequent fragment analysis very promising applica  on for NIPD of HD.
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Fragmented cell-free fetal DNA (cff DNA) present in maternal plasma is a poten  al 
source for prenatal gene  c analysis of the fetus early in gesta  on. Although the amount of fe-
tal fragments in maternal plasma is rela  vely low as compared to the excess of maternal DNA, 
results from the study of Lo et al. showed that the en  re fetal genome is present in maternal 
plasma (L  et al., 2010). In theory, this could mean that every gene  c defect in the fetus can 
be detected in maternal plasma by noninvasive prenatal diagnosis (NIPD). Since the whole 
fetal genome is present, a genome wide approach for NIPD could be used. Shotgun Whole ge-
nome sequencing (WGS) has already been applied for NIPT. However, for NIPD, shotgun WGS 
currently has its limita  ons. Many millions of sequencing reads can be obtained genome wide. 
Yet, shotgun sequencing occurs randomly and is not muta  on specifi c. Hence, the coverage 
of a muta  on or region of interest may be too low for reliable NIPD. A universal approach, 
such as WGS, for NIPD may therefore not be achievable or the preferred method of choice 
yet. Novel applica  ons as well as other approaches  could be considered and explored. There 
is a growing demand for less invasive alterna  ves in prenatal diagnos  cs. Therefore, it is to 
be expected that in the near future the number of available tests will increase drama  cally. 
In this thesis, we have described several applica  ons that make use of cfDNA from maternal 
plasma in NIPD and NIPT, such as fetal trisomy screening and targeted detec  on of paternally 
inherited muta  ons. 
Fetal markers
In both NIPD and NIPT determina  on of the fetal frac  on in maternal plasma can be 
important. Male specifi c markers (e.g. DYS14 and SRY) are used most o  en for this purpose. 
Despite the high sensi  vity and specifi city obtained in diagnos  c tests with these markers, 
a posi  ve result can only be obtained in case of a male fetus. Preferably a universal and sex 
independent marker such as fetal methylated RASSF1A (mRASSF1A) should be used to confi rm 
the presence of cff DNA in maternal plasma. This universal marker is diff eren  ally expressed 
between mother and fetus. In chapter 2 we have described a novel approach for the detec  on 
of mRASSF1A in maternal plasma. We have used a combina  on of bisulfi te conversion and py-
rophosphorolysis-ac  vated polymeriza  on (PAP) for the detec  on of mRASSF1A. Bisulfi te con-
version is necessary to reveal the diff erences in methyla  on of cytosines between maternal 
and fetal sequences. PAP is an extremely sensi  ve and specifi c technique which can be used 
to detect specifi c sequences within a high background, in this case fetal specifi c sequences 
within the maternal background. Previously, the use of PAP in NIPD has proven to be of value 
in fetal sexing (B  et al., 2007). PAP has also been described for the detec  on of residual 
tumour cells in blood, serum or plasma (M  et al., 2008). RASSF1A is a tumour suppressor 
gene and RASSF1A promoter hypermethyla  on is associated with loss of expression in tumour 
cells (H  et al., 2003). The fact that RASSF1A expression is also tumour related is a very 
important considera  on. Unknown underlying malignancies or circula  ng tumour cells in the 
maternal circula  on may result in false posi  ve results, although the prevalence of cancer in 
the reproduc  ve age group is considered to be small. The laboratory should therefore always 
be informed when women op  ng for NIPD have a history of cancer. Other alterna  ve tests 
could then be performed to confi rm the presence of cff DNA in plasma, such as the determi-
na  on of paternally inherited SNPs (A  et al., 2002; P -C  et al., 2006). This 




in mind that SNPs may not always be informa  ve. Parents could have all tested SNPs in com-
mon, or the fetus did not inherit an informa  ve paternal SNP.
The mRASSF1A-PAP we currently perform for fetal sexing is merely a qualita  ve test, 
rather than quan  ta  ve. Quan  ta  ve detec  on of a sex independent fetal marker would be 
extremely benefi cial in both NIPD and NIPT to determine the fetal frac  on in a sample.  A 
digitalized quan  ta  ve PAP assay has previously been described, though these assays were 
performed without prior bisulfi te conversion of the DNA (M  et al., 2012; S  et al., 
2014; B  et al., 2014). It has to be elucidated whether this combina  on of bisulfi te con-
version and subsequent digitalized PAP for the detec  on of mRASSF1A in maternal plasma 
would work. It would be very advantageous to combine such a digitalized PAP assay with NIPD 
of monogenic disorders. Not only the fetal paternally inherited muta  on could then be detect-
ed, also the amount of cff DNA in the sample could be determined to defi ne fetal frac  on using 
the same sample. This in contrast to NIPT, where the amount of fetal DNA is determined either 
prior or a  er sample prep. At present, it is not yet clear which one of these determina  ons 
is the best predictor for the actual fetal frac  on of a sample, since it is also not yet clear how 
these results will best represent the fetal frac  on in the actual NGS data.  
In the last few years, the search for other diff eren  ally methylated regions (DMRs) has 
con  nued (P  et al., 2009; I  et al., 2014; X  et al., 2014). Most of this 
research is performed with methylated DNA immunoprecipita  on sequencing (MeDIP-Seq) 
together with compara  ve arrays to provide global methyla  on landscapes. The diff erences 
in methyla  on between mother and fetus are based on rela  ve diff erences in expression or 
methyla  on level. Some candidate DMRs show a high level of heterogeneity between individ-
ual fetuses. Yet, good candidate DMRs for use in NIPT or NIPD require a high level of homoge-
neity between individual fetuses and should be able to exclude maternal DNA easily (X  et 
al., 2014). Even though MeDIP-Seq will give a good indica  on of which regions are diff eren  al-
ly methylated, for use in a PAP assay, it has to be confi rmed at nucleo  de level whether these 
regions are indeed good candidate DMRs. The focus for the discovery of novel DMRs has been 
on chromosome 21 and 18. These DMRs have mostly been used for fetal trisomy screening 
(T  et al., 2006; C  et al., 2008; T  et al., 2010a; T  et al., 2010b). Furthermore, 
recent studies have shown the determina  on of the fetal methylome and transcriptome (L  
et al., 2013; T  et al., 2014). In the near future, perhaps more candidate DMRs will be dis-
covered that can be useful for NIPD or NIPT.
NIPT
For NIPT, we have proposed Helicos Single Molecule Sequencing (SMS) as an alterna  ve 
non-PCR-based sequencing pla  orm in chapter 3 and 4. In contrast to PCR-based pla  orms, 
Helicos SMS data show no GC bias. In this study, SMS was successful for both T21 and T18 
detec  on. For T13 however, it appeared less op  mal. In several NIPT studies performed on 
PCR-based pla  orms, the detec  on rate for NIPT of fetal trisomy 13 was reported to be lower 
as compared to T21 and T18 detec  on (G  et al., 2014). In several other studies, the lower de-
tec  on rate has been explained by the diff erence in GC content between these chromosomes, 
mainly because chromosome 13 has the lowest average GC content of these three chromo-
somes (C  et al., 2011; B  et al., 2012; L  et al., 2012b; P  et al., 2012; N  
et al., 2012; S  et al., 2012a). In chapter 3 we have shown that the mean number of reads 
per 50 kb bin increases when GC content increases on a PCR based sequencing pla  orm. For 
Helicos the mean read count was not infl uenced by GC content, thus Helicos data display no 
GC bias. Therefore, the diff erence in GC content could not explain the lower detec  on rate of 
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T13 with SMS. Kalousek et al. showed that all placentas from T13 and T18 fetuses examined 
in their study were mosaic (K  et al., 1996). In case of such confi ned placental mosai-
cism (CPM), the presence of large quan   es of cells with diff erent karyotypes may infl uence 
results of fetal aneuploidy detec  on. Even though CPM occurs frequently in T13 and T18 pla-
centa’s, in our preliminary study using SMS possible CPM could also not explain lower perfor-
mance observed for T13, since full karyotyping of the samples showed CPM was not present. 
It should however be noted, that the number of samples tested for these preliminary studies 
using SMS has been low. Extending this data set would be very useful to elucidate the reason 
for the lower detec  on rate of T13 screening and to inves  gate the role of GC content and/
or bias for this par  cular chromosome. Unfortunately, since 2012 Helicos services were no 
longer available because of bankruptcy of the company and these tests could therefore not be 
performed for this thesis. A revival of the company might open possibili  es to run addi  onal 
samples to extend this data for fetal trisomy screening by use of SMS. 
We have compared Helicos SMS with the Illumina GAII pla  orm, which was mostly used 
for noninvasive fetal trisomy screening at that  me. Since then, many improvements in the 
Illumina sequencing technology have been extremely benefi cial for NIPT purposes and at pres-
ent, Illumina sequencers (e.g. HiSeq) are most frequently used for NIPT. Newer updates with 
features such as a rapid run modus and decreased turn-around  me are extremely benefi cial 
for NIPT. With the introduc  on of novel sequencers such as HiSeq X Ten, which combines 
Nano technology to obtain suffi  cient data for a few genomes per single run, the costs for 
running NIPT samples may even further be reduced (B  et al., 2014; H , 2014).
Calcula  on methods and downstream analysis pipelines for NIPT have been improved 
in the last few years. Studies that use ra  o calcula  ons for fetal trisomy detec  on as described 
in chapter 3 and 4  have not been reported since. Currently the Z-score, NCV (Appendix 3) 
and student’s t-test-based methods are mostly used, either as stand-alone methods or com-
bined (C  et al., 2008; S  et al., 2011; J  et al., 2012a; L  et al., 2014; S  et 
al., 2014; B  et al., 2015). Thousands of NIPT samples have been processed in the past 
few years by many diff erent groups and all these groups have been pu   ng a lot of eff ort into 
op  mizing NIPT for use in their laboratory se   ng, most frequently using the Illumina pla  orm 
for sequencing. 
Other single molecule sequencing pla  orms beside Helicos SMS have been developed 
in the past years, although not every pla  orm may be as suitable for NIPT purposes. The 
PacBio sequencer by Pacifi c Biosciences  is a single molecule real-  me (SMRT) DNA sequenc-
ing system that records light pulses emi  ed as a by-product of nucleo  de incorpora  on. One 
of the most important features of SMRT sequencing is fast run  me (within hrs) and the ex-
tremely long read length that can be obtained. Compared to the 8-9 day running  me of the 
Helicos fl ow cells, the PacBio sequencer is faster and scalable in run  me, which is favourable 
for NIPT turn-around  me. Depending upon PacBio star  ng library, over half of the data are 
in reads > 14,000 base pairs long, star  ng from around 3000 bp with the longest reads over 
40,000 bp. Such long read lengths can indeed be benefi cial for several applica  ons, neverthe-
less cfDNA in maternal plasma is on average a hundredfold shorter than the reads that can be 
obtained with this pla  orm. Therefore, PacBio is not a suitable pla  orm for NIPT. Also Oxford 
Nanopores, a pla  orm that uses nanopores as biosensors, has similar advantages (e.g. fast 
and scalable run  me) as compared to the PacBio. Sequencing with the Oxford Nanopores 
pla  orm can also result in very long read lengths, although in contrast to PacBio where the 
fragment of interest is analysed mul  ple  mes, the read length on the Nanopore pla  orm 




purposes (e.g. single molecule, base detec  on without labels, low GC bias, mul  plexing and 
scalable in data output), the use of this pla  orm for NIPT has not been described yet (B -
 et al., 2014; Z  et al., 2014).
Ion Torrent Technology on the other hand has both the advantage of producing short 
reads in a fast and cost-effi  cient manner, although the total amount of data per run is rela  ve-
ly low compared to the previously men  oned sequencing pla  orms. NIPT with semiconductor 
sequencing has indeed been described successfully (Y  et al., 2013; L  et al., 2014). With 
the Ion Proton and/or improved chips for the Ion Torrent that will yield a larger number of 
reads, it is possible to run mul  ple samples at once and to handle a true clinical throughput 
of mul  ple samples per week (W  et al., 2014; J  et al., 2014). Hence, the improved Ion 
Torrent and especially the Ion Proton could be good alterna  ve sequencing pla  orms for NIPT 
purposes.
Many diff erent factors may infl uence the success rate of NIPT, such as the presence of 
(unknown) maternal chromosomal abnormali  es, CPM, true fetal mosaicism (TFM) or a van-
ishing twin (B  et al., 2012; H  et al., 2013; W  et al., 2013; F  et al., 2013; L  et 
al., 2014). As men  oned previously fetal frac  on is one of the key factors for successful NIPT 
and NIPD. Fetal frac  on is determined with Real-Time PCR or is calculated from NGS data. 
With Real-Time PCR it is diffi  cult to determine fetal frac  on when the percentage is very low. 
If this is the case, the data are not robust since measurement is performed in only a few copies 
of the fetal genome. When calcula  ng fetal frac  on from the actual sequencing data by using 
Y chromosomal reads, one should take into account that there is also a small percentage of 
reads from maternal origin that can be incorrectly assigned to the Y chromosome (C  et al., 
2011a; H  et al., 2014). Fetus specifi c Y chromosomal reads need to be deduced from 
the maternal background. The downside of these two methods is that they are sex depend-
ent. In a genome wide or a targeted NGS approach, millions of reads are produced from the 
cfDNA present in the sample. It is generally accepted that for NIPT ~10 million unique mappa-
ble reads are required for reliable analysis. Some studies addi  onally stress out that for such 
coun  ng-based technologies a fetal frac  on of at least 4% is required for analysis (E  et 
al., 2011; P  et al., 2011; P  et al., 2012). Low fetal frac  on may result in sample 
rejec  on or incorrect outcome. When the percentage of fetal sequences in a sample is too 
low as compared to the maternal background sequences, the rela  ve contribu  on of a third 
chromosome in case of fetal trisomy is too low for this sample to be dis  nguished from the 
euploid foetus.
As previously described for fetal markers, both the presence and in this case quan  fi ca-
 on of cff DNA should preferably be performed with a sex independent method. The DANSR 
assay is an example of a NGS based sex-independent approach to determine fetal frac  on. 
Here a set of 192 SNPs-containing loci on chromosome 1-12 was assessed for fetal trisomy de-
tec  on (S  et al., 2012a; A  et al., 2013; B  et al., 2013). This SNP based approach 
is a targeted approach, since analysis involves a selec  on of autosomes. However, for WGS 
such a SNP based targeted approach is not cost effi  cient at this moment, since it requires a 
much higher horizontal and especially ver  cal coverage of SNPs to be analysed. The study of 
Lo et al., in which they show by using WGS that the complete fetal genome is present in ma-
ternal plasma, already indicated that extremely large amounts of reads are required in WGS 
to have suffi  cient coverage of a given SNP (L  et al., 2010). At present, suffi  cient sequencing 
depth cannot be accomplished without extremely high costs and is therefore not feasible yet. 
Another method to determine fetal frac  on in a sex independent way that could be of inter-
est for NIPT was described by Yu et al. They describe the analysis of library fragment size by 
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determining a ra  o between short fetal and longer maternal fragments (Y  et al., 2014). The 
advantage of this method is that it does not require addi  onal experiments since library frag-
ment size determina  on is widely used in standard protocols and is therefore easily applied  
for this purpose as well.
Monogenic disorders
For the detec  on of monogenic disorders, at present a genome wide approach by use 
of NGS is not cost-effi  cient. To ensure that a given muta  on in the fetus will be covered suf-
fi ciently to be detected in maternal background, this would require high ver  cal coverage of 
the region of interest (L  et al., 2010). For NIPT only ~10 million unique mappable reads are 
required for analysis. In the paper by L  et al. where a genome wide approach was used for 
the detec  on of a monogenic disorder, almost 4 billion reads were produced, equivalent to 
an average 65-fold coverage of the human genome (L  et al., 2010). Even then, the fetal-spe-
cifi c read sequencing depth of a SNP ranged from only 1-8 reads per SNP. The detec  on of 
monogenic disorders by use of a genome wide approach would ul  mately lead to much high-
er sequencing costs since the amount of data necessary for analysis is many  mes higher as 
compared to NIPT. A whole exome sequencing (WES) approach would therefore be a be  er 
alterna  ve for NIPD of monogenic disorders. Instead of focussing on the en  re genome, only 
the protein-coding genes are targeted, represen  ng ~1% of the human genome. However, 
WES also has its limita  ons for NIPD. Even though muta  ons in exons are more likely to have 
severe consequences, intronic muta  ons can occur and these intronic muta  ons will not be 
targeted by use of exome sequencing. Targeted gene or disease specifi c approaches may be 
custom designed for some gene  c condi  ons, targe  ng genes with causa  ve muta  ons. How-
ever, certain regions of the genome or exome may be diffi  cult to target, such as GC rich regions 
and repeats. 
Instead of using NGS, in chapter 5 and 6 we have described alterna  ve methods for 
the detec  on of monogenic disorders. Because of the wide variety in gene  c defects, (e.g. 
point muta  on or repeat expansion) each defect may require a diff erent approach. In chapter 
5 we have pursued the op  on of blocking the maternal background in maternal plasma to 
enhance the detec  on of the fetal paternally inherited muta  on. We showed that the detec-
 on of a muta  on in the fetus can be enhanced by blocking the maternal background by use 
of complementary locked nucleic acid (LNA) probes in high resolu  on mel  ng curve analysis 
(HR-MCA). These short LNA probes were designed to perfectly match maternal wild-type (WT) 
sequences. Binding of these LNA probes subsequently resulted in preven  on of PCR amplifi -
ca  on of these maternal sequences. Moreover preferen  al amplifi ca  on and enhanced de-
tec  on of the paternally inherited allele is enabled. This method can only be applied in case 
of PCR based targeted detec  on of single muta  ons and possibly small inser  ons or duplica-
 ons. LNA probes are short, only around 12 nt in size. The target muta  on should therefore 
not exceed this size. Beside HR-MCA, the use of LNA probes in Real-Time PCR could also be an 
a  rac  ve applica  on in NIPD, to block maternal sequences and  monitor the mutant allele in 
real-  me. LNA probes will only bind with high affi  nity to complementary sequences. Because 
of the LNA modifi ca  ons, the probe will not interfere in the PCR itself by ac  ng as a poten  al 
primer or target. When LNA probes are used for blocking purposes, it remains essen  al that 
the parental genotypes are known, because there are highly polymorphic regions present in 
the human genome. In these regions the chance is high that there is a SNP present in the ma-
ternal genome at a posi  on covered by the LNA probe. Hence, the LNA probe will not bind and 




mul  ple LNA probes each containing one of the SNP variants could solve this problem. 
As described previously for NIPT, all PCR based techniques are infl uenced by the GC con-
tent of the template. Therefore, GC rich areas of the human genome (e.g. promoter areas) are 
more diffi  cult to amplify or target. The same holds for AT rich areas. First a  empts to design 
HR-MCA detec  on and LNA probes for a familial muta  on in a GC rich area in exon 4 of the 
NOTCH3 gene resulted in non-func  onal primers and a detec  on probe with a very high melt-
ing temperature (Tm) (unpublished data). A diff erence between Tm of the LNA probe and Tm 
of the primers is required to facilitate LNA binding and thus blocking prior to primer binding 
and extension of the template sequences. The restric  on of the amplicon size in combina  on 
with high GC content of the template was the main reason for failure in se   ng up an HR-
MCA assay for this par  cular muta  on. Increasing amplicon size could facilitate in the design 
of primers with a lower Tm when this genomic region is less GC rich. A strategy of blocking 
maternal background sequences is not necessary when the focus is on detec  ng polymorphic 
paternally inherited (extended) CAG repeats such as in Hun  ngton disease (HD). Generally 
the maternal repeats are in the normal range. Size selec  on or selec  ve blocking of shorter 
repeats in PCR cannot be accomplished with a blocking approach as was described for the 
detec  on of paternally inherited muta  ons. Because LNA probes target a specifi c sequences 
of ~12 nt, they are not able to dis  nguish between shorter or longer repeats, and in theory 
would block every repeat. 
The size of fragmented cff DNA is also a restric  on in PCR-based assays in general, for 
example in amplicon design. The large majority of cff DNA fragments have been shown to be 
on average <150 bp in length (F  et al., 2010; L  et al., 2010). This implies that these size 
constraints should be taken into account when designing NIPD assays to detect a given fetal 
target. In case a disease is caused by a repeat expansion, such as the CAG expansions in HD, 
the detec  on becomes more complex. These repeats vary greatly in length and are known to 
be unstable upon transmission. Therefore, repeat size is not predictable in advance and re-
peats may expand into a repeat size that exceeds the fragment size of cff DNA. When analysing 
a point muta  on or small inser  on or dele  on, the constraint can be accommodated quite 
easily by designing small amplicons of ~100 bp to ensure effi  cient amplifi ca  on of the target 
sequence. Fetal sequences >150 bp are also present in maternal plasma, although in minority. 
As shown in the original paper on the discovery of cff DNA in maternal plasma, Y chromosome 
specifi c primers designed to amplify a sequence (DYS14) with an amplicon size of 198 bp were 
used (L  et al., 1990; L  et al., 1997). This is larger than the average amplicon size for cff DNA 
of ~143 bp that was reported a few years later by the same group (L  et al., 2010). These re-
sults show that there is quite a range in cff DNA size. For PCR-based approaches for muta  on 
detec  on, preferably amplicon sizes should be used that do not exceed the average reported 
size of ~143 bp. 
In chapter 6 we have described the applica  on of NIPD for HD by directly measuring the 
fetal paternally inherited CAG repeat from the Hun  ng  n (HTT) gene in maternal plasma. This 
has been accomplished through a PCR based approach and subsequent fragment analysis of 
total cfDNA. For this approach to be successful for NIPD, it requires a PCR protocol that is op-
 mized for low DNA input. Also, the Taq polymerase should prevent preferen  al amplifi ca  on 
of smaller fragment as much as possible. Even though preferen  al amplifi ca  on could not be 
completely prevented, the Taq polymerase used in PCR for NIPD of HD shows that longer frag-
ments are being amplifi ed in suffi  cient amounts to be detected in fragment analysis. This is 
absolutely essen  al for detec  ng the fetal expanded paternally inherited repeats in maternal 
plasma. When directly targe  ng fetal paternally inherited CAG repeats in Hun  ngton disease, 
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we showed that we could detect a trinucleo  de repeat up to 53 and even 70 CAG repeats, 
represen  ng cff DNA fragments with a size of >170 bp and larger. As men  oned previously, 
fragments of this size have indeed been reported, though with a very low occurrence, which 
makes the detec  on of such rare long fragments even more challenging (C  et al., 2004). 
Besides restric  ons in the maximum size of repeats in the expanded HD range, our results 
show that there are restric  ons in detec  ng the paternally inherited repeats in the normal 
range. No paternally inherited repeat could be iden  fi ed in approximately 50% of the cases 
presented, because the  paternally inherited repeat coincided with the maternal repeat pat-
tern. When NIPD results are inconclusive due to absent or low levels of cff DNA, prospec  ve 
parents are given the op  on to provide a new blood sample for NIPD later on in gesta  on to 
retest for the paternally inherited fetal repeat. Nevertheless, in all cases where no paternal 
contribu  on in maternal plasma could be detected or in cases with inconclusive results, an 
invasive procedure to confi rm the fetal genotype on fetal gDNA is indicated. 
Fragment size analysis is at present the best strategy for NIPD for HD. Detec  on of large 
repeats for NIPD using other technologies such as NGS is currently diffi  cult, if not impossible. 
CAG repeats that encode for long glutamine (Q) stretches are present all through the human 
genome. To date, a total  of nine polyQ diseases have been reported (F  et al., 2014). A NGS 
mediated approach for repeat determina  on and/ or detec  on for NIPD of HD would require 
paired-end sequencing of a specifi ed and targeted repeat, in this case the HTT gene. Although 
the repe   ve sequence of a repeat is simple, errors in NGS data may interfere with correct 
data analysis. Moreover, since CAG repeat are common throughout the genome, bioinformat-
ics will have to focus on HTT specifi c CAG repeats to determine repeat size confi dently. 
Concluding remarks
Noninvasive prenatal diagnos  cs and tes  ng have strongly improved in  me and more 
and more applica  ons have become available. Since the en  re fetal genome is present in 
maternal plasma, it is to be expected that in the future the large majority if not all of prenatal 
diagnos  cs is preferably be performed using cff DNA. Whether or not this will always be per-
formed in a universal and genome wide approach using WGS has to be elucidated. Currently, 
there are s  ll limita  ons in using WGS for some prenatal requests. With WGS large amounts of 
data can be generated, which can be useful in detec  ng known but also unknown variants or 
de novo muta  ons in fetuses without a prior history or predisposi  on of a familial muta  on. 
However, shotgun sequencing is not muta  on specifi c and is currently not always cost-effi  -
cient for use in the detec  on of these specifi c muta  ons. 
The majority of prenatal requests are for fetal aneuploidy detec  on. In the Netherlands, 
during a two year na  onal implementa  on study, NIPT is currently available for high risk preg-
nant women. It is to be expected that NIPT will soon become available for low risk pregnant 
women as well. In addi  on to this, in the near future it is desirable for gene  c laboratories 
to have several NIPD alterna  ves available for prospec  ve prenatal requests. As men  oned 
previously and as shown in this thesis, no universal approach, par  cularly for NIPD, is available 
yet. For each novel applica  on, one should clearly consider the best approach in detec  ng the 
gene  c defect using NIPD. Moreover, some applica  ons (e.g. detec  on of point muta  ons) 
do not have to be restricted only to couples where the father is carrier of the mutant allele. 
In conclusion, we show several novel applica  ons for the use of cff DNA for NIPD and 
NIPT. We also show that each applica  on at present may require a diff erent approach. In the 
near future, it is to be expected that more noninvasive alterna  ves for a wider variety of ge-










Current prenatal diagnos  cs is mainly based on obtaining fetal DNA through invasive 
procedures which are associated with a small, but signifi cant risk of fetal loss. The discovery of 
the presence of cell-free fetal DNA (cff DNA) in maternal plasma opened possibili  es for less or 
noninvasive alterna  ve procedures.
Cff DNA is comprised of small fragments of fetal extracellular DNA derived from placen-
tal cells that go into apoptosis. It circulates in maternal plasma and can be detected already 
very early in gesta  on. However, the majority of total cell-free DNA (cfDNA) in maternal plas-
ma is of maternal origin and the fetal contribu  on is rela  vely small in the fi rst trimester. 
Despite this high maternal background, the use of cff DNA in noninvasive prenatal diagnos  cs 
(NIPD) and noninvasive prenatal tes  ng (NIPT) has been described successfully. In this thesis, 
we describe novel applica  ons and approaches for the use of cff DNA in both NIPD and NIPT.
For all these novel applica  ons, either NIPT or NIPD, it is important to know the fetal 
frac  on in the maternal background. Independent confi rma  on of the presence of fetal DNA 
in the sample is therefore required. Most o  en male specifi c markers (e.g. SRY and DYS14) 
are used to confi rm the presence of cff DNA or to determine the fetal frac  on in a sample. 
However, using these markers a posi  ve result can only be obtained in case of a male fetus. 
Therefore we have developed a novel approach to detect and confi rm the presence of cff DNA 
in maternal plasma in a sex-independent way. Chapter 2 describes a novel assay for the detec-
 on of fetal specifi c methylated RASSF1A (mRASSF1A) using a combina  on of bisulfi te conver-
sion and pyrophosphorolysis-ac  vated polymeriza  on. RASSF1A is diff eren  ally methylated 
between mother and fetus. These diff erences in methyla  on were used to specifi cally detect 
and thus confi rm the presence of fetal mRASSF1A sequences. We have shown that this qual-
ita  ve approach to determine cff DNA in maternal plasma can be used successfully with high 
sensi  vity and specifi city and can be applied early in gesta  on. In the future, digitaliza  on and 
thus quan  fi ca  on of this assay could be benefi cial in the determina  on of the fetal frac  on.
NIPT for fetal aneuploidy screening is perhaps one of the best studied applica  ons for 
the use of cff DNA and is frequently performed on PCR based sequencing pla  orms. These 
pla  orms are known for GC content related bias in sequencing data. Chapter 3 describes the 
use of Helicos Single Molecule Sequencing (SMS) as an alterna  ve non-PCR based sequencing 
pla  orm for NIPT of fetal trisomy 21 (T21). We have directly compared SMS to the PCR based 
Illumina pla  orm and show that when using SMS, the mean number of sequencing reads is 
not infl uenced by GC content, thereby showing that SMS sequencing data is not GC biased. 
While, using the Illumina pla  orm, the mean number of sequencing reads generated increas-
es when GC content of the chromosome increases. Moreover, we show that when using SMS, 
all fetuses with T21 can be correctly iden  fi ed and dis  nguished more clearly from euploid 
fetuses. In chapter 4, we addi  onally describe the use of SMS for other fetal trisomies. We 
show that SMS is also successful for trisomy 18 (T18) screening. However, for trisomy 13 (T13) 
screening SMS turns out to be less successful. To elucidate the cause of this poor performance 
further tes  ng is needed. 
In contrast to NIPT, NIPD for monogenic disorders currently represents only a small part 
of the fi eld of noninvasive prenatal gene  c tes  ng. NIPD can be used for the detec  on of pa-
ternally inherited sequences. However, not all NIPD can currently be addressed by a single or 
universal approach, such as for instance NGS. Chapter 5 describes the use of High-Resolu  on 
Mel  ng Curve Analysis (HR-MCA) as a non-NGS PCR mediated alterna  ve for the detec  on 




maternal background with locked nucleic acid (LNA) blocking probes, the detec  on of the 
paternally inherited allele of the fetus can be enhanced. We show this proof of principle for 
both an autosomal dominant and an autosomal recessive disorder.
Chapter 6 addi  onally shows the use of another PCR based approach for the detec  on 
of fetal paternally inherited repeats in Hun  ngton disease (HD). HD is caused by the expansion 
of a trinucleo  de (CAG) repeat in the Hun  ng  n (HTT) gene. The fetal paternally inherited 
repeat can detected by use of a PCR based approach with primers fl anking the repeat. We de-
scribe a valida  on study for NIPD for HD and showed that we could detect a fetal repeat of up 
to 70 CAG repeats in maternal plasma. In this valida  on study, all paternally inherited repeats 
for all fetuses at risk for HD could be detected. We addi  onally show that in cases where the 
fetus has inherited the normal paternal allele, the detec  on strongly depends on the parental 
genotypes. 
In the future, the number of applica  ons for NIPT and par  cularly NIPD is expected to 
increase. Even though the use of fragmented cff DNA from maternal plasma s  ll has its chal-
lenges (e.g. rela  ve low amounts, short in size), we show that by careful considera  on of the 
most effi  cient approach for each applica  on, these challenges may be overcome. This makes 
cff DNA a very poten  al source for use in NIPT and NIPD. Based on  the ongoing improvements 
of these tests, both NIPT and NIPD will soon become available to more women, although a 
universal approach for all applica  ons is not feasible yet. Nevertheless, it is to be expected 




Samenva   ng
De huidige prenatale diagnos  ek is voornamelijk gebaseerd op analyse van foetaal 
DNA verkregen met behulp van invasieve procedures. Deze procedures zijn geassocieerd met 
een klein, maar signifi cant risico op een miskraam. De ontdekking dat er kleine stukjes celvrij 
foetaal DNA (cff DNA) in het (bloed)plasma van moeder aanwezig zijn, opende mogelijkheden 
voor minder of niet invasieve alterna  even voor het verkrijgen van foetaal DNA voor prenatale 
diagnos  ek.
Cff DNA bestaat uit kleine fragmenten foetaal extracellulair DNA dat a  oms  g is uit 
cellen van de placenta die in apoptose zijn gegaan (ofwel geprogrammeerde cel dood heb-
ben ondergaan). Dit DNA circuleert in het plasma van de zwangere vrouw en kan al vroeg in 
de zwangerschap gedetecteerd worden. De meerderheid van het aanwezige cel-vrije DNA in 
maternaal plasma is echter van maternale origine en de bijdrage van de foetus in het eerste 
trimester van de zwangerschap is rela  ef klein. Ondanks deze hoge maternale achtergrond 
is het gebruik van cff DNA voor niet-invasieve prenatale diagnos  ek (NIPD) en niet-invasieve 
prenatale testen (NIPT) al eerder succesvol beschreven. In dit proefschri   worden een aantal 
nieuwe applica  es en toepassingen besproken voor het gebruik van cff DNA voor zowel NIPD 
als NIPT.
Voor zowel NIPD of NIPT, is het van belang om de foetale frac  e in de maternale achter-
grond te weten. Daarom is het noodzakelijk om de aanwezigheid van cff DNA in een sample te 
bepalen. Voor het beves  gen van de aanwezigheid van foetaal DNA of voor het bepalen van 
de foetale frac  e worden meestal markers gebruikt die op het Y chromosoom liggen en die 
dus specifi ek zijn voor mannelijke sequen  es, zoals SRY en DYS14. Helaas kunnen deze mark-
ers alleen een resultaat geven indien de foetus mannelijk is. Daarom is een nieuwe methode 
om de aanwezigheid van cff DNA te kunnen beves  gen ontwikkeld, die in elke zwangerschap 
gebruikt kan worden, dus ongeacht het geslacht van de foetus. In hoofdstuk 2 wordt een nieu-
we test beschreven voor de detec  e van foetus specifi eke sequen  es van gemethyleerd RASS-
F1A (mRASSF1A), waarbij gebruik gemaakt wordt van een combina  e van bisulfi et omze   ng 
en pyrophosphorolyse-geac  veerde polymerisa  e (PAP). RASSF1A is diff eren  eel gemethyl-
eerd tussen moeder en foetus. Deze verschillen in methyla  e patroon worden gebruikt om 
specifi ek de foetale sequen  es te kunnen detecteren en daarmee dus de aanwezigheid van 
deze sequen  es te kunnen beves  gen. De resultaten laten zien dat deze kwalita  eve toe-
passing al vroeg in de zwangerschap met hoge sensi  viteit en specifi citeit succesvol gebruikt 
kan worden. In de toekomst zou digitalisa  e en kwan  fi ca  e van deze test tevens uitkomst 
kunnen bieden in het bepalen van de foetale frac  e in een sample.
NIPT, voor het screenen naar foetale aneuploïdieën, is op dit moment een van de best 
bestudeerde toepassingen van het gebruik van cff DNA. Voor NIPT wordt meestal gebruik ge-
maakt van Next Genera  on Sequencing (NGS) pla  ormen die PCR gebaseerd zijn. Deze plat-
formen staan bekend om de invloed die het GC percentage van een chromosoom hee   op de 
hoeveelheid data die geproduceerd wordt. In hoofdstuk 3 beschrijven we het gebruik van Hel-
icos Single Molecule Sequencing (SMS) bij NIPT voor trisomy 21 (T21 ofwel Down Syndroom) 
detec  e als een alterna  ef pla  orm dat niet gebaseerd is op een PCR techniek. We hebben 
SMS een-op-een vergeleken met het PCR gebaseerde Illumina pla  orm en laten zien dat het 
gemiddelde aantal sequen  es bij SMS niet beïnvloed wordt door het GC percentage. Bij het 
Illumina pla  orm daarentegen zien we dat het gemiddeld aantal sequen  es toeneemt bij 
toenemend GC percentage. Daarbij laten we ook zien dat bij SMS alle T21 foetussen correct 
geïden  fi ceerd worden en zelfs nog beter te onderscheiden zijn van euploïde foetusen als 
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vergeleken met het Illumina pla  orm. In hoofdstuk 4 laten we bovendien de toepassing van 
SMS zien voor het screenen naar andere trisomieën. Het gebruik van SMS is ook succesvol voor 
trisomie 18 (T18 ofwel Edward’s syndroom) screening. Voor trisomie 13 (T13 ofwel syndroom 
van Patau) is deze methode minder succesvol. Om de exacte reden van deze mindere presta  e 
beter te kunnen duiden, zou verder onderzoek uitgevoerd moeten worden.
In tegenstelling tot NIPT, beslaat NIPD voor monogene erfelijke aandoeningen slechts 
een klein deel van het veld van niet-invasief prenataal testen. NIPD kan gebruikt worden voor 
de detec  e van paternaal overgeërfde sequen  es. Momenteel is het nog niet mogelijk om 
alle NIPD uit te voeren met één enkele of universele aanpak, zoals bijvoorbeeld het gebruik 
van NGS. In hoofdstuk 5 wordt het gebruik van PCR en hoge resolu  e smelt curve analyse 
(HR-MCA) als een alterna  ef voor NGS beschreven. Door het blokken van de maternale ach-
tergrond  jdens de PCR met behulp van een LNA probe, wordt de detec  e van het paternaal 
overgeërfde allel in de foetus sterk verbeterd. Als “proof of principle” tonen we dit voor zowel 
een autosomaal dominant als een autosomaal recessief overervende aandoening aan.
Daarnaast wordt in hoofdstuk 6 nog een andere PCR gebaseerde toepassing getoond 
voor de ziekte van Hun  ngton (HD) en de detec  e van het paternale allel in de foetus. HD 
wordt veroorzaakt door een expansie van een trinucleo  de (CAG) herhaling/repeat in het 
hun  ng  ne gen (HTT). De paternale overgeërfde repeat in de foetus kan worden gedetecteerd 
met behulp van een PCR waarbij gebruik gemaakt wordt van primers die rondom de repeat 
liggen. In deze valida  e studie voor NIPD van HD konden we een foetale repeat van tot wel 
70 CAG herhalingen aantonen in maternaal plasma. Bovendien laten we zien dat we bij alle 
foetussen die risico lopen op het krijgen van HD, de paternaal overgeërfde repeat werd aange-
toond. Bij de foetussen die het normale allel van vader hebben gekregen, blijkt de detec  e 
ervan sterk a  ankelijk te zijn van het genotype van beide ouders.
Het is zeer waarschijnlijk dat het aantal toepassingen voor NIPT en zeker voor NIPD de 
komende  jd sterk zal toenemen. Ondanks het feit dat het gebruik van gefragmenteerd cff D-
NA uit maternaal plasma nog steeds uitdagingen kent (bijvoorbeeld de rela  ef lage hoe- veel-
heid en de korte lengte), laat dit proefschri   zien dat deze uitdagingen overwonnen kunnen 
worden door voor iedere toepassing de meest effi  ciënte aanpak te gebruiken. Kortom, cff DNA 
is een uitermate geschikte bron van foetaal DNA voor NIPT en NIPD. Met het verbeteren van 
de huidige technieken, zullen zowel NIPT als NIPD in de toekomst voor meer vrouwen beschik-
baar komen, alhoewel het op dit moment nog niet mogelijk lijkt om hiervoor een universele 
aanpak voor te gebruiken. Desalnie  emin is de verwach  ng dat in de toekomst het merendeel 
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Eindelijk is het dan zover. Jaren van hard werken en studeren worden beloond met een mooi slot; een 
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het lab eens een keertje wat vroeger achter ons dicht te trekken. Jij hebt afgelopen jaar een nieuwe stap 
gemaakt in jouw carrière en helaas zien we je daardoor minder vaak. Maar gelukkig is er al  jd een reden 
voor sushi te verzinnen.
Bert, als promotor heb je mij de kans gegeven om als promovendus aan de slag te gaan op het lab. Be-
dankt! Ik kon al  jd bij je binnenlopen voor een vraag, advies of een praatje. Zeker  jdens een overleg ver-
baasde ik me toch elke keer dat je precies dat ene boek of proefschri   wist te pakken waar de benodigde 
informa  e in stond. Bij deze kan er nog een exemplaar aan de verzameling worden toevoegd.
Nicole, bedankt voor onze gesprekken  jdens onze samenwerking. Ze hebben me doen inzien dat pro-
moveren wel eens een goede vervolgstap voor mij zou zijn. En ik heb er zeker geen spijt van gehad.
Joris, bedankt dat je het vertrouwen had in mij, en mij de kans hebt geboden om een paar maanden in 
Leuven te werken. Niet alleen heb ik een top  jd gehad bij het CME, het hee   me ook geholpen om goed 
na te kunnen denken over mijn toekomst na het behalen van mijn PhD.
De “borrelclub”, bedankt dat jullie me regelma  g van het lab haalden om wat iets leuks te gaan doen. Dat 
had ik echt even nodig!
De collega’s van het LDGA voor al jullie hulp, het beantwoorden van mijn vragen, jullie geduld als ik weer 
eens met samples kwam waar iets aparts mee moest gebeuren en alle leuke gesprekken  jdens de pauzes.
Speciaal een bedankje voor de collega’s van sec  e Prenataal die de meeste, zo niet alle samples uit dit 
proefschri   wel voorbij hebben zien komen. Zonder jullie hulp, harde werk en enthousiasme zou dit 
proefschri   niet zijn wat het nu is. 
Dan mijn paranimfen. Sahila, eind 2010 zijn we samen aan deze uitdaging begonnen. Dankzij al jouw voor-
werk had ik een vliegende start. Ook al zijn onze wegen (en werkzaamheden) daarna wat verder uit elkaar 
gaan lopen, het stond al heel lang vast dat jij een van mijn paranimfen zou worden. En gelukkig zei je “ja”!
En Nienke, mijn vraagbaak en ervaringsdeskundige wat betre   het promoveren. Bedankt voor al je feed-
back, adviezen en antwoorden op al mijn vragen. Vergeleken met jouw promo  e zijn we voor deze een 
stuk minder op pad geweest. En al hee   het even geduurd, nu dan eindelijk zelf ook een keer paranimf. 
Fijn dat ook jij naast me staat vandaag.
Lieve familie en schoonfamilie, “mijn boekje” is eindelijk klaar. Bedankt voor al jullie interesse in de afge-
lopen jaren!
Pa en ma, ik weet dat jullie trots op me zijn. Ook al is het weer een behoorlijke reis, fi jn dat jullie er 
vandaag weer bij zijn in dit voor jullie reeds bekende gebouw. 
En tot slot Danny, mijn grote steun en toeverlaat. Promoveren is niet al  jd even makkelijk. Fijn dat je daar 
al  jd begrip voor hebt gehad. Bedankt voor je onvoorwaardelijke steun, posi  viteit en op  misme, zeker 
 jdens het afgelopen jaar.





Appendix 1: Confi ned placental mosaicism
Placental villi obtained with CVS can be analyzed by two dis  nct culturing methods. 
With a semi-direct method (short-term culture or STC) cells from the invading cytotrophoblast 
are analyzed. A  er culture (long-term culture or LTC) cells of the mesenchymal lineage are 
evaluated. Dis  nc  on between these two culturing methods and knowledge of the origin of 
the cells is very important for interpreta  on of the outcome of prenatal gene  c tes  ng on 
CVS material, since cells of diff erent embryogenic progenitors are analyzed for chromosomal 
analysis of the fetus with these two dis  nct culturing methods (B  et al., 1993). When 
culturing is successful and suffi  cient sample is provided, preferably a combina  on of both STC 
and LTC should be used to interpret prenatal fi ndings.
In the majority of pregnancies the karyotype of the placental cells is similar to the kar-
yotype of the fetus. However, in ~2% of the pregnancies studied by CVS a cytogene  c abnor-
mality is found, most o  en a trisomy (K  et al., 1996). The existence of a discrepancy 
between the karyotype from chorionic  ssue and embryonic/fetal  ssue is caused by complex 
developmental events during early embryogenesis. When a trisomy is formed soon a  er fer-
 liza  on before the trophoblast and the inner cell mass are diff eren  ated, the discrepancy 
(or mosaic) can be generalized to both placenta and fetal  ssues. When it is formed a  er the 
separa  on of the fetal and placental compartments, the abnormal  ssue may be confi ned to 
either the placenta (confi ned placental mosaicism or CPM) or the fetus, but not necessarily 
to both  ssues (S  et al., 1992). Therefore, in case of mosaicism it is very important to 
dis  nguish between a true fetal mosaicism (TFM) and CPM and confi rmatory karyotyping on 
amniocytes is required to asses which type of mosaicism is present. Mosaicism can be classi-
fi ed according to the distribu  on of the abnormal cell line (Table 1) (G , 2014).
Table 1: Diff erent types of mosaic outcome: (CPM; confi ned placental mosaisicm, TFM; true fetal mosaicism) found 
a  er chorionic villous and amniocytes karyotyping. Adapted from (GRATI, 2014).
Since cff DNA is derived from trophoblast cells, the presence of a possible CPM can also 
infl uence results of noninvasive prenatal tes  ng (NIPT) for common fetal aneuploidies. Due 
to feto-placental mosaicism poten  al false posi  ve (CPM type I or III) and false nega  ve (TFM 
type V) results may occur for mosaics in which the trophoblast is cytogene  cally discrepant 
from the fetus. Even though a discrepancy between karyotypes occurs only in around 2% of 
the cases, in the majority of cases, the mosaicism is confi ned to the placenta (i.e. CPM type I, 
~35%). CPM type III and TFM type V are found in around 10% and 6% of the cases respec  vely 
(G , 2014). For NIPT, addi  onal gene  c analysis of either amniocytes or a combina  on of 
STC and LTC is therefore required to determine fetal karyotype in case of an aberrant result.
Type Nature Trophoblast (direct) Mesenchyme (culture) Amniocytes
I CPM Abnormal Normal Normal
II CPM Normal Abnormal Normal
III CPM Abnormal Abnormal Normal
IV TFM Abnormal Normal Abnormal
V TFM Normal Abnormal Abnormal
VI TFM Abnormal Abnormal Abnormal




Appendix 2: Epigene  c allelic ra  o, haplotype ra  o analysis and rela-
 ve muta  on dosage.
Analysis of the epigene  c allelic ra  o (EAR) is a method to assess copy number of a 
par  cular chromosome of interest for fetal aneuploidy detec  on by determining the ra  o 
of an informa  ve single nucleo  de polymorphism (SNP) on fetal alleles. This SNP is present 
within a fetal specifi c amplifi ed DNA molecule in a diff eren  ally methylated region (DMSR) on 
the chromosome of interest. Bisulfi te converted DNA samples are amplifi ed with methyla  on 
specifi c PCR (MSP). Subsequently, methyla  on diff erences are assessed with allele-specifi c 
primer extension. This primer extension u  lizes internal primers which anneal to a PCR-gener-
ated template and terminate immediately 5’ adjacent to the informa  ve single base varia  on 
(G  et al., 1997). Extension of these allele specifi c primers can dis  nguish between 
an allele with a nucleo  de that is not aff ected by the conversion (allele A) and an allele with 
a polymorphism that is aff ected by the bisulfi te conversion (allele B with an unmethylated 
cytosine (C) which is converted into a thymidine). The extension reac  ons are designed to 
generate products of dis  nct masses (and thus dis  nct peaks) when analyzing the alleles with 
Mass Spectrometry. 
In euploid fetuses there are equal amounts of allele A and B. Therefore, the theore  cal 
rela  ve peak frequency of allele A and B is both 50% (or 0.5). The EAR can subsequently be 
calculated by dividing the rela  ve peak frequency of A by the rela  ve peak frequency of B (1). 
Hence, for euploid fetuses, the EAR is 1. 
In case of a fetus with a trisomy, instead of two alleles, three alleles are present. More-
over, there is an overrepresenta  on of one of these alleles (e.g. either allele A (AAB) or allele 
B (ABB)). For AAB, there is twice the amount of A alleles contribu  ng to the total amount of 
three alleles (e.g. twice as much A compared to B). Therefore, the contribu  on of A rela  ve to 
the total amounts of alleles is 2 out of 3 (i.e. 67% or 0.67), while rela  ve the B allele is present 
in only 1 of the 3 alleles (i.e. a rela  ve peak frequency of 33% or 0.33 for B). Therefore, the 
EAR for AAB is 2 (i.e. 0.67/0.33). In case a fetal trisomy with only one A allele and two B alleles 
(i.e. ABB), the rela  ve contribu  on for A is 0.33 and 0.67 for B, resul  ng in an EAR for ABB of 
0.5 (i.e. 0.33/0.67). An EAR that has deviated from 1 (i.e. euploid fetus) is indica  ve for a fetal 
trisomy. Adapted from (T  et al., 2006).
(1)
Another method for fetal aneuploidy detec  on is the determina  on of the haplotype 
ra  o (HR). In HR analysis only highly heterozygous tandem SNPs on the chromosomes of inter-
est exhibi  ng three diff erent alleles (haplotypes) are considered informa  ve (i.e. two diff erent 
maternal alleles and a third dis  nc  ve paternally inherited fetal allele) (Fig. 1). In contrast to 
EAR, for HR it is not required to have SNPs only present in DMR, since this method is not based 
on diff erences in methyla  on. 
For HR, fi rst Mul  plexed Linear Amplifi ca  on (MLA) is performed on DNA from maternal 
buccal swaps. This linear amplifi ca  on product is used as a template in a “sequence specifi c” 
PCR and Cycling Temperature Capillary Electrophoresis (CTCE). When results of the maternal 
buccal swaps indicate that the maternal tandem SNP status is homozygous, the SNPs are not 
informa  ve. When the maternal SNPs are heterozygous, maternal plasma can be processed 
similar to the maternal buccal DNA and analyzed subsequently. Fetal chromosome dosage can 
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be determined by calcula  ng HR using the area under the curve of the three dis  nct peaks 
(p1, p2 and p3) in the electropherogram a  er CTCE (8). As a control, gDNA from maternal 
buccal swabs or maternal lymphocytes is analyzed and compared to the mixed profi le of both 
mother and fetus in maternal plasma (Fig. 1). The maternal contribu  on to the fetal haplotype 
can be (quan  ta  vely) compared to the paternally inherited haplotype (yellow peaks) to de-
termine fetal aneuploidy status. In Fig. 1, each peak is schema  cally represented as a triangle 
and represents one haplotype; either only from the mother (e.g. no fetal contribu  on; white), 
only the fetus (e.g. the paternally inherited haplotype; only yellow) or a shared haplotype 
between mother and fetus (white and yellow). In a maternal plasma sample from a mother 
carrying a euploid fetus, the presence of three diff erent alleles are informa  ve (Figure 1 A 
and B). There is a unique non-shared maternal haplotype (white), a haplotype that is shared 
between mother and fetus (white and yellow) and a dis  nct unique paternally inherited hap-
lotype (yellow). In a euploid fetus the paternally inherited peak p3 is equal to the rela  ve 
diff erence between p1 and p2, resul  ng in HR = 1 (2). Both maternal and paternal contribu  on 
to the fetal genotype is equal.
Figure 1: Theore  cal CTCE electropherogram output from maternal buccal swab and maternal plasma using tandem 
SNP analysis. Adapted from (GHANTA et al., 2010).
In case of a plasma sample from a mother carrying a fetus with a trisomy, the CTCE elec-
tropherogram shows an uneven contribu  on between paternal (p3) and maternal haplotypes 
(p1 and/or p2) of the fetus. Fetal trisomy can be caused either by a familial form (e.g. Rober-
sonian transloca  on) or, in the majority of cases, by a meio  c nondisjunc  on event. A normale 
gamete (ovum or sperm) has one copy of each chromosome, containing 23 chromosomes in 
total (n). With nondisjunc  on, chromosomes fail to separate normally, resul  ng in a gain or 












Nondisjunc  on can occur both in mitosis and meiosis. Failure of sister chroma  ds to 
separate during mitosis may lead to mosaicism. Failure of a pair of homologue chromosomes 
to separate in meiosis I (i.e. primary nondisjunc  on) will result in both members of this homo-
logues pair to be present into the same daughter cell (Fig. 2 le  ) resul  ng in a fer  lized egg 
with an abnormal number of chromosomes (i.e. aneuploidy). Failure of the sister chroma  ds 
to separate during meiosis II (i.e. secondary nondisjunc  on) will result in both daughter chro-
mosomes going into the same gamete, also resul  ng in an abnormal number of chromosome 
in the fer  lized cell (Fig. 2 right). 
Figure 2: Nondisjunc  on occurring at meiosis I (le  ) and meiosis II (right). Nondisjunc  on in meiosis I will lead to 
two gametes with an extra chromosome (n+1) and two gametes with a missing chromosome (n-1). A  er fer  liza  on 
this will result in a trisomy or monosomy respec  vely. Nondisjunc  on in meiosis II will lead to two normal gametes (n) 
and two abnormal gametes with either an extra chromosome (n+1) or missing one chromosome (n-1).
In case of fetal trisomy, the CTCE plots can also provide informa  on about whether 
primary or secondary nondisjunc  on has occurred. When both maternal haplotypes (p1 and 
p2) are shared in the fetus, nondisjunc  on occurred during maternal meiosis I. The HR value 
for maternal meiosis I equals 0 (p1 = p2; therefore the rela  ve diff erence between p1 and p2 
= 0) (Figure 1 C). With secondary maternal nondisjunc  on, three alleles with diff erent areas 
are reported whereas p1 or p2 is equal to twice the area of p3, resul  ng in HR = 2 (Figure 1 D). 
Adapted from (G  et al., 2010)
In addi  on to previous described methods used for fetal aneuploidy detec  on, also 
digital PCR can be used for fetal aneuploidy detec  on to determine the rela  ve overrep-
resenta  on of a chromosome by calcula  ng rela  ve chromosome dosage (RCD). With RCD 
the total copy number of a chromosome is assessed in a sample to determine whether this 
chromosome is overrepresented when compared to a reference chromosome. However, the 
use of digital PCR is not only restricted to fetal aneuploidy detec  on in NIPT. Similar to RCD, 
the principle of digital rela  ve muta  on dosage (RMD) can also be applied to NIPD of mono-
genic diseases. With digital RMD it is no longer required to test only for paternally inherited 
muta  ons or fetal sequences that are diff erent (e.g. methylated RASSF1A) or absent (e.g. SRY) 
in the mother. With RMD it is possible to compare and measure rela  ve amounts of both the 
maternal mutant (M) and wild type alleles (N) in maternal plasma to determine the inherited 
dosage of the mutant allele by the fetus (Fig. 3). Therefore, it is no longer necessary to dis  n-
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guish between fetal and maternal sequences. Digital RMD, performed by digital PCR, deter-
mines whether the M or N alleles are in balance in maternal plasma (Fig. 3). When a pregnant 
woman and her fetus are both heterozygous for a certain muta  on, the amounts of the M al-
lele and N allele are in balance (M=N). When the fetus is homozygous for the muta  on, there 
will be an over-representa  on of the mutant allele (M>N). When the fetus is wild type, there 
will be an under-representa  on of the mutant allele (M<N) in the RMD. Adapted from (C  
et al., 2009; L  et al., 2008b).
Figure 3: Rela  ve muta  on dosage of mutant (M) and normal (N) wild type alleles. Adapted from (C  et al., 2009)
Appendix 3: Calcula  ons for trisomy detec  on
Rela  ve sequence tag density (RSTD): 
Shotgun sequencing of numerous of short cfDNA sequences produced a  er massive 
parallel sequencing (MPS) are mapped to the chromosome of origin. For each chromosome, 
these short sequence fragments or reads are counted and summed. In addi  on, the median 
of these summed reads from all the autosomes was calculated. To correct for input, for each 
sample the sum of the reads per chromosome is normalized by dividing this value by the medi-
an of all autosomes; the sequence tag density (STD). Male plasma samples or maternal plasma 
samples from women carrying male euploid fetuses can be used as a reference. STD was also 
calculated for the controls or reference samples, by fi rst calcula  ng the average of summed 
tags per chromosome from all reference samples. Subsequently, the median is determined 
over the values of the autosomes. The average of summed tags per chromosome is normal-
ized by dividing this number by the median value of the autosomes (3). Rela  ve sequence tag 
density (RSTD) can be determined for each sample by calcula  ng ra  os between normalized 
value per chromosome from each maternal plasma sample and normalized value per chromo-
some for the controls (4) (Adapted from (F  et al., 2008). 
By determining these ra  os, the over- or underrepresenta  on of any chromosome in 




require the diff eren  a  on between maternal and fetal sequence tags. When a woman carries 
a healthy fetus, both mother and fetus have 2 copies of each autosome. The RSTD between 









A fetus with a trisomy (e.g. trisomy 21) has an addi  onal copy of chromosome 21 as 
compared to mother. Theore  cally, the RSTD of chromosome 21 between mother and this af-
fected fetus would be 1.5 (e.g. the mother has 2 copies of chromosome 21 while the fetus has 
3 copies). However, in maternal plasma, the fetal contribu  on to cfDNA in maternal plasma 
is only ~10% in the fi rst trimester. Therefore, the RSTD for a plasma sample from a fetus with 
trisomy 21 is expected to be between 1 and 1.5 due to the rela  vely small contribu  on of the 
addi  onal fetal chromosome 21 as compared to the maternal background (Table 2).
Table 2: Theore  cal example of fold increase of chromosome 21 in fetal trisomy 21 in gDNA from chorionic villus 
sampling (CVS) and maternal plasma.
Z-scores: 
In fetal trisomy detec  on, the Z-score refers to the number of standard devia  ons that 
the percentage of reads from a par  cular chromosome in a test sample diff ers from the mean 
% of that par  cular chromosome in a reference data set. Such reference set contains plasma 
samples from pregnancies of women carrying euploid fetuses. The advantage of a reference 
set and reference values is that they have to be established only once for a certain run se   ng. 
It is therefore no longer required to run control samples together with unknown samples. 
For Z-score calcula  ons, fi rst the % representa  on of unique sequences mapped to a 
chromosome is calculated by dividing the number of unique count for chromosome N (chr N) 
by the total counts from that sample (5). Subsequently, the diff erence between % chr N (x) 
and the mean % of chr N (μ) in the reference set is determined and divided by the standard 
devia  on (SD; σ) of the % chr N in the reference set to determine the Z score for chromosome 
N (6). With this Z-score, disease status of the fetus is determined by looking at the overrep-
resenta  on of a certain chromosome. For example, a maternal plasma sample with a % chr 21 
that is > 3 SD from the mean of the % chr 21 of the euploid reference set is considered to be a 
fetal trisomy 21 (Adapted from (C  et al., 2008) and ISPD preconference NGS Course, 2012).
Sample Fetal DNA content ↑ chr 21 (21) ↑ chr 21 (fold)
CVS 100 % 50 % 1.5
Maternal plasma ~10 % 5 % 1.05
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Normalized chromosome value (NCV) calcula  ons are based on correc  on for the in-
trarun and interrun sequencing varia  on in the chromosomal distribu  on of sequence reads. 
These varia  ons may obscure the eff ects of fetal aneuploidy on the distribu  on of mapped 
sequence sites. For NCV calcula  ons, a chromosome ra  o is calculated (7), in which the count 
of mapped sites for the chromosome of interest is normalized to counts of another predeter-
mined chromosome (or set of chromosomes) of the same sample (8); Modifi ed from (S  
et al., 2011). 
Sehnert et al. used a training set, consis  ng of pregnancies with unaff ected fetuses. 
For each chromosomes of interest (e.g. chr 13, 18, and 21) they determined the denomina-
tor chromosome that minimized the varia  on of the chromosome ra  os within and between 
the runs (Table 3). They also used the training set to determine parameters and boundaries 
for sample classifi ca  on (i.e.. mean, SD and NCV classifi ca  on). An NCV > 4.0 classifi es the 
chromosome as aff ected (i.e. aneuploidy for that chromosome). An NCV < 2.5 classifi es the 
chromosome as unaff ected. Samples with an NCV between 2.5 and 4.0 were classifi ed as “no 
call”. Similar to Z-score calcula  ons, this method does not require addi  onal control sample to 
be sequenced together with maternal plasma samples when all parameters and boundaries 
have been established. Adapted and modifi ed from (S  et al., 2011).
(7) #
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Table 3: Numerator and denominator combina  ons for noninvasive trisomy detec  on.
Note: Determina  on of appropriate control groups and calcula  on methods that have 
been addressed in Appendix 3 were used for fetal aneuploidy detec  on as described in chap-
ters 3 and 4. 
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A
